Compositions and methods for treating autoimmune disorders
By combining nanodisks and modifying IL-2 technology, inducing and amplifying antigen-specific Treg cells, the problem of poor induction of Treg cells in the prior art was solved, and effective treatment and long-term immune tolerance of autoimmune diseases are achieved. sex.
Patent Information
- Application Number
- CN202380035415.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-22
- Filing Date
- 2023-02-22
- Publication Date
- 2024-11-29
AI Technical Summary
The prior art is difficult to effectively induce antigen-specific Treg cells, resulting in poor treatment effects of autoimmune diseases.
Nanodisks were combined with modified IL-2, and systemically administered IL-2 or its mutant proteins after subcutaneous administration of the nanodisk to induce and amplify antigen-specific Treg cells and maintain their proliferation through mTOR inhibitors.
It significantly increases the frequency and number of antigen-specific Treg cells, improves the therapeutic effect on autoimmune diseases, and provides long-term immune tolerance.
Smart Images

Figure CN119053336A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Patent Application Serial No. 63 / 312,452, filed on February 22, 2022, the contents of which are incorporated herein by reference in their entirety.
[0003] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0004] This invention was made with government support under R01NS122536 awarded by the National Institutes of Health. The government has certain rights in the invention.
[0005] Sequence Listing
[0006] The text of the computer-readable sequence listing submitted herewith, entitled "40287_601_SequenceListing," was created on February 22, 2023, with a file size of 722,461 bytes, which is hereby incorporated by reference in its entirety. Technical Field
[0007] The present invention relates to compositions comprising nanoparticles associated with or without one or more tolerogenic antigens, and compositions comprising immunomodulators (e.g., human interleukin-2 (IL-2), IL-2 muteins, IL-2 variants, or IL-2: anti-IL-2 antibody immune complexes (IL-2 / IC)), and related methods of co-administering such compositions for the purpose of inducing expansion of regulatory T cells (Tregs) (e.g., antigen-specific regulatory Tregs). The present invention also provides methods of treating autoimmune disorders by administering to a subject a composition comprising nanoparticles associated with or without one or more tolerogenic antigens associated with the autoimmune disorder prior to administering to the subject a composition comprising an immunomodulator. Background Art
[0008] Autoimmune disorders occur when the body's immune system attacks its own normal tissues, organs, or other body components due to an immune system abnormality for which no cause can be found. These autoimmune disorders are systemic and can occur in almost any part of the body, including the nervous system, gastrointestinal system, endocrine system, skin, skeletal system, and vascular tissue. Autoimmune disorders are known to affect approximately 5-8% of the world's population, but the reported prevalence of autoimmune disorders is lower than the actual level due to limitations in the understanding of autoimmune disorders and the methods used to diagnose these diseases.
[0009] There is a need for improved compositions and methods for treating autoimmune disorders.
[0010] The present invention addresses these needs. Summary of the invention
[0011] Experiments conducted during the development of embodiments of the present invention led to the development of new strategies for inducing high frequencies of antigen-specific Tregs in vivo without the need for ex vivo cell manipulation. Such experiments led to the development and optimization of new strategies for combining nanodiscs with modified IL-2 to elicit unprecedented levels of antigen-specific Tregs in vivo. Notably, IL-2: anti-IL-2 antibody (clone: JES6-1) immune complexes (IL-2 / IC) have been shown to selectively induce polyclonal Tregs
[14] . Administration of IL-2 / IC together with free peptide or peptide tetramers has been reported to induce antigen-specific Tregs [15, 16]. However, the results of these previous attempts were rather poor antigen-specific Treg responses, with antigen-specific Treg frequencies in the CD4+ T cell compartment being less than 0.25% [15, 16].
[0012] It is foreseeable that it would be ideal to deliver peptide antigens to lymphoid tissues together with IL-2 / IC to maximize antigen-specific Treg induction. The experiments described herein report for the first time that lymphatic-targeted nanodisc-mediated peptide delivery combined with IL-2 / IC resulted in a significant expansion of antigen-specific Tregs compared to IL-2 / IC alone.
[0013] It is also foreseeable that the actual treatment method will be crucial. Such experiments show that the nanodiscs are first ideally administered (e.g., subcutaneously), followed by systemic administration of IL-2 and / or mutant proteins / engineering IL-2. This ensures that antigen-specific Tregs are first prepared and generated, and then the administration of mutant proteins / engineering IL-2 triggers the strong proliferation of antigen-specific Tregs. It is further envisioned that the nanodiscs and / or mutant proteins / engineering IL-2 administered at a maintenance dose are used to maintain antigen-specific Tregs for a long time.
[0014] Thus, the present invention relates to compositions comprising nanoparticles associated (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, mixed) with or without one or more tolerogenic antigens, and compositions comprising immunomodulators (e.g., human interleukin-2 (IL-2), IL-2 muteins, IL-2 variants, or IL-2: anti-IL-2 antibody immune complexes (IL-2 / IC)), and to related methods of co-administering such compositions for the purpose of inducing expansion of regulatory T cells (Tregs) (e.g., antigen-specific regulatory Tregs). The present invention also provides methods of treating autoimmune disorders by administering to a subject a composition comprising nanoparticles associated with or without one or more tolerogenic antigens associated with the autoimmune disorder prior to administering to the subject a composition comprising an immunomodulator.
[0015] In certain embodiments, the present invention provides for the regulation of regulatory Tregs (e.g., CD4 + CD25 高 Foxp3 + ), comprising administering to the subject a composition comprising one or more nanoparticles, and subsequently administering to the subject (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.) a composition comprising one or more immunomodulators (e.g., IL-2, IL-2 mutant proteins, IL-2 variants, or IL-2 / IC) capable of expanding Tregs in the subject. In some embodiments, the composition comprising one or more nanoparticles is associated (e.g., compounded, conjugated, encapsulated, absorbed, adsorbed, mixed) with an mTOR inhibitor (e.g., rapamycin or a variant thereof). In some embodiments, antigen-specific regulatory Tregs (e.g., CD4 + CD25 高 Foxp3 + ) is specific for a particular tissue region (e.g., a particular tissue region associated with one or more autoimmune disorders).
[0016] In certain embodiments, the present invention provides regulatory Tregs (e.g., CD4 + CD25 高 Foxp3 +), comprising administering to the subject a composition comprising one or more nanoparticles associated with one or more tolerogenic antigens, and subsequently administering to the subject (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.) a composition comprising one or more immunomodulators (e.g., human cytokines (e.g., IL-2, IL-2 muteins, IL-2 variants, or IL-2 / IC)) capable of expanding antigen-specific Tregs, wherein "antigen specificity" is specific to the one or more tolerogenic antigens (which are associated with the nanoparticles comprising the one or more tolerogenic antigens). In some embodiments, antigen-specific regulatory Tregs (e.g., CD4 + CD25 高 Foxp3 + ) is specific for a particular tissue region (e.g., a particular tissue region associated with one or more autoimmune disorders).
[0017] In certain embodiments, the present invention provides a method for promoting strong immune tolerance to an antigen associated with an autoimmune disease in a subject (e.g., a human subject having an autoimmune disease or at risk of having an autoimmune disease), comprising administering to the subject a composition comprising one or more nanoparticles, and subsequently (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.), administering to the subject a composition comprising a Treg cell capable of expanding Tregs (e.g., CD4 + CD25 高 Foxp3 + ) is a composition comprising one or more immunomodulators (e.g., human cytokines (e.g., IL-2, IL-2 mutant proteins, IL-2 variants, or IL-2 / IC)) of a subject. In some embodiments, the composition comprising one or more nanoparticles is associated (e.g., compounded, conjugated, encapsulated, absorbed, adsorbed, mixed) with an mTOR inhibitor (e.g., rapamycin or a variant thereof). In some embodiments, promoting strong immune tolerance to antigens associated with autoimmune diseases in a subject is specific to a specific tissue region (e.g., a specific tissue region associated with one or more autoimmune diseases).
[0018] In certain embodiments, the invention provides a method for promoting strong immune tolerance to an antigen associated with an autoimmune disorder in a subject (e.g., a human subject having an autoimmune disorder or at risk of having an autoimmune disorder), comprising administering to the subject a composition comprising one or more nanoparticles associated with one or more tolerogenic antigens, and subsequently (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.), administering to the subject a composition comprising a nanoparticle capable of expanding antigen-specific Tregs (e.g., CD4 + CD25 高 Foxp3 + ), wherein the "antigen specificity" is specific for one or more tolerogenic antigens associated with the nanoparticles comprising the one or more tolerogenic antigens associated with the nanoparticles. In some embodiments, promoting strong immune tolerance to an antigen associated with an autoimmune disorder in a subject is specific for a specific tissue region (e.g., a specific tissue region associated with one or more autoimmune disorders).
[0019] In certain embodiments, the invention provides a method for increasing the ratio of CD3+FOXP3+ cells to CD3+FOXP3- cells in a T cell population in a subject (e.g., a human subject having an autoimmune disorder or at risk of having an autoimmune disorder), comprising administering to the subject a composition comprising one or more nanoparticles, and subsequently (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.) administering to the subject a composition comprising a nanoparticle capable of expanding Tregs (e.g., CD4 + CD25 高 Foxp3 + ) is a composition comprising one or more immunomodulators (e.g., human cytokines (e.g., IL-2, IL-2 mutant proteins, IL-2 variants, or IL-2 / IC)). In some embodiments, the composition comprising one or more nanoparticles is associated (e.g., compounded, conjugated, encapsulated, absorbed, adsorbed, mixed) with an mTOR inhibitor (e.g., rapamycin or a variant thereof). In some embodiments, increasing the ratio of CD3+FOXP3+ cells to CD3+FOXP3- cells in a T cell population in a subject is specific to a specific tissue region (e.g., a specific tissue region associated with one or more autoimmune diseases).
[0020] In certain embodiments, the invention provides a method for increasing the ratio of CD3+FOXP3+ cells to CD3+FOXP3- cells in a T cell population in a subject (e.g., a human subject having an autoimmune disorder or at risk of having an autoimmune disorder), comprising administering to the subject a composition comprising one or more nanoparticles associated with one or more tolerogenic antigens, and subsequently (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.) administering to the subject a composition comprising a nanoparticle capable of expanding antigen-specific Tregs (e.g., CD4 + CD25 高 Foxp3 + ), wherein "antigen specificity" is specific for one or more tolerogenic antigens associated with nanoparticles comprising the one or more tolerogenic antigens. In some embodiments, increasing the ratio of CD3+FOXP3+ cells to CD3+FOXP3- cells in a T cell population in a subject is specific for a particular tissue.
[0021] In certain embodiments, the present invention provides a method for treating, preventing and / or ameliorating a disorder, comprising administering to a subject (e.g., a human subject having an autoimmune disorder (e.g., celiac disease) or at risk of having an autoimmune disorder (e.g., celiac disease)), comprising administering to the subject a composition comprising one or more nanoparticles, and subsequently (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.) administering to the subject a composition comprising a Treg cell capable of expanding Tregs (e.g., CD4 + CD25 高 Foxp3 + ) is a composition comprising one or more immunomodulators (e.g., human cytokines (e.g., IL-2, IL-2 mutant proteins, IL-2 variants, or IL-2 / IC)) of a subject. In some embodiments, the composition comprising one or more nanoparticles is associated (e.g., compounded, conjugated, encapsulated, absorbed, adsorbed, mixed) with an mTOR inhibitor (e.g., rapamycin or a variant thereof). In some embodiments, the treatment, prevention, and / or alleviation of one or more autoimmune diseases of the subject is specific to a specific tissue region (e.g., a specific tissue region associated with an autoimmune disease).
[0022] In certain embodiments, the invention provides a method for treating, preventing, and / or ameliorating a disorder, comprising administering to a subject (e.g., a human subject having an autoimmune disorder (e.g., celiac disease) or at risk of having an autoimmune disorder (e.g., celiac disease)) a composition comprising one or more nanoparticles associated with one or more tolerogenic antigens (e.g., one or more tolerogenic antigens associated with an autoimmune disorder), and subsequently (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.) administering to the subject a composition comprising a nanoparticle capable of expanding antigen-specific Tregs (e.g., CD4 + CD25 高 Foxp3 + ), wherein the "antigen specificity" is specific for one or more tolerogenic antigens associated with the nanoparticles comprising the one or more tolerogenic antigens associated with the nanoparticles. In some embodiments, the treatment, prevention and / or alleviation of one or more disorders in the subject is specific for a specific tissue region (e.g., a specific tissue region associated with the disorder).
[0023] This approach is not limited to treating a specific condition.
[0024] In some embodiments, the disorder is an autoimmune disorder. Such methods are not limited to treating a specific autoimmune disorder. Examples of autoimmune disorders include, but are not limited to, multiple sclerosis (MS), celiac disease, rheumatoid arthritis, primary biliary cholangitis, primary sclerosing cholangitis, MOG antibody disease, diabetes (e.g., type 1 diabetes), thyroid autoimmune diseases (e.g., Hashimoto's thyroiditis, Graves' disease), thyroid-related eye and skin diseases, hypoparathyroidism, Addison's disease, premature ovarian failure, autoimmune hypophysitis, pituitary autoimmune diseases, immune gastritis, pernicious anemia, celiac disease, vitiligo, myasthenia gravis, pemphigus vulgaris, and the like. variants, bullous pemphigoid, dermatitis herpetiformis, Duling disease, epidermolysis bullosa acquisita, systemic sclerosis, mixed connective tissue disease, Sjögren's syndrome, systemic lupus erythematosus, Goodpasture's syndrome, rheumatic heart disease, autoimmune polyglandular syndrome type 1, Aicardi-Goutières syndrome, acute pancreatitis, age-dependent macular degeneration, alcoholic liver disease, liver fibrosis, metastasis, myocardial infarction, nonalcoholic steatohepatitis (NASH), Parkinson's disease, polyarthritis / fetal and neonatal anemia, sepsis, and inflammatory bowel disease.
[0025] In some embodiments, the disorder is a transplant-related disorder. In some embodiments, the disorder is one or more allergies. In some embodiments, the disorder is a respiratory disorder (e.g., asthma). In some embodiments, the disorder is graft-versus-host disease (GvHD).
[0026] In some embodiments, such a method (e.g., administering a composition comprising nanoparticles associated with one or more tolerogenic antigens, followed by administration of a composition comprising an immunomodulator capable of expanding Tregs) is further followed by administration of one or more tolerogenic antigens to a specific tissue region (e.g., a specific tissue region associated with one or more autoimmune diseases). In some embodiments, the administration of one or more tolerogenic antigens to the specific tissue region is performed by injection and / or topical administration and / or subcutaneous administration. In some embodiments, the administration of one or more tolerogenic antigens to the specific tissue region prevents immune tolerance in the specific tissue region.
[0027] In some embodiments, the nanoparticle is associated with an immunomodulator and is not associated with a tolerogenic antigen. In some embodiments, the nanoparticle is associated with a tolerogenic antigen and is further associated with an immunomodulator.
[0028] The methods described herein are not limited to a particular type or class of compositions comprising one or more immunomodulatory agents capable of expanding Tregs and / or antigen-specific Tregs.
[0029] In some embodiments, a composition comprising an immunomodulator capable of expanding Tregs is included within a nanoparticle such that the nanoparticle is associated with the immunomodulator capable of expanding Tregs (e.g., thereby providing a composition comprising nanoparticles associated with an immunomodulator capable of expanding Tregs).
[0030] Such embodiments are not limited to a particular immunomodulatory agent.
[0031] In some embodiments, the one or more immunomodulators are selected from the group consisting of: fingolimod; rapamycin; 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) or related ligands; trichostatin A; suberoylanilide hydroxamic acid (SAHA); statins; mTOR inhibitors; TGF-β signaling agents; TGF-β receptor agonists; histone deacetylase inhibitors; corticosteroids; mitochondrial function inhibitors; NF-κβ inhibitors; adenosine receptor agonists; prostaglandin E2 agonists (PGE2; phosphodiesterase inhibitors; proteasome inhibitors; kinase inhibitors; G protein-coupled receptor agonists; G protein-coupled receptor antagonists; glucocorticoids; retinoids; cytokine inhibitors; cytokine receptor inhibitors; cytokine receptor activators; peroxisome proliferator-activated receptor antagonists; peroxisome proliferator-activated receptor agonists; histone deacetylase inhibitors; calcineurin inhibitors; phosphatase inhibitors; PI3 KB inhibitors; autophagy inhibitors; aryl hydrocarbon receptor inhibitors; proteasome inhibitor I (PSI); oxidized ATP IDO; vitamin D3; cyclosporine; aryl hydrocarbon receptor inhibitors; resveratrol; azathioprine (Aza); 6-mercaptopurine (6-MP); 6-thioguanine (6-TG); FK506; sanglifehrin A; salmeterol; mycophenolate mofetil (MMF); aspirin and other COX inhibitors; niflumic acid; estriol; triptolide; OPN-305, OPN-401; eritoran (E5564); TAK-242; Cpn10; NI-0101; 1A6; AV411; IRS-954 (DV-1079); IMO-3100 ;CPG-52363;CPG-52364;OPN-305;ATNC05;NI-0101;IMO-8400;hydroxychloroquine;CU-CPT22;C29;ortho-vanillin;SSL3 protein;OPN-305;5SsnB;Vizantin;(+)-N-phenylethylnoroxymorphone;VB3323;monosaccharide 3;(+)-naltrexone and (+)-naloxone;HT52;HTB2;compound 4a;CNTO2424;TH1020;INH-ODN;E6446;AT791;CpG ODN 2088; ODN TTAGGG; COV08-0064; 2R9; GpG oligonucleotide; 2-aminopurine; Amiloxanol; Bay11-7082; BX795; CH-223191; Chloroquine; CLI-095; CU-CPT9a; Cyclosporine A; CTY387; Gefitinib; Glibenclamide; H-89; H-131; Isoliquiritigenin; MCC950; MRT67307; OxPAPC; Parthenolide; Pepinh-MYD; Pepinh-TRIF; Polymyxin B; R406; RU.521; VX-765; YM201636; Z-VAD-FMK; and AHR-specific ligands; including but not limited to 2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD); tryptamine (TA); and 6-formylindole [3,2b] carbazole (FICZ). .
[0032] In some embodiments, the immunomodulator is a cytokine. In some embodiments, the cytokine is a human cytokine. In some embodiments, the cytokine is selected from TGFβ, IL-1, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12A, IL12B, IL-15, IL-21 and IL-18.
[0033] In some embodiments, the immunomodulator is human IL-2. In some embodiments, the immunomodulator is low-dose IL-2. In some embodiments, the immunomodulator is PT101 or a variant thereof. In some embodiments, the immunomodulator is a mutant protein IL-2 and / or a variant thereof. In some embodiments, IL-2 is any one of the IL-2 cytokines, IL-2 mutant proteins and / or IL-2 variants described below: U.S. Patent Nos. 11,091,527, 11,091,526, 11,077,195, 11,077,172, 10,960,079, 10,946,068, 10,766,938, 10,722,460, 10,174,092, 10,174,091; European Patent No. 3808764 and / or U.S. Patent Application Publication No. US20120315245.
[0034] In some embodiments, the immunomodulator is IL-2:anti-IL-2 antibody immune complex (IL-2 / IC).
[0035] In some embodiments, IL-2 is IL-2 with extended pharmacokinetic (PK). In some embodiments, the IL-2 with extended PK includes a fusion protein. In some embodiments, the fusion protein includes an IL-2 portion and a portion selected from the group consisting of an immunoglobulin fragment, human serum albumin, and Fn3. In some embodiments, the fusion protein includes an IL-2 portion operably connected to an immunoglobulin Fc domain. In some embodiments, the fusion protein includes an IL-2 portion operably connected to human serum albumin. In some embodiments, the IL-2 with extended PK includes an IL-2 portion conjugated to a non-protein polymer. In some embodiments, the non-protein polymer is polyethylene glycol.
[0036] In some embodiments, the PK-extending IL-2 mutation results in an altered affinity (eg, higher affinity) for the IL-2Rα receptor compared to unmodified IL-2.
[0037] Site-directed mutagenesis can be used to isolate IL-2 mutants that exhibit high affinity binding to CD25 (i.e., IL-2Rα) compared to wild-type IL-2. Increasing the affinity of IL-2 for IL-2Rα on the cell surface will increase receptor occupancy within a limited range of IL-2 concentrations and increase the local concentration of IL-2 on the cell surface.
[0038] In some embodiments, IL-2 mutants are provided, which may be, but not necessarily, substantially purified and may be used as high-affinity CD25 binders (binders). IL-2 is a T cell growth factor that induces the proliferation of antigen-activated T cells and the stimulation of NK cells. Exemplary IL-2 mutants as high-affinity binders include those described in WO2013 / 177187A2. Other exemplary IL-2 mutants with increased affinity for CD25 are disclosed in U.S. Pat. No. 7,569,215, the contents of which are incorporated herein by reference.
[0039] In certain embodiments, a composition comprising an immunomodulator (e.g., a human cytokine (e.g., IL-2, IL-2 mutein, IL-2 variant, or IL-2 / IC)) is capable of expanding Treg cells in a subject or sample. In fact, such a composition comprising an immunomodulator is capable of increasing the ratio of Treg to non-regulatory T cells. The ratio can be measured by determining the ratio of CD3+FOXP3+ cells to CD3+FOXP3- cells in a T cell population. The typical frequency of Tregs in human blood is 5-10% of total CD4+CD3+T cells, however, in autoimmune diseases, this percentage may be lower or higher. In a preferred embodiment, the percentage of Treg increases by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1000%. For a particular disease, the maximum multiple increase of Treg may be different; however, the maximum Treg frequency that can be obtained by IL-2 mutant protein treatment is 50% or 60% of total CD4+CD3+T cells. In certain embodiments, a composition comprising an immunomodulator (e.g., a human cytokine (e.g., IL-2, IL-2 mutant protein, IL-2 variant or IL-2 / IC)) is administered to a subject, and the ratio of regulatory T cells (Treg) to non-regulatory T cells in the subject's peripheral blood increases.
[0040] The methods described herein are not limited to a particular composition comprising one or more nanoparticles associated with or not associated with one or more tolerogenic antigens.
[0041] Such compositions are not limited to specific nanoparticles. In some embodiments, the nanoparticles are sHDL nanoparticles. In some embodiments, the average size of the nanoparticles is between 6 and 500 nm (e.g., 7 to 20 nm, 21 to 50 nm, 51 to 100 nm, 101 to 200 nm, 201 to 300 nm, 301 to 400 nm, and 401 to 500 nm). In some embodiments, the average particle size of the sHDL nanoparticles is between 6-70 nm (e.g., 7 to 10 nm, 11 to 20 nm, 21 to 30 nm, 31 to 40 nm, 41 to 50 nm, 51 to 60 nm, and 61 to 70 nm).
[0042] In some embodiments, the phospholipid is selected from the group consisting of: 1,2-dilauroyl-sn-glycero-3-phosphocholine; 1,2-dimyristoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1,2-distearoyl-sn-glycero-3-phosphocholine; 1,2-diazaoyl-sn-glycero-3-phosphocholine; 1,2-dibehenoyl-sn-glycero-3-phosphocholine; 1,2-dilignoceroyl-sn-glycero-3-phosphocholine; 1,2-dimyristoleoyl-sn-glycero-3-phosphocholine; 1,2-dimyristoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1,2-distearoyl-sn-glycero-3-phosphocholine; 1,2-diazaoyl-sn-glycero-3-phosphocholine; 1,2-dibehenoyl-sn-glycero-3-phosphocholine; 1,2-dilignoceroyl-sn-glycero-3-phosphocholine; 1,2-dimyristoleoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; -sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1,2-dioleoyl-sn-glycero-3-phosphocholine; 1,2-dioleoyl-sn-glycero-3-phosphocholine; 1,2-diarachidonoyl-sn-glycero-3-phosphocholine; 1,2-dineuroyl-sn-glycero-3-phosphocholine; 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine; 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine; 1,2-dipentadecanoyl-sn-glycero-3-phosphoethanolamine; 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine 1,2-Di-stearoyl-sn-glycero-3-phosphoethanolamine; 1,2-dipalmitoleoyl-sn-glycero-3-phosphoethanolamine; 1,2-di-re-oleoyl-sn-glycero-3-phosphoethanolamine; 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; dioleoyl-sn-glycero-3-phosphoethanolamine-N-[3-(2-pyridyldithio)propionate]; 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine; 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidophenyl)butyramide]; 1,2-di-hexadecanoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p- Maleimidophenyl) butyramide]; 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidomethyl)cyclohexane-carboxamide]; 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidomethyl)cyclohexane-carboxamide]; N-[(3-maleimido-1-oxyylidenepropyl)aminopropylpolyethylene glycol-carbamoyl]distearoylphosphatidyl-ethanolamine; N-[(3-maleimido-1-oxyylidenepropyl)aminopropylpolyethylene glycol-carbamoyl]distearoylphosphatidyl-ethanolamine; Distearoyl-N-(3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine;N-[(3-maleimido-1-oxyylidenepropyl)aminopropyl polyethylene glycol-carbamoyl] distearoylphosphatidyl-ethanolamine; dimyristoyl-N-(3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine; dioleoyl-N-(3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine; dipalmitoyl-N-(3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine; 1-palmitoyl-2-oleoyl-N-(3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine; phosphatidylcholine; phosphatidylinositol; phosphatidylserine; phosphatidylethanolamine; distearoyl-N-(succinyl iminooxy-glutaryl)-L-α-phosphatidylethanolamine; dioleoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine; 1-palmitoyl-2-oleoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine; dipalmitoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine; dimyristoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine; 3-(N-succinimidyloxyglutaryl)aminopropyl and polyethylene glycol-carbamoyl distearoyl phosphatidyl-ethanolamine; N-(3-oxyylidenepropoxypolyethylene glycol)carbamoyl-distearoyl-ethanolamine. ;
[0043] In some embodiments, the HDL apolipoprotein component is selected from the group consisting of apolipoprotein AI (apo AI), apolipoprotein A-II (apo A-II), apolipoprotein A-II xxx (apo A-II-xxx), apolipoprotein A4 (apo A4), apolipoprotein Cs (apo Cs), apolipoprotein E (apo E), apolipoprotein AI milano (apo AI-milano), apolipoprotein AI paris (apoA-I-paris), apolipoprotein M (apoM), HDL apolipoprotein mimics, prepro apolipoproteins, prepro ApoA-I, pro ApoAI, prepro ApoA-II, pro ApoAII, prepro ApoA-IV, pro ApoA-IV, ApoA-V, prepro ApoE, pro ApoE, prepro ApoA I Milano , pro-ApoA-I Milano , Maehara ApoA-I Paris , pro-ApoA-I Paris and mixtures thereof.
[0044] In some embodiments, the ApoA-I mimetic is described by any of the following: SEQ ID NO: 1-336 and WDRVKDLATVYVDVLKDSGRDYVSQF (SEQ ID NO: 341), LKLLDNWDSVTSTFSKLREOL (SEQ ID NO: 342), PVTOEFWDNLEKETEGLROEMS (SEQ ID NO: 343), KDLEEVKAKVQ (SEQ ID NO: 344), KDLEEVKAKVO (SEQ ID NO: 345), PYLDDFQKKWQEEMELYRQKVE (SEQ ID NO: 346), PLRAELQEGARQKLHELOEKLS (SEQ ID NO: 347), PLGEEMRDRARAHVDALRTHLA (SEQ ID NO: 348), PYSDELRQRLAARLEALKENGG (SEQ ID NO: 349), ARLAEYHAKATEHLSTLSEKAK (SEQ ID NO: 350), PALEDLROGLL (SEQ ID NO: 351), PVLESFKVSFLSALEEYTKKLN (SEQ ID NO: 352), PVLESFVSFLSALEEYTKKLN (SEQ ID NO: 353), PVLESFKVSFLSALEEYTKKLN (SEQ ID NO: 352), TVLLLTICSLEGALVRRQAKEPCV (SEQ ID NO: 354), QTVTDYGKDLME (SEQ ID NO: 355), KVKSPELOAEAKSYFEKSKE (SEQ ID NO: 356), VLTLALVAVAGARAEVSADOVATV (SEQ ID NO: 357), NNAKEAVEHLOKSELTOOLNAL (SEQ ID NO: 358), LPVLVWLSIVLEGPAPAOGTPDVSS (SEQ ID NO: 359), LPVLVVVLSIVLEGPAPAQGTPDVSS (SEQ ID NO: 360), ALDKLKEFGNTLEDKARELIS (SEQ ID NO: 361), VVALLALLASARASEAEDASLL (SEQ ID NO: 362), HLRKLRKRLLRDADDLQKRLAVYOA (SEQ ID NO: 363), AQAWGERLRARMEEMGSRTRDR (SEQ ID NO: 364), LDEVKEQVAEVRAKLEEQAQ (SEQID NO:365), DWLKAFYDKVAEKLKEAF (SEQ ID NO:236), DWLKAFYDKVAEKLKEAFPDWAKAAYDKAAEKAKEAA (SEQ ID NO:366), PVLDLFRELLNELLEALKQKL (SEQ ID NO:367), PVLDLFRELLNELLEALKQKLA (SEQ ID NO:368) ,PVLDLFRELLNELLEALKQKLK (SEQ ID NO:4),PVLDLFRELLNELLEALKQKLA (SEQ ID NO:369),PVLDLFRELLNELLEALKKLLK (SEQ ID NO:370),PVLDLFRELLNELLEALKKLLA (SEQ ID NO:371),PLLDLFRELLNELLEALKKLLA (SEQ IDNo:372) and EVRSKLEEWFAAFREFAEEFLARLKS (SEQ ID NO:373).
[0045] In some embodiments, the one or more tolerogenic antigens is a plurality of tolerogenic antigens.
[0046] In some embodiments, the plurality of tolerogenic antigens is a tolerogenic antigen comprising: 3 amino acids to 50 amino acids in length (e.g., about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41, about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, or about 50 amino acids in length).
[0047] In some embodiments, the plurality of tolerogenic antigens are tolerogenic antigens comprising a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 375-796.
[0048] In some embodiments, the plurality of tolerogenic antigens are human allograft antigens. In some embodiments, the human allograft antigens are selected from subunits of various MHC class I and MHC class II haplotype proteins, and single amino acid polymorphisms on minor blood group antigens including RhCE, Kell, Kidd, Duffy, and Ss.
[0049] In some embodiments, the plurality of tolerogenic antigens are specific for type 1 diabetes. In some embodiments, the type 1 diabetes tolerogenic antigens are selected from insulin, proinsulin, preproinsulin, glutamic acid decarboxylase 65 (GAD-65), GAD-67, insulinoma-associated protein 2 (IA-2), insulinoma-associated protein 2β (IA-2β), ICA69, ICA12 (SOX-13), carboxypeptidase H, Imogen 38, GLIMA38, chromogranin A, HSP-60, carboxypeptidase E, peripherin, glucose transporter 2, hepatocarcinoma-enteric-pancreatic / pancreas-associated protein, S100β, glial fibrillary acidic protein, regeneration gene II, pancreatic duodenal homeobox 1, dystrophic myotonic kinase, islet-specific glucose-6-phosphatase catalytic subunit-associated protein, and SST G protein-coupled receptors 1-5.
[0050] In some embodiments, the tolerogenic antigen is specific for one or more of the following autoimmune diseases: rheumatoid arthritis, multiple sclerosis, primary biliary cholangitis, primary sclerosing cholangitis, MOG antibody disease, diabetes (e.g., type 1 diabetes), thyroid autoimmune diseases (e.g., Hashimoto's thyroiditis, Graves' disease), thyroid-related eye and skin diseases, hypoparathyroidism, Addison's disease, premature ovarian failure, autoimmune hypophysitis, pituitary autoimmune diseases, immune gastritis, pernicious anemia, celiac disease, vitiligo, myasthenia gravis, Pemphigus vulgaris and its variants, bullous pemphigoid, dermatitis herpetiformis, Duling disease, epidermolysis bullosa acquisita, systemic sclerosis, mixed connective tissue disease, Sjögren's syndrome, systemic lupus erythematosus, Goodpasture's syndrome, rheumatic heart disease, autoimmune polyglandular syndrome type 1, Aicardi-Goutières syndrome, acute pancreatitis, age-dependent macular degeneration, alcoholic liver disease, liver fibrosis, metastasis, myocardial infarction, non-alcoholic steatohepatitis (NASH), Parkinson's disease, polyarthritis / fetal and neonatal anemia, sepsis and inflammatory bowel disease.
[0051] In some embodiments, the plurality of tolerogenic antigens include one or more of the tolerogenic antigens selected from the group consisting of thyroglobulin (TG), thyroid peroxidase (TPO), thyroid stimulating hormone receptor (TSHR), sodium iodide transporter (NIS), megalin, thyroid autoantigens including TSHR, insulin-like growth factor 1 receptor, calcium sensing receptor, 21-hydroxylase, 17α-hydroxylase and P450 side chain cleavage enzyme (P450scc), ACTH receptor, P450c21, P450c17, FSH receptor, α-enolase, pituitary-specific protein factor (PGSF) 1a and 2, and type 2 iodothyronine deiodinase, myelin basic protein, myelin oligodendrocyte glycoprotein, proteolipid protein, collagen II, H + , K + -ATPase, tissue transglutaminase and gliadin, tyrosinase, tyrosinase-related proteins 1 and 2, acetylcholine receptor, desmocollins 3, 1 and 4, pemphaxin, desmocollins, plakoglobin, perifocalin, desmoplakin, acetylcholine receptor, BP180, BP230, plectin, laminin 5, endomysium, tissue transglutaminase, collagen VII, matrix metalloproteinases 1 and 3, collagen-specific chaperone heat-shock protein 47, fibrillin 1, PDGF receptor, Scl-70, U1 RNP, Th / To, Ku, Jo1, NAG-2, centromere proteins, topoisomerase I, nucleolar proteins, RNA polymerases I, II and III, PM-Slc, fibrillarin, B23, U1snRNP, nuclear antigens SS-A and SS-B, cytosolic proteins, poly (ADP-ribose) polymerase, topoisomerase, nuclear proteins including SS-A, high mobility group protein B1 (HMGB1), nucleosomes, histones, double-stranded DNA, glomerular basement membrane proteins including collagen IV, cardiac myosin, aromatic L-amino acid decarboxylase, histidine decarboxylase, cysteine sulfenic acid decarboxylase, tryptophan hydroxylase, tyrosine hydroxylase, phenylalanine hydroxylase, hepatic P450 cytochromes P450 1A2 and 2A6, SOX-9, SOX-10, calcium-sensing receptor protein, and type 1 interferons interferon alpha, beta, and omega.
[0052] Such compositions are not limited to specific tolerogenic antigens. In some embodiments, the tolerogenic antigen is a foreign antigen against which the patient has generated an undesirable immune response. In some embodiments, a plurality of tolerogenic antigens are specific for celiac disease. In some embodiments, the tolerogenic antigen is selected from gliadins, glutenins, and fragments thereof capable of inducing an immune response. In some embodiments, the tolerogenic antigen is selected from gliadins (e.g., α-, γ-, and ω-gliadins) or fragments thereof. In some embodiments, the tolerogenic antigen is selected from the group consisting of α, γ, and ω gliadins or fragments thereof. In some embodiments, the tolerogenic antigen comprises a polypeptide having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%) sequence identity with the polypeptide sequence of any one of SEQ ID NOs: 375-580. In some embodiments, the tolerogenic antigen comprises a polypeptide having at least 95% (e.g., 96%, 97%, 98%, 99%, or 100%) sequence identity to any of the polypeptide sequences of SEQ ID NOs: 375-580. In some embodiments, the tolerogenic antigen comprises a polypeptide having a polypeptide sequence of any of SEQ ID NOs: 375-580. In some embodiments, the tolerogenic antigen comprises two or more (e.g., two, three, four, five, and six) polypeptide sequences having a sequence of any of SEQ ID NOs: 375-580.
[0053] In some embodiments, the tolerogenic antigen is an autoantigen to which a subject (e.g., a human patient) has generated an autoimmune response or may generate an autoimmune response. Examples include proinsulin (e.g., for subjects with diabetes or at risk of diabetes), collagen (e.g., for subjects with rheumatoid arthritis or at risk of rheumatoid arthritis), and myelin basic protein (e.g., for subjects with multiple sclerosis or at risk of multiple sclerosis). There are many proteins that are human autoimmune proteins, a term that refers to various autoimmune diseases in which one or more proteins causing the disease are known or can be determined by conventional tests. Embodiments include testing patients to identify autoimmune proteins and generating antigens for molecular fusion and generating immune tolerance to the protein. Embodiments include antigens, or selecting antigens from one or more of the following proteins. In type 1 diabetes, several major antigens have been identified: insulin, proinsulin, preproinsulin, glutamic acid decarboxylase-65 (GAD-65), GAD-67, insulinoma-associated protein 2 (IA-2), and insulinoma-associated protein 2β (IA-2β); others include ICA69, ICA12 (SOX-13), carboxypeptidase H, Imogen 38, GLIMA38, chromogranin A, HSP-60, carboxypeptidase E, peripherin, glucose transporter 2, hepatocarcinoma-entero-pancreatic / pancreas-associated protein, S100β, glial fibrillary acidic protein, regeneration gene II, pancreatic duodenal homeobox 1, dystrophic myotonic kinase, islet-specific glucose-6-phosphatase catalytic subunit-associated protein, and SSTG protein-coupled receptors 1-5. In thyroid autoimmune diseases, including Hashimoto's thyroiditis and Graves' disease, the major antigens include thyroglobulin (TG), thyroid peroxidase (TPO), and thyroid-stimulating hormone receptor (TSHR); other antigens include the sodium-iodide transporter (NIS) and megalin. In thyroid-related eye and skin diseases, in addition to thyroid autoantigens including TSHR, the antigen is the insulin-like growth factor 1 receptor. In hypoparathyroidism, the major antigen is the calcium-sensing receptor. In Addison's disease, the major antigens include 21-hydroxylase, 17α-hydroxylase, and P450 side-chain cleavage enzyme (P450scc); other antigens include ACTH receptor, P450c21, and P450c17. In premature ovarian failure, the major antigens include FSH receptor and α-enolase. In autoimmune hypophysitis or pituitary autoimmune diseases, the major antigens include pituitary-specific protein factor (PGSF) 1a and 2; another antigen is type 2 iodothyronine deiodinase. In multiple sclerosis, the major antigens include myelin basic protein, myelin oligodendrocyte glycoprotein, and proteolipid protein. In rheumatoid arthritis, the major antigen is collagen II. In immune gastritis, the major antigen is H +, K + -ATPase. In pernicious anemia, the major antigen is intrinsic factor. In celiac disease, the major antigens are tissue transglutaminase and gliadin. In vitiligo, the major antigens are tyrosinase, and tyrosinase-related proteins 1 and 2. In myasthenia gravis, the major antigen is the acetylcholine receptor. In pemphigus vulgaris and variants, the major antigens are desmocollins 3, 1, and 4; other antigens include annexins (pemphaxin), desmocollins, plakoglobin, perifollicular proteins, desmoplakin, and acetylcholine receptors. In bullous pemphigoid, the major antigens include BP180 and BP230; other antigens include plectin and laminin 5. In dermatitis herpetiformis Duling disease, the major antigens include endomysial and tissue transglutaminase. In epidermolysis bullosa acquisita, the major antigen is collagen VII. In systemic sclerosis, the major antigens include matrix metalloproteinases 1 and 3, the collagen-specific chaperone heat-shock protein 47, fibrillin 1, and the PDGF receptor; other antigens include Scl-70, U1 RNP, Th / To, Ku, Jo1, NAG-2, centromere proteins, topoisomerase I, nucleolar proteins, RNA polymerases I, II, and III, PM-Slc, fibrillin, and B23. In mixed connective tissue disease, the major antigen is U1snRNP. In Sjögren's syndrome, the major antigens are the nuclear antigens SS-A and SS-B; other antigens include cytosolic proteins, poly(ADP-ribose) polymerase, and topoisomerase. In systemic lupus erythematosus, the major antigens include nuclear proteins, including SS-A, high-mobility group protein B1 (HMGB1), nucleosomes, histones, and double-stranded DNA. In Goodpasture's syndrome, the major antigens include glomerular basement membrane proteins containing collagen IV. In rheumatic heart disease, the major antigen is cardiac myosin. Other autoantigens found in type 1 autoimmune polyglandular syndrome include aromatic L-amino acid decarboxylase, histidine decarboxylase, cysteine sulfenic acid decarboxylase, tryptophan hydroxylase, tyrosine hydroxylase, phenylalanine hydroxylase, hepatic P450 cytochromes P450 1A2 and 2A6, SOX-9, SOX-10, calcium-sensing receptor protein, and type 1 interferons interferon alpha, beta, and omega.
[0054] In some cases, the tolerogenic antigen is a foreign antigen against which the patient has developed an undesirable immune response. An example is a food antigen. Embodiments include testing the patient to identify the foreign antigen and generating a molecule fusion comprising the antigen and treating the patient to develop immune tolerance to the antigen or food. Examples of such foods and / or antigens are provided. Examples are from peanut: conarachin (Ara h 1), allergen II (Ara h 2), peanut agglutinin, conglutin (Ara h 6); from apple: 31 kDa major allergen / disease resistance protein homolog (Mal d 2), lipid transfer protein precursor (Mal d 3), major allergen Mal d 1.03D (Mal d 1); from milk: α-lactalbumin (ALA), lactotransferrin; from kiwifruit: actinidin (Act c 1, Act d 1), phytocystatin, thaumatin-like protein (Act d 2), kiwellin (Act d 5); from mustard: 2S albumin (Sin a 1), 11S globulin (Sin a 2), lipid transfer protein (Sin a 3), inhibitor protein (Sina 4); from celery: inhibitory protein (Api g 4), high molecular weight glycoprotein (Api g 5); from shrimp: Pen a 1 allergen (Pen a 1), allergen Pen m 2 (Pen m 2), tropomyosin fast isomer; from wheat and / or other cereals: high molecular weight glutenin, low molecular weight glutenin, α- and γ-gliadins, hordeins, secalins, avenins; from strawberries: major strawberry allergy Fra a 1-E (Fra a 1), from banana: inhibitory protein (Musxp 1).
[0055] In some embodiments, the tolerogenic antigen is a multimeric tolerogenic antigen comprising the following N-terminal to C-terminal structure:
[0056] (P4-L4) n4 -(P3-L3) n3 -P2-(L1-P1) n1
[0057] Among them, P1, P2, P3 and P4 are each independently a tolerogenic antigen;
[0058] L1, L3 and L4 are each independently a linker; and
[0059] n1, n3 and n4 are each independently 0 or 1, wherein at least one of n1, n3 and n4 is 1.
[0060] In some embodiments, n1 is 1, n3 is 0, and n4 is 0, and the tolerogenic antigen comprises the following N-terminal to C-terminal structure:
[0061] P2-L1-P1.
[0062] In some embodiments, L1 is a peptide linker comprising: 2 to 200 amino acids (e.g., 5 to 50 (e.g., 5 to 20, 15 to 30, 25 to 40, or 35 to 50), 45 to 100 (e.g., 45 to 60, 55 to 70, 65 to 80, 75 to 90, or 85 to 100), 95 to 150 (e.g., 95 to 110, 105 to 120, 115 to 130, 125 to 140, or 135 to 150), or 145 to 200 amino acids (e.g., 145 to 160, 155 to 170, 165 to 180, 175 to 190, or 185 to 200). In some embodiments, L1 is a peptide linker comprising glycine (G) and serine (S) residues. In some embodiments, L1 is a peptide linker comprising (GS) x 、(GGS) x or (GGGGS) x In some embodiments, P1 and P2 each comprise a different tolerogenic antigen. In some embodiments, P1 and P2 each comprise the same tolerogenic antigen.
[0063] In some embodiments, n1 is 1, n3 is 1, and n4 is 0, and the tolerogenic antigen comprises the following N-terminal to C-terminal structure:
[0064] P3-L3-P2-L1-P1.
[0065] In some embodiments, L1 and L3 are each independently selected peptide linkers comprising 2 to 200 amino acids (e.g., 5 to 50 (e.g., 5 to 20, 15 to 30, 25 to 40, or 35 to 50), 45 to 100 (e.g., 45 to 60, 55 to 70, 65 to 80, 75 to 90, or 85 to 100), 95 to 150 (e.g., 95 to 110, 105 to 120, 115 to 130, 125 to 140, or 135 to 150), or 145 to 200 amino acids (e.g., 145 to 160, 155 to 170, 165 to 180, 175 to 190, or 185 to 200). In some embodiments, L1 and L3 are each independently selected peptide linkers comprising glycine (G) and serine (S) residues. In some embodiments, L1 and L3 are each independently selected peptide linkers comprising (GS) x、(GGS) x or (GGGGS) x In some embodiments, P1, P2 and / or P3 each comprise a different tolerogenic antigen. In some embodiments, P1, P2 and P3 each comprise the same tolerogenic antigen.
[0066] In some embodiments, n1 is 1, n3 is 1, and n4 is 1, and the tolerogenic antigen comprises the following N-terminal to C-terminal structure:
[0067] P4-L4-P3-L3-P2-L1-P1.
[0068] In certain embodiments, L1 and L2 are each independently selected peptide linkers comprising 2 to 200 amino acids (e.g., 5 to 50 (e.g., 5 to 20, 15 to 30, 25 to 40, or 35 to 50), 45 to 100 (e.g., 45 to 60, 55 to 70, 65 to 80, 75 to 90, or 85 to 100), 95 to 150 (e.g., 95 to 110, 105 to 120, 115 to 130, 1 25 to 140 or 135 to 150), or 145 to 200 amino acids (e.g., 145 to 160, 155 to 170, 165 to 180, 175 to 190, or 185 to 200). In some embodiments, L1, L2, and L3 are each independently selected peptide linkers comprising glycine (G) and serine (S) residues. In some embodiments, L1, L2, and L3 are each independently selected peptide linkers comprising (GS) x 、(GGS) x or (GGGGS (SEQ ID NO: 219)) x In some embodiments, P1, P2, P3 and / or P4 each comprise a different tolerogenic antigen. In some embodiments, P1, P2, P3 and P4 each comprise the same tolerogenic antigen.
[0069] In some embodiments, the number of tolerogenic antigens associated with a particular nanoparticle comprises a population of 1 to 30 (e.g., 1-10, 9 to 15, 12 to 18, 15 to 22, 18 to 25, 20 to 27, 22 to 28, or 25 to 30) tolerogenic antigens per nanoparticle. In some embodiments, the number of tolerogenic antigens associated with a particular nanoparticle comprises a population of 6 tolerogenic antigens per particle. In some embodiments, the number of tolerogenic antigens associated with a particular nanoparticle comprises a population of 8 tolerogenic antigens per particle. In some embodiments, the population of tolerogenic antigens associated with a particular nanoparticle is the same antigen. In some embodiments, the population of tolerogenic antigens associated with a particular nanoparticle comprises 1 to 5 (e.g., 2, 3, 4, and 5) different tolerogenic antigens. In some embodiments, the population of tolerogenic antigens associated with a particular nanoparticle comprises 3 to 4 different tolerogenic antigens. In some embodiments, the population of tolerogenic antigens is specific for 1 to 3 different diseases. In some embodiments, the population of tolerogenic antigens is specific for the same disease.
[0070] In some embodiments, the population of tolerogenic antigens associated with specific nanoparticles includes: (i) a first polypeptide population including an amino acid sequence of any one of SEQ ID NOs: 406-588, or a biologically active fragment or variant thereof, (ii) a second polypeptide population including an amino acid sequence of any one of SEQ ID NOs: 406-588, or a biologically active fragment or variant thereof, and (iii) a third polypeptide population including an amino acid sequence of any one of SEQ ID NOs: 406-588, or a biologically active fragment or variant thereof.
[0071] In some embodiments, the first polypeptide population includes the amino acid sequence of SEQ ID NO: 474, or a biologically active fragment or variant thereof, (ii) the second polypeptide population includes the amino acid sequence of any one of SEQ ID NO: 406-588, or a biologically active fragment or variant thereof, and (iii) the third polypeptide population includes the amino acid sequence of any one of SEQ ID NO: 406-588, or a biologically active fragment or variant thereof.
[0072] In some embodiments, the population of tolerogenic antigens associated with specific nanoparticles includes: (i) a first polypeptide population including an amino acid sequence of SEQ ID NO: 474, or a biologically active fragment or variant thereof, (ii) a second polypeptide population including an amino acid sequence of SEQ ID NO: 475, or a biologically active fragment or variant thereof, and (iii) a third polypeptide population including an amino acid sequence of any one of SEQ ID NOs: 406-588, or a biologically active fragment or variant thereof. In some embodiments, the third polypeptide population includes an amino acid sequence of SEQ ID NO: 476, or a biologically active fragment or variant thereof. In some embodiments, the second polypeptide population includes an amino acid sequence of SEQ ID NO: 477, or a biologically active fragment or variant thereof, and / or the third polypeptide population includes an amino acid sequence of SEQ ID NO: 478, or a biologically active fragment or variant thereof.
[0073] In some embodiments, the tolerogenic antigen comprises a polypeptide having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%) sequence identity to the polypeptide sequence of SEQ ID NO: 374. In some embodiments, the tolerogenic antigen comprises the polypeptide sequence of SEQ ID NO: 374. In some embodiments, the tolerogenic antigen comprises a fragment of SEQ ID NO: 373 comprising a length of 6-12 (e.g., 7, 8, 9, 10, 11, and 12) amino acid residues.
[0074] In some embodiments, the tolerogenic antigen comprises an amide group at the C-terminus. In some embodiments, the tolerogenic antigen comprises a pyroglutamic acid residue at the N-terminus. In another embodiment, the tolerogenic antigen comprises an acetyl group at the N-terminus. In some embodiments, the tolerogenic antigen comprises a pyroglutamic acid residue at the N-terminus and an amide group at the C-terminus. In some embodiments, the tolerogenic antigen comprises an acetyl group at the N-terminus and an amide group at the C-terminus. In some embodiments, the tolerogenic antigen comprises an N-terminus or a C-terminus modified with a cysteine residue bound to a linker. In some embodiments, the tolerogenic antigen comprises an N-terminus and a C-terminus modified with a cysteine residue bound to a linker.
[0075] In some embodiments of any of the compositions described herein, a population of tolerogenic antigens is conjugated to the nanoparticle phospholipids in a manner such that strong immune tolerance is promoted upon administration to a subject (e.g., a human subject having or at risk of having an autoimmune disorder such as MS, celiac disease, rheumatoid arthritis, primary biliary cholangitis, primary sclerosing cholangitis, MOG antibody disease, diabetes (e.g., type 1 diabetes), thyroid autoimmune disease (e.g., Hashimoto's thyroiditis, Graves' disease), thyroid-related eye and skin diseases, hypoparathyroidism, Addison's disease, premature ovarian failure, autoimmune hypophysitis, pituitary autoimmunity, diseases, immune gastritis, pernicious anemia, celiac disease, vitiligo, myasthenia gravis, pemphigus vulgaris and its variants, bullous pemphigoid, dermatitis herpetiformis, Duling disease, epidermolysis bullosa acquisita, systemic sclerosis, mixed connective tissue disease, Sjögren's syndrome, systemic lupus erythematosus, Goodpasture's syndrome, rheumatic heart disease, autoimmune polyglandular syndrome type 1, Aicardi-Goutières syndrome, acute pancreatitis, age-dependent macular degeneration, alcoholic liver disease, liver fibrosis, metastasis, myocardial infarction, non-alcoholic steatohepatitis (NASH), Parkinson's disease, polyarthritis / fetal and neonatal anemia, sepsis and inflammatory bowel disease).
[0076] In some embodiments, multiple tolerogenic antigens are conjugated to the nanoparticle phospholipids via thiol-reactive and reduction-insensitive bonds between the tolerogenic antigens and the nanoparticle phospholipids. Indeed, the thiol-reactive and reduction-insensitive bonds between the tolerogenic antigens and the nanoparticle phospholipids promote strong immune tolerance. In some embodiments, the phospholipid is N-(3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine.
[0077] In some embodiments, the tolerogenic antigen is conjugated to the nanoparticle phospholipid via an amine-mediated interaction (e.g., dioleoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine (DOPE-NHS)). In some embodiments, the amine-mediated interaction is dioleoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine (DOPE-NHS). In some embodiments, the amine-mediated interaction is through an amine-reactive phospholipid with a self-destructive bond (e.g., a linker comprising an o-dithiobenzyl, p-dithiobenzyl, β-dithiobenzylcarbamate moiety, 2,2-dimethyl-4-mercapto-butyric acid, or a disulfide-carbonate / salt-based traceless linker).
[0078] In some embodiments, the composition does not include an adjuvant.
[0079] In certain embodiments, compositions comprising one or more immunomodulatory agents are provided.
[0080] Additional embodiments will be apparent to persons skilled in the relevant arts based on the teachings contained herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0081] Figure 1 Analysis of HDL nanodiscs by dynamic light scattering. Shown are the hydrodynamic size, polydispersity index (PDI), and intensity and volume distribution of nanodiscs before and after loading with OVA-II peptide.
[0082] Figure 2 . Analysis of Nanodisc-OVA-II by LC-MS. Shown are the chromatograms before and after conjugation of DOPE-MAL to OVA-II peptide, the conjugation efficiency of DOPE-MAL to OVA-II peptide, and the loading efficiency of DOPE-OVA-II in nanodiscs.
[0083] Figure 3 Blank nanodiscs and nanodisc-OVA-II were analyzed by GPC. Shown are their chromatograms.
[0084] Figure 4 .Schematic diagram of the treatment regimen of ND-OVA-II combined with IL-2 / IC therapy.
[0085] Figure 5 PBMCs were analyzed by flow cytometry on day 7. Shown are representative dot plots. Numbers in the plots represent the frequency of the parent gate.
[0086] Fig. 6A-F PBMCs were analyzed by flow cytometry on day 7. Shown are a) CD4 + % of T cells, b) CD4 in PBMC + OT-II tetramers in T cells + % of T cells, c) CD4 + Foxp3 in T cells + CD25 + T reg %, d) CD4 + OT-II tetramers in T cells + Foxp3 + CD25 + T reg % e) Foxp3 + CD25 + T reg Mean fluorescence intensity (MFI) of CD25 in the PD-1 cell line, and f) OT-II tetramer+ Foxp3 + CD25 + T reg MFI of CD25 in medium.
[0087] Figure 7 PBMCs were analyzed by flow cytometry on day 14. Shown are representative dot plots. Numbers in the plots represent the frequency of the parent gate.
[0088] Figure 8A-F PBMCs were analyzed by flow cytometry on day 14. Shown are a) CD4 + % and number of T cells, b) CD4 + OT-II tetramers in T cells + % and number of T cells, c) CD4 + Foxp3 in T cells + CD25 + T reg % and number, d) CD4 + OT-II tetramers in T cells + Foxp3 + CD25 + T reg %, e) MFI of CD25 and f) Foxp3 + CD25 + T reg and OT-II tetramer + Foxp3 + CD25 + T reg GITR in.
[0089] Figure 9A-C . Shown are peripheral CD4 on days 7 and 14 + a) Total Foxp3 in T cells + CD25 + T reg , b) OT-II tetramer + Foxp3 + CD25 + T reg , and c) OT-II tetramer + Foxp3 - CD25 + T conv changes.
[0090] Fig.10 .Schematic representation of the treatment regimen of ACT+ND-OVA-II combined with IL-2 / IC therapy followed by antigen challenge in the ear on day 25.
[0091] Figure 11A-C Ear tissues were analyzed by flow cytometry 24 hours after intradermal challenge with MOG or OVA-II peptide in the left or right ear, respectively. Shown are a) CD4 + The number of cells, b) CD4 + CD25 + Foxp3 + The number of cells, and c) CD25 + Foxp3 + OT-II tetramer + The number of cells.
[0092] Fig.12 Schematic diagram of the treatment regimen of ND-OVA-II combined with wild-type IL-2 (wtIL-2) or IL-2 / IC. The first dose of ND-OVA-II was given on day -4, day -3, or day -1, and three doses of IL-2 / IC or five doses of wtIL-2 were given daily starting from day 0. The same regimen was repeated ten days after the initial date for each group.
[0093] Fig. 13A-D CD4 T cells from peripheral blood were analyzed by flow cytometry on days 5, 10, and 15 after IL-2 or IL-2 / IC treatment. + T cells. Shown are a) CD3 + CD4 + The frequency of cells, b) CD4 + CD25 in T cells + Foxp3 + The frequency of Treg cells, c) CD4 + OT-II tetramers in T cells + CD44 hi The frequency of cells, and d) CD25 + Foxp3 + OT-II tetramers in Treg cells + CD44 hi The frequency of cells.
[0094] Fig. 14A-F CD8 T cells from peripheral blood were analyzed by flow cytometry on days 5, 10, and 15 after IL-2 or IL-2 / IC treatment. + T cells and NK cells. Shown are a) CD3 + CD8 + The frequency of cells, c) CD8 + CD44 in T cells hi The frequency of cells, e) CD3 -SSC 低 CD49b + Frequency of NK cells in 2 mL of blood b) CD8 + T cells, d) CD8 + CD44hi T cells, and f) SSC 低 CD49b + The number of NK cells.
[0095] Figure 15A-C .A) Schematic diagram of the treatment regimen of ACT+ND combined with IL-2 / IC therapy. Six days after the last IL-2 treatment, mice were transplanted with 3 million pre-activated BDC splenocytes and 3 million pre-activated NY8.3 splenocytes via retro-orbital injection. Diabetes incidence was detected via OneTouch Ultra 2. B) Mice were treated with p31-ND or p31-ND+IL-2 / IC combination. C) Mice were treated with InsB-ND and InsC-ND or InsB-ND+InsC-ND+IL-2 / IC combination.
[0096] definition
[0097] The term "about" is used herein to refer to a value of ± 10% of the stated value.
[0098] As used herein, "administration" means a method of administering a dose of a composition described herein (e.g., a nanoparticle or a nanoparticle associated with an antigen) (e.g., an immunomodulator) to a subject. The composition used in the methods described herein can be administered by any suitable route, including, for example, by inhalation, atomization, aerosolization, intranasal, intratracheal, intrabronchial, oral, parenteral (e.g., intravenous, subcutaneous or intramuscular), oral, nasal, rectal, topical or oral. The composition used in the methods described herein can also be administered topically or systemically. The preferred method of administration can vary depending on various factors (e.g., the components of the composition administered, and the severity of the condition being treated).
[0099] As used herein, the term "associated with..." refers to the state of two or more entities (e.g., nanoparticles and one or more immunomodulators) connected by direct or indirect covalent or non-covalent interactions. In some embodiments, the association is covalent. In some embodiments, the covalent association is mediated by a linker portion. In some embodiments, the association is non-covalent (e.g., charge interaction, affinity interaction, metal coordination, physical adsorption, host-guest interaction, hydrophobic interaction, TT stacking interaction, hydrogen bond interaction, van der Waals interaction, magnetic interaction, electrostatic interaction, dipole-dipole interaction, etc.). For example, in some embodiments, the immunomodulator is mixed with nanoparticles. In some embodiments, the immunomodulator is conjugated with nanoparticles. In some embodiments, the immunomodulator is encapsulated in nanoparticles. In some embodiments, the immunomodulator is absorbed into nanoparticles. In some embodiments, the immunomodulator is adsorbed onto nanoparticles. In some embodiments, the immunomodulator is mixed with nanoparticles.
[0100] As used herein, the term "absorbed" refers to a biomacromolecular agent (eg, an antigen) being absorbed and stably retained within the interior, ie, the outer surface, of a nanoparticle and / or microparticle.
[0101] As used herein, the term "mixed" refers to a biomacromolecule (eg, antigen) dissolved, dispersed, or suspended in a nanoparticle and / or microparticle. In some cases, the biomacromolecule may be uniformly mixed in the nanoparticle and / or microparticle.
[0102] As used herein, the term "adsorption" refers to the attachment of a biomacromolecule (e.g., an antigen) to the outer surface of a nanoparticle and / or microparticle. Such adsorption preferably occurs through electrostatic attraction. Electrostatic attraction is the attraction or bonding generated between two or more oppositely charged or ionic chemical groups. In general, adsorption is usually reversible.
[0103] As used herein, the term "mutant protein" is intended to include proteins and polypeptides with altered amino acid sequences, and which are produced by mutation or recombinant DNA processes. As used herein, the term "IL-2 mutant protein molecule" or "IL-2 mutant protein" refers to an IL-2 variant that preferentially activates Treg cells.
[0104] As used herein, the term "antigenic determinant" is synonymous with "antigen" and "epitope", and refers to a site on a polypeptide macromolecule (e.g., a continuous stretch of amino acids or a conformational configuration consisting of different regions of non-continuous amino acids) with which an antigen binding portion forms an antigen binding portion-antigen complex. Useful antigenic determinants can be found, for example, on the surface of tumor cells, on the surface of virus-infected cells, on the surface of other diseased cells, on the surface of immune cells, free in serum and / or in the extracellular matrix (ECM). The protein referred to herein as an antigen can be a full-length 33-mer polypeptide from α-gliadin (SEQ ID NO: 374) or any fragment thereof or disclosed as CD4 in Table 3. + Any polypeptide of an epitope recognized by a T cell (SEQ ID NO: 375-405). When referring to a particular protein in this article, the term includes "full-length", unprocessed protein and any form of the protein produced by processing in the cell. The term also includes variants of naturally occurring proteins, such as splice variants or allelic variants.
[0105] As used herein, the terms "autoimmune disorder" and "autoimmune disease," which are used interchangeably herein, refer to a medical condition in which a subject's immune system mistakenly attacks the subject's own body.
[0106] As used herein, "combination therapy" or "combination administration" means that two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) different agents or treatments are administered to a subject as part of a determined treatment regimen for a specific disease or condition (e.g., an autoimmune disorder (e.g., MS or celiac disease)). The treatment regimen defines the dosage and cycle of each agent so that the effects of different agents on the subject overlap. In some embodiments, the delivery of two or more agents is simultaneous or concurrent, and the agents can be co-formulated. In some embodiments, two or more agents are not co-formulated and are administered in a sequential manner as part of a prescribed regimen. In some embodiments, the combined administration of two or more agents or treatments results in a greater reduction in symptoms or other parameters associated with the disorder than observed with one agent or treatment alone or in the absence of another. The effects of the two treatments can be partially additive, fully additive, or greater than additive (e.g., synergistic). Sequential administration or substantially simultaneous administration of each therapeutic agent can be achieved by any suitable route, including but not limited to by inhalation, nebulization, aerosolization, intranasal, intratracheal, intrabronchial, oral, parenteral (e.g., intravenous, subcutaneous or intramuscular), oral, nasal, rectal, topical, buccal or direct absorption through mucosal tissue. The therapeutic agents can be administered by the same route or different routes. For example, the first therapeutic agent of the combination can be administered by intravenous injection, while the second therapeutic agent of the combination can be administered orally.
[0107] As used herein, the term "complexed" as used herein relates to the non-covalent interaction of a biomacromolecular agent (eg, an antigen) with a nanoparticle and / or microparticle.
[0108] As used herein, the term "conjugated" as used herein refers to a covalent bond association between a biomacromolecular agent (eg, an antigen) and a nanoparticle and / or microparticle.
[0109] As used herein, the term "drug" or "therapeutic agent" is intended to include any molecule, molecular complex or substance that is administered to an organism for diagnostic or therapeutic purposes, including medical imaging, monitoring, contraception, cosmetics, nutraceuticals, pharmaceuticals and preventive applications. The term drug is further intended to include any such molecule, molecular complex or substance that is chemically modified and / or operably attached to an organism or a biocompatible structure.
[0110] The term "T regulatory cells" (also referred to as "Tregs" or "Treg cells") has its ordinary meaning in the art and is intended to describe a subpopulation of T cells characterized by "suppressing" the activity of effector T cells in vitro and / or in vivo. Therefore, Treg cells are an important component of a healthy immune system. Regulatory T cells are involved in controlling effector T cells, which regulate the immune system, maintain tolerance to self-antigens, and eliminate autoimmune and / or inflammatory diseases. Tregs have many recognized biomarkers known in the art. Regulatory T cells include two subpopulations that are distinguished from each other by the expression of CD45RA, which are defined as "naive Tregs" that express FOXP3 and CD45RA and "effector Tregs" that express FOXP3 but do not express CD45RA. Cells suitable for expansion are naive Tregs because they are highly proliferative under stimulating conditions and in the presence of IL-2, while effector Tregs are poorly proliferative under these conditions. Therefore, FoxP3+CD4+T cells can be divided into (1) naive / resting Treg cells (naive Tregs) with a CD127lowCD25++CD45RA+FoxP3low phenotype and (2) effector Tregs ("effector Treg cells") with a CD127lowCD25+++CD45RA-FoxP3high phenotype, both of which are highly suppressive in vitro, and (3) non-suppressive CD4+T cells with a CD127lowCD25++CD45RA-FoxP3low phenotype. Therefore, the term "effector Treg cells" (also called "eTreg cells") refers to active Treg cells that display the regulatory function or suppressive function of effector T cells (literally "effectors" of Treg cells). The demonstration of the regulatory / inhibitory function of eTreg cells can be determined by any suitable method known in the art (see Miyara, M. et al. Functional Delineation and Differentiation Dynamics of Human CD4(+)T Cells Expressing the FoxP3 Transcription Factor. Immunity 30, 899-911 (2009)). Specifically, examples of such tests are listed in the Examples section. Specifically, Examples and Figure 2 The test performed in is considered a standard in vitro test for assessing regulatory T cell function.
[0111] As used herein, the term "fragment" refers to an amino acid sequence less than 100% of a full-length reference protein (e.g., 99%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, etc. of the full-length sequence), but includes, for example, 5, 10, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350 or more amino acids. A fragment can be of sufficient length so as to maintain the desired function of the full-length protein. For example, regulation of the alternative complement pathway in the fluid phase by a fragment of, for example, factor H is maintained. Such a fragment is a "biologically active fragment."
[0112] As used herein, the term "expand" refers to increasing the number of cells (eg, Tregs) in a cell population or sample due to cell replication.
[0113] As used herein, the term "HDL" or "high-density lipoprotein" refers to high-density lipoprotein. HDL includes a complex of approximately equal amounts of lipids and proteins, which acts as a transporter of cholesterol in the blood. HDL is synthesized and secreted primarily in the liver and intestinal epithelial cells. HDL is in the form of discoid particles containing apolipoprotein AI (also referred to as apoA-I) and phospholipids as its main components just after secretion, and is also referred to as nascent HDL. This nascent HDL receives free cholesterol from the cell membrane of peripheral cells or produced during the hydrolysis of other lipoproteins in the blood, and forms mature spherical HDL, while retaining cholesterol esters converted from the cholesterol by the action of LCAT (phosphatidylcholine cholesterol acyltransferase) in its hydrophobic center. HDL plays an extremely important role in the lipid metabolism process known as "reverse cholesterol transport", which takes cholesterol in the blood out of peripheral tissues and transports it to the liver. High levels of HDL are associated with a reduced risk of atherosclerosis and coronary heart disease (CHD), because reverse cholesterol transport is considered to be one of the main mechanisms of HDL's role in preventing atherosclerosis.
[0114] As used herein, the term "immunomodulator" refers to a compound that stimulates or suppresses the immune system. Immunomodulators include, but are not limited to, statins; mTOR inhibitors such as rapamycin or rapamycin analogs; TGF-β signaling agents; TGF-β receptor agonists; histone deacetylase inhibitors such as trichostatin A; corticosteroids; mitochondrial function inhibitors, such as rotenone; P38 inhibitors; NF-κβ inhibitors such as 6Bio, dexamethasone, TCPA-1, IKK VII; adenosine receptor agonists; prostaglandin E2 agonists (PGE2) such as misoprostol; phosphodiesterase inhibitors such as phosphodiesterase 4 inhibitors (PDE4) such as rolipram; proteasome inhibitors; kinase inhibitors; G protein-coupled receptor agonists; G protein-coupled receptor antagonists; glucocorticoids; retinoids; cytokine inhibitors; cytokine receptor inhibitors; cytokine receptor activators; peroxisome proliferator-activated receptor antagonists; peroxisome proliferator-activated receptor agonists; histone deacetylase inhibitors; calcineurin inhibitors; phosphatase inhibitors; PI3 KB inhibitors, such as TGX-221; autophagy inhibitors, such as 3-methyladenine; aryl hydrocarbon receptor inhibitors; proteasome inhibitor I (PSI); and oxidized ATP, such as P2X receptor blockers. In some embodiments, the immunomodulator is an immunosuppressant.Examples of immunosuppressants include, but are not limited to, IDO, vitamin D3, cyclosporins such as cyclosporine A, aryl hydrocarbon receptor inhibitors, resveratrol, azathioprine (Aza), 6-mercaptopurine (6-MP), 6-thioguanine (6-TG), FK506, sangliferin A, salmeterol, mycophenolate mofetil (MMF), aspirin and other COX inhibitors, niflumic acid, estriol; triptolide; OPN-305, OPN-401; eritoran (E5564); TAK-242; Cpn10; NI-0101; 1A6; AV411; IRS-954 (DV-107 9); IMO-3100; CPG-52363; CPG-52364; OPN-305; ATNC05; NI-0101; IMO-8400; hydroxychloroquine; CU-CPT22; C29; o-vanillin; SSL3 protein; OPN-305; 5SsnB; Vizantin; (+)-N-phenylethylnoroxymorphone; VB3323; monosaccharide 3; (+)-naltrexone and (+)-naloxone; HT52; HTB2; compound 4a; CNTO2424; TH1020; INH-ODN; E6446; AT791; CpG ODN 2088; ODN TTAGGG; COV08-0064; 2R9; GpG oligonucleotide; 2-aminopurine; amlexanox; Bay11-7082; BX795; CH-223191; chloroquine; CLI-095; CU-CPT9a; cyclosporine A; CTY387; gefitinib; glibenclamide; H-89; H-131; isoliquiritigenin; MCC950; MRT67307; OxP APC; parthenolide; Pepinh-MYD; Pepinh-TRIF; polymyxin B; R406; RU.521; VX-765; YM201636; Z-VAD-FMK; and AHR-specific ligands; including but not limited to 2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD); tryptamine (TA); and 6-formylindole[3,2b]carbazole (FICZ).In a specific embodiment, the immunosuppressant is FTY720 (also known as fingolimod) (Chung and Harung, Clin. Neuropharmacol 33:91-101, 2010), AhR activation by 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) or related ligands (Yeste A, et al. Proc. Natl. Acad. Sci. USA 109:11270-11275, 2012; Quintana FJ, et al Proc. Natl. Acad. Sci. USA 107:20768-20773, 2010), trichostatin A (TSA) (Reilly CM et al. J. Autoimmun 31:123-130. 2008). Suberoylanilide hydroxamic acid (SAHA), histone deacetylase inhibitors (Lucas JL, et al. Cell Immunol 257:97-104, 2009) and / or rapamycin (Rapa) (Maldonado, RA, et al Proc. Natl. Acad. Sci. USA 112:E156-165, 2015). In embodiments, the immunosuppressant may include any agent provided herein.
[0115] As used herein, the term "nucleic acid" can be DNA or RNA, such as mRNA. In embodiments, the composition includes a complement of any nucleic acid provided herein, such as a full-length complement, or a degenerate (due to the degeneracy of the genetic code). In embodiments, the nucleic acid is an expression vector that can be transcribed when transfected into a cell line. In embodiments, the expression vector may include a plasmid, a retrovirus, or an adenovirus, etc. Nucleic acids can be isolated or synthesized using standard molecular biology methods, such as by using a polymerase chain reaction to produce nucleic acid fragments, which are then purified and cloned into an expression vector. Additional techniques that can be used to implement the present invention can be found in: Current Protocols in Molecular Biology 2007 by John Wiley and Sons, Inc.; Molecular Cloning: A Laboratory Manual (Third Edition) Joseph Sambrook, Peter MacCallum Cancer Institute, Melbourne, Australia; David Russell, University of Texas Southwestern Medical Center, Dallas, Cold Spring Harbor.
[0116] As used herein, the term "in vitro" refers to an artificial environment and a process or reaction that occurs in an artificial environment. An in vitro environment can consist of, but is not limited to, a test tube and cell culture.
[0117] The term "in vivo" refers to the natural environment (eg, an animal or a cell) and processes or reactions that occur within a natural environment.
[0118] As used herein, the term "lipid" or "lipid molecule" refers to a water-insoluble fatty substance, and includes fats, oils, waxes and related compounds. They can be produced in the blood (endogenous), or taken in the diet (exogenous). Lipids are essential for normal body function, and whether produced by exogenous or endogenous sources, they must be transported and then released for use by cells. The production, transportation and release of lipids for cell use are referred to as lipid metabolism. Although there are several types of lipids, two major categories are cholesterol and triglycerides. Cholesterol can be taken in the diet and produced by cells of most organs and tissues (mainly in the liver) in the body. Cholesterol can exist in free form, or more commonly, it is combined with fatty acids to form so-called cholesterol esters. As used herein, "lipid" or "lipid molecule" refers to any lipophilic compound. Non-limiting examples of lipid compounds include fatty acids, cholesterol, phospholipids, complex lipids and derivatives or analogs thereof. They are generally divided into at least three categories: (1) "simple lipids," which include fats and oils as well as waxes; (2) "complex lipids," which include phospholipids and glycolipids; and (3) "derivatized lipids," such as steroids. Lipids or lipid molecules suitable for use in the present invention include both membrane-forming lipids and non-membrane-forming lipids.
[0119] As used herein, the term "lipoprotein" refers to a compound constructed so that water-insoluble lipids are contained in a partially water-soluble shell. Depending on the type of lipoprotein, the contents include varying amounts of free and esterified cholesterol, triglycerides, and apoproteins or apolipoproteins. There are five major types of lipoproteins, which differ in function and their lipid and apoprotein content and are classified according to increased density: (i) chylomicrons and chylomicron remnants, (ii) very low density lipoproteins ("VLDL"), (iii) intermediate density lipoproteins ("IDL"), (iv) low density lipoproteins ("LDL"), and (v) high density lipoproteins ("HDL"). Cholesterol circulates in the blood as particles associated with lipoproteins.
[0120] As used herein, the term "non-naturally occurring amino acid" means an alpha amino acid that is not naturally produced or present in mammals. Examples of non-naturally occurring amino acids include D-amino acids; amino acids having an acetamidomethyl group attached to the sulfur atom of cysteine; PEGylated amino acids; amino acids of the formula NH2(CH2) nω amino acids of COOH, wherein n is 2-6, neutral non-polar amino acids such as sarcosine, tert-butylalanine, tert-butylglycine, N-methylisoleucine and norleucine; oxymethionine; phenylglycine; citrulline; methionine sulfoxide; cysteic acid; ornithine; diaminobutyric acid; 3-aminoalanine; 3-hydroxy-D-proline; 2,4-diaminobutyric acid; 2-aminopentanoic acid; 2-aminooctanoic acid, 2-carboxypiperazine; piperazine-2-carboxylic acid, 2-amino-4-phenylbutyric acid; 3-(2-naphthyl)alanine and hydroxyproline. The other amino acids are α-aminobutyric acid, α-amino-α-methylbutyric acid, aminocyclopropane-carboxylic acid / salts, aminoisobutyric acid, aminonorbornyl-carboxylic acid / salts, L-cyclohexylalanine, cyclopentylalanine, LN-methylleucine, LN-methylmethionine, LN-methylnorvaline, LN-methylphenylalanine, LN-methylproline, LN-methylserine, LN-methyltryptophan, D-ornithine, LN-methylethylglycine, L-norleucine, α-methyl-aminoisobutyric acid / salts, α-methylcyclohexylalanine, D-α-methylalanine, and α-methylaminoisobutyric acid / salts. amino acid, D-α-methylarginine, D-α-methylasparagine, D-α-methylaspartic acid, D-α-methylcysteine, D-α-methylglutamine, D-α-methylhistidine, D-α-methylisoleucine, D-α-methylleucine, D-α-methyllysine, D-α-methylmethionine, D-α-methylornithine, D-α-methylphenylalanine, D-α-methylproline, D-α-methylserine, DN-methylserine, D-α-methylthreonine, D-α-methyltryptophan, D-α-methyltyrosine, D- α-Methylvaline, DN-methylalanine, DN-methylarginine, DN-methylasparagine, DN-methylaspartic acid, DN-methylcysteine, DN-methylglutamine, DN-methylglutamic acid, DN-methylhistidine, DN-methylisoleucine, DN-methylleucine, DN-methyllysine, N-methylcyclohexylalanine, DN-methylornithine, N-methylglycine, N-methylaminoisobutyric acid, N-(1-methylpropyl)glycine, N-(2-methylpropyl)glycine, DN-methyltryptophan, DN-methyl Tyrosine, DN-methylvaline, γ-aminobutyric acid, L-tert-butylglycine, L-ethylglycine, L-homophenylalanine, L-α-methylarginine, L-α-methylaspartic acid, L-α-methylcysteine, L-α-methylglutamine, L-α-methylhistidine, L-α-methylisoleucine, L-α-methylleucine, L-α-methylmethionine, L-α-methylnorvaline, L-α-methylphenylalanine, L-α-methylserine, L-α-methyltryptophan, L-α-methylvaline, N-(N-(2,2-diphenylethyl)carbamoylmethylglycine, 1-carboxy-1-(2,2-diphenyl-ethylamino)cyclopropane, 4-hydroxyproline, ornithine, 2-aminobenzoyl (o-aminobenzoyl), D-cyclohexylalanine, 4-phenyl-phenylalanine, L-citrulline, α-cyclohexylglycine, L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, L-thiazolidine-4-carboxylic acid, L-homotyrosine, L-2-furanylalanine, L-histidine (3-methyl), N-(3-guanidinopropyl)glycine, O-methyl-L-tyrosine, O- Glycan-serine, meta-tyrosine, nor-tyrosine, LN,N′,N″-trimethyllysine, homolysine, nor-lysine, N-glycan asparagine, 7-hydroxy-1,2,3,4-tetrahydro-4-fluorophenylalanine, 4-methylphenylalanine, bis-(2-pyridylmethyl)amine, pentafluorophenylalanine, dihydroindole-2-carboxylic acid, 2-aminobenzoic acid, 3-amino-2-naphthoic acid, asymmetric dimethylarginine, L-tetrahydroisoquinoline-1-carboxylic acid, D-tetrahydroisoquinoline-1-carboxylic acid, 1-amino-cyclohexane Acetic acid, D / L-allylglycine, 4-aminobenzoic acid, 1-amino-cyclobutanecarboxylic acid, 2- or 3- or 4-aminocyclohexanecarboxylic acid, 1-amino-1-cyclopentanecarboxylic acid, 1-aminoindene-1-carboxylic acid, 4-amino-pyrrolidine-2-carboxylic acid, 2-aminotetralin-2-carboxylic acid, azetidine-3-carboxylic acid, 4-benzyl-pyrrolidine-2-carboxylic acid, tert-butylglycine, b-(benzothiazolyl-2-yl)-alanine, b-cyclopropylalanine, 5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid, (2R,4S)4-hydroxypiperidin-2- carboxylic acid, (2S,4S) and (2S,4R)-4-(2-naphthylmethoxy)-pyrrolidine-2-carboxylic acid, (2S,4S) and (2S,4R)-4-phenoxy-pyrrolidine-2-carboxylic acid, (2R,5S) and (2S,5R)-5-phenyl-pyrrolidine-2-carboxylic acid, (2S,4S)-4-amino-1-benzoyl-pyrrolidine-2-carboxylic acid, tert-butylalanine, (2S,5R)-5-phenyl-pyrrolidine-2-carboxylic acid, 1-aminomethyl-cyclohexane-acetic acid, 3,5-bis-(2-amino)ethoxy-benzoic acid, 3,5-Diaminobenzoic acid, 2-methylaminobenzoic acid, N-methylanthranilic acid, LN-methylalanine, LN-methylarginine, LN-methylasparagine, LN-methylaspartic acid, LN-methylcysteine, LN-methylglutamine, LN-methylglutamic acid, LN-methylhistidine, LN-methylisoleucine, LN-methyllysine, LN-methylnorleucine, LN-methylornithine, LN-methylthreonine, LN-methyltyrosine, LN-methylvaline, LN-methyl-tert-butylglycine, L-norvaline, α-methyl-γ-aminobutyric acid / salt, 4,4' -biphenylalanine, α-methylcyclopentylalanine, α-methyl-α-naphthoic acid, α-methylpenicillamine, N-(4-aminobutyl)glycine, N-(2-aminoethyl)glycine, N-(3-aminopropyl)glycine, N-amino-α-methylbutyric acid / salt, α-naphthoic acid, N-benzylglycine, N-(2-carbamoylethyl)glycine, N-(carbamoylmethyl)glycine, N-(2-carboxyethyl)glycine, N-(carboxymethyl)glycine, N-cyclobutylglycine, N-cyclodecylglycine, N-cycloheptylglycine, N-cyclohexylglycine, N-cyclodecylglycine, N-cyclo Dodecylglycine, N-cyclooctylglycine, N-cyclopropylglycine, N-cycloundecylglycine, N-(2,2-diphenylethyl)glycine, N-(3,3-diphenylpropyl)glycine, N-(3-guanidinopropyl)glycine, N-(1-hydroxyethyl)glycine, N-(hydroxyethyl))glycine, N-(imidazolylethyl))glycine, N-(3-indolethyl)glycine, N-methyl-γ-aminobutyric acid / salt, DN-methylmethionine, N-methylcyclopentylalanine, DN-methylphenylalanine, DN-methylproline, DN-methylthreonine, N-(1-methylethyl)glycine acid, N-methyl-naphthylalanine, N-methylpenicillamine, N-(p-hydroxyphenyl)glycine, N-(thiomethyl)glycine, penicillamine, L-α-methylalanine, L-α-methylasparagine, L-α-methyl-tert-butylglycine, L-methylethylglycine, L-α-methylglutamic acid, L-α-methylhomophenylalanine, N-(2-methylthioethyl)glycine, L-α-methyllysine, L-α-methylnorleucine, L-α-methylornithine, L-α-methylproline, L-α-methylthreonine, L-α-methyltyrosine, LN-methyl-homophenylalanine, N-(N-(3,3-diphenylpropyl)carbamoylmethylglycine, L-pyroglutamic acid, D-pyroglutamic acid, O-methyl-L-serine, O-methyl-L-homoserine, 5-hydroxylysine, α-carboxyglutamic acid, phenylglycine, L-piperidinic acid (homoproline), L-homoleucine, L-lysine (dimethyl), L-2-naphthylalanine, L-dimethyldopa or L-dimethoxy-phenylalanine, L-3-pyridylalanine, L-histidine (benzoyloxymethyl), N-cycloheptylglycine, L-diphenylalanine, O-methyl-L-homotyrosine acid, L-β-homolysine, O-polysaccharide-threonine, o-tyrosine, LN,N′-dimethyllysine, L-homoarginine, neotryptophan, 3-benzothienylalanine, isoquinoline-3-carboxylic acid, diaminopropionic acid, homocysteine, 3,4-dimethoxyphenylalanine, 4-chlorophenylalanine, L-1,2,3,4-tetrahydronorharman-3-carboxylic acid, adamantylalanine, symmetric dimethylarginine, 3-carboxythiomorpholine, D-1,2,3,4-tetrahydronorharman-3-carboxylic acid, 3 -aminobenzoic acid, 3-amino-1-carboxymethyl-pyridin-2-one, 1-amino-1-cyclohexanecarboxylic acid, 2-aminocyclopentanecarboxylic acid, 1-amino-1-cyclopropanecarboxylic acid, 2-aminoindene-2-carboxylic acid, 4-amino-tetrahydrothiopyran-4-carboxylic acid, azetidine-2-carboxylic acid, b-(benzothiazol-2-yl)-alanine, neopentylglycine, 2-carboxymethylpiperidine, b-cyclobutylalanine, allylglycine, diaminopropionic acid, homocyclohexylalanine, (2S,4R)-4-hydroxypiperidine-2-carboxylic acid, octahydroindole-2-carboxylic acid Acid, (2S, 4R) and (2S, 4R)-4-(2-naphthyl), pyrrolidine-2-carboxylic acid, hexahydronicotinic acid, (2S, 4R) and (2S, 4S)-4-(4-phenylbenzyl) pyrrolidine-2-carboxylic acid, (3S)-1-pyrrolidine-3-carboxylic acid, (2S, 4S)-4-tritylthiopyrrolidine-2-carboxylic acid, (2S, 4S)-4-mercaptoproline, tert-butylglycine, N, N-bis(3-aminopropyl)glycine, 1-amino-cyclohexane-1-carboxylic acid, N-mercaptoethylglycine and selenocysteine. In some embodiments, the amino acid residue can be charged or polar. Charged amino acids include alanine, lysine, aspartic acid or glutamic acid, or non-naturally occurring analogs thereof. Polar amino acids include glutamine, asparagine, histidine, serine, threonine, tyrosine, methionine or tryptophan, or non-naturally occurring analogs thereof. It is particularly contemplated that in some embodiments, the terminal amino group in the amino acid may be an amide group or a carbamate group.
[0121] " Percentage (%) sequence identity " about reference polynucleotide or peptide sequence is defined as after comparing sequence and introducing gap (if necessary) to realize maximum percentage sequence identity, the percentage of nucleic acid or amino acid identical with the nucleic acid or amino acid in reference polynucleotide or peptide sequence in candidate sequence.Comparison for determining percentage nucleic acid or amino acid sequence identity purpose can be realized in various ways within the capabilities of those skilled in the art, for example, using publicly available computer software such as BLAST, BLAST-2 or Megalign software.Those skilled in the art can determine the appropriate parameters for comparing sequences, including any algorithm required for maximum comparison on the total length of the sequence being compared.For example, the sequence comparison computer program BLAST can be used to generate percentage sequence identity value.As an illustration, the percentage sequence identity of given nucleic acid or amino acid sequence A and, with or relative to given nucleic acid or amino acid sequence B (or it can be expressed as and, with or relative to given nucleic acid or amino acid sequence B, given nucleic acid or amino acid sequence A has a certain percentage of sequence identity) is calculated as follows:
[0122] 100 times (fraction X / Y)
[0123] wherein X is the number of nucleotides or amino acids scored as identical matches by a sequence alignment program (e.g., BLAST) in an alignment of A and B, wherein , and Y is the total number of nucleic acids in B. It will be understood that when the length of nucleic acid or amino acid sequence A is not equal to the length of nucleic acid or amino acid sequence B, the percent sequence identity of A to B will not be equal to the percent sequence identity of B to A.
[0124] The term "protein" refers to a polymer of amino acids (e.g., naturally occurring amino acids and non-natural amino acids) of any length. The term also encompasses modified amino acid polymers; for example, disulfide bond formation, glycosylation, acetylation, phosphorylation, lipidation, or conjugation with a labeling component.
[0125] As used herein, the term "peptide" refers to a polymer in which the monomers are amino acids covalently linked together by amide bonds. The length of a peptide is two or usually more amino acid monomers.
[0126] A "pharmaceutical composition" refers to any composition comprising a therapeutic or biologically active agent (e.g., nanoparticles comprising 1-30 (e.g., 2-30, 3-30, 4-30, 5-30, 6-30, 7-30, or 8-30 tolerogenic antigens)) suitable for administration to a subject. The biologically active agent includes nanoparticles containing 1-30 (e.g., 8-30 tolerogenic antigens per nanoparticle). The 1-30 tolerogenic antigens associated with a particular nanoparticle can all have the same sequence identity, or the 1-30 tolerogenic antigens associated with a particular nanoparticle can include a population of 1 to 5 different tolerogenic antigens having different sequence identities. Any of these formulations can be prepared by methods well known and accepted in the art. See, e.g., Remington: The Science and Practice of Pharmacy (21 st ed.), ed. A. R. Gennaro, Lippincott Williams & Wilkins, 2005, and Encyclopedia of Pharmaceutical Technology, ed. J. Swarbrick, Informa Healthcare, 2006, each of which is incorporated herein by reference.
[0127] "Pharmaceutically acceptable diluent, excipient, carrier or adjuvant" means a diluent, excipient, carrier or adjuvant that is physiologically acceptable to a subject while retaining the therapeutic properties of the pharmaceutical composition with which it is administered.
[0128] As used herein, the term "sample" is used in its broadest sense. In a sense, it is meant to include specimens or cultures obtained from any source, as well as biological and environmental samples. Biological samples can be obtained from animals (including humans) and include fluids, solids, tissues and gases. Biological samples include blood products, such as plasma, serum, etc. Environmental samples include environmental materials, such as surface materials, soil, water, crystals and industrial samples. However, these examples should not be construed as limiting the sample types applicable to the present invention.
[0129] As used herein, the term "subject" refers to any animal (e.g., mammal) that will be the recipient of a particular treatment, including but not limited to humans, non-human primates, rodents, etc. Generally, the terms "subject" and "patient" are used interchangeably herein when referring to a human subject.
[0130] As used herein, the terms "synthetic HDL", "sHDL", "reconstituted HDL" and "rHDL" refer to particles that are structurally similar to native HDL and consist of one or more lipids associated with at least one HDL protein, preferably ApoA-I or a mimetic thereof. Typically, the components of sHDL may be derived from blood or produced by recombinant technology.
[0131] "Therapeutically effective amount" refers to the amount of the composition administered in a clinically relevant manner to improve, inhibit or alleviate the symptoms of a condition or illness or disease (e.g., celiac disease) in a subject. Any improvement in a subject is considered sufficient to achieve treatment. Preferably, an amount sufficient for treatment is an amount that reduces, inhibits or prevents the occurrence of a disease or disorder (e.g., celiac disease) or one or more symptoms, or reduces the severity or length of time that a subject suffers from one or more symptoms of a disease or disorder (e.g., celiac disease) (e.g., for a control subject not treated with a composition described herein, a reduction of at least about 10%, about 20%, or about 30%, more preferably at least about 50%, about 60%, or about 70%, most preferably at least about 80%, about 90%, about 95%, about 99% or more). The effective amount of the pharmaceutical composition used to implement the methods described herein (e.g., treatment of celiac disease) varies depending on the mode of administration and the age, weight, and general health of the subject being treated. A physician or researcher can determine the appropriate amount and dosage regimen.
[0132] As used herein, the term "tolerogenic antigen" refers to a molecule capable of binding to an antibody or an antigen receptor on a T cell, particularly one that induces an immune response.
[0133] As used herein, the term "solvent" refers to the medium in which the reaction is carried out. The solvent can be a liquid but is not limited to liquid form. Solvent classes include, but are not limited to, non-polar, polar, protic and aprotic. DETAILED DESCRIPTION
[0134] Regulatory T cells (Treg, CD4 + CD25 高 Foxp3 + ) plays a crucial role in immune tolerance against autoimmune diseases [1]. A large number of studies have shown that adoptive transfer of Tregs can reduce inflammation and restore immune tolerance in preclinical models. However, it is still unknown how to effectively induce and maintain high frequencies of Tregs in vivo without the need to manipulate Tregs (such as CAR-Tregs) ex vivo. Tregs require exogenous IL-2 via high-affinity IL2R complexes to survive and proliferate [2]. Although low-dose IL-2 has been shown to induce Tregs in vivo, IL-2 can also promote effector T cells and NK cells that may exacerbate inflammation [3, 4].
[0135] Recently, engineered IL-2 and mutant IL-2 proteins, such as PT101, have been developed that selectively trigger Tregs without inducing effector T cells and NK cells [5-8]. In clinical studies, PT101 has been reported to induce polyclonal Tregs in humans [9]. However, previous studies have shown that antigen-specific Tregs have significantly better therapeutic potential for immune tolerance in a targeted manner compared to polyclonal Tregs [10-13]. Therefore, new methods are needed to induce high frequencies of antigen-specific Tregs in vivo.
[0136] Experiments conducted during the development of embodiments of the present invention led to the development of new strategies for inducing high frequencies of antigen-specific Tregs in vivo without the need for ex vivo cell manipulation. Such experiments led to the development and optimization of new strategies for combining nanodiscs with modified IL-2 to elicit unprecedented levels of antigen-specific Tregs in vivo. Notably, IL-2: anti-IL-2 antibody (clone: JES6-1) immune complexes (IL-2 / IC) have been shown to selectively induce polyclonal Tregs
[14] . Administration of IL-2 / IC together with free peptide or peptide tetramers has been reported to induce antigen-specific Tregs [15, 16]. However, the results of these previous attempts were rather poor antigen-specific Treg responses, with antigen-specific Treg frequencies in the CD4+ T cell compartment being less than 0.25% [15, 16].
[0137] It is foreseeable that it will be critical to properly deliver peptide antigens to lymphoid tissues together with IL-2 / IC to maximize antigen-specific Treg induction. The experiments described herein report for the first time that lymphatic-targeted nanodisc-mediated peptide delivery combined with IL-2 / IC resulted in a significant expansion of antigen-specific Tregs compared to IL-2 / IC alone.
[0138] It is also foreseeable that the actual treatment method will be crucial. Such experiments show that the nanodiscs are first ideally administered (e.g., subcutaneously), followed by systemic administration of IL-2 and / or mutant proteins / engineering IL-2. This ensures that antigen-specific Tregs are first prepared and generated, and then the administration of mutant proteins / engineering IL-2 triggers the strong proliferation of antigen-specific Tregs. It is further envisioned that the nanodiscs and / or mutant proteins / engineering IL-2 administered at a maintenance dose are used to maintain antigen-specific Tregs for a long time.
[0139] Compared to CAR-Treg or other cell therapies, the nanodiscs described herein are synthetic, well characterized, and easy to manufacture [17, 18]. Therefore, this combined approach opens new doors for immunotherapy against various autoimmune diseases in a targeted manner. More broadly, it is envisioned that the nanodiscs described herein can be combined with mutant IL-2, other endogenous or engineered cytokines, growth factors, or antibodies to achieve synergistic effects and induce Tregs.
[0140] Thus, the present invention relates to compositions comprising nanoparticles associated with or without one or more tolerogenic antigens, and compositions comprising immunomodulators (e.g., interleukin-2 (IL-2) or IL-2 variants or IL-2 / IC), and to related methods of co-administering such compositions for the purpose of inducing expansion of regulatory T cells (Tregs) (e.g., antigen-specific regulatory Tregs). The present invention also provides methods of treating autoimmune disorders by administering to a subject a composition comprising nanoparticles associated with or without one or more tolerogenic antigens associated with the autoimmune disorder prior to administering to the subject a composition comprising an immunomodulator.
[0141] In certain embodiments, the present invention provides for the regulation of regulatory Tregs (e.g., CD4 + CD25 高 Foxp3 + ), comprising administering to the subject a composition comprising one or more nanoparticles, and subsequently (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.) administering to the subject a composition comprising one or more immunomodulators (e.g., IL-2, IL-2 mutant proteins, IL-2 variants, or IL-2 / IC) capable of expanding Tregs in the subject. In some embodiments, the composition comprising one or more nanoparticles is associated (e.g., compounded, conjugated, encapsulated, absorbed, adsorbed, mixed) with an mTOR inhibitor (e.g., rapamycin or a variant thereof). In some embodiments, antigen-specific regulatory Tregs (e.g., CD4 + CD25 高 Foxp3 + ) is specific for a particular tissue region (e.g., a particular tissue region associated with one or more autoimmune disorders).
[0142] In certain embodiments, the present invention provides regulatory Tregs (e.g., CD4+ CD25 高 Foxp3 + ), comprising administering to the subject a composition comprising one or more nanoparticles associated with one or more tolerogenic antigens, and subsequently administering to the subject (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.) a composition comprising one or more immunomodulators (e.g., human cytokines (e.g., IL-2, IL-2 muteins, IL-2 variants, or IL-2 / IC)) capable of expanding antigen-specific Tregs, wherein "antigen specificity" is specific to the one or more tolerogenic antigens (which are associated with the nanoparticles comprising the one or more tolerogenic antigens). In some embodiments, antigen-specific regulatory Tregs (e.g., CD4 + CD25 高 Foxp3 + ) is specific for a particular tissue region (e.g., a particular tissue region associated with one or more autoimmune disorders).
[0143] In certain embodiments, the present invention provides a method for promoting strong immune tolerance to an antigen associated with an autoimmune disease in a subject (e.g., a human subject having an autoimmune disease or at risk of having an autoimmune disease), comprising administering to the subject a composition comprising one or more nanoparticles, and subsequently (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.), administering to the subject a composition comprising a Treg cell (e.g., CD4 + CD25 高 Foxp3 + ) is a composition comprising one or more immunomodulators (e.g., human cytokines (e.g., IL-2, IL-2 mutant proteins, IL-2 variants, or IL-2 / IC)). In some embodiments, the composition comprising one or more nanoparticles is associated (e.g., compounded, conjugated, encapsulated, absorbed, adsorbed, mixed) with an mTOR inhibitor (e.g., rapamycin or a variant thereof). In some embodiments, promoting strong immune tolerance to antigens associated with autoimmune disorders in a subject is specific to a specific tissue region (e.g., a specific tissue region associated with one or more autoimmune disorders).
[0144] In certain embodiments, the invention provides a method for promoting strong immune tolerance to an antigen associated with an autoimmune disorder in a subject (e.g., a human subject having an autoimmune disorder or at risk of having an autoimmune disorder), comprising administering to the subject a composition comprising one or more nanoparticles associated with one or more tolerogenic antigens, and subsequently (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.), administering to the subject a composition comprising a nanoparticle capable of expanding antigen-specific Tregs (e.g., CD4 + CD25 高 Foxp3 + ), wherein the "antigen specificity" is specific for one or more tolerogenic antigens associated with the nanoparticles comprising the one or more tolerogenic antigens associated with the nanoparticles. In some embodiments, promoting strong immune tolerance to an antigen associated with an autoimmune disorder in a subject is specific for a specific tissue region (e.g., a specific tissue region associated with one or more autoimmune disorders).
[0145] In certain embodiments, the invention provides a method for increasing the ratio of CD3+FOXP3+ cells to CD3+FOXP3- cells in a T cell population in a subject (e.g., a human subject having an autoimmune disorder or at risk of having an autoimmune disorder), comprising administering to the subject a composition comprising one or more nanoparticles, and subsequently (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.) administering to the subject a composition comprising a nanoparticle capable of expanding Tregs (e.g., CD4 + CD25 高 Foxp3 + ) is a composition comprising one or more immunomodulators (e.g., human cytokines (e.g., IL-2, IL-2 mutant proteins, IL-2 variants, or IL-2 / IC)). In some embodiments, the composition comprising one or more nanoparticles is associated (e.g., compounded, conjugated, encapsulated, absorbed, adsorbed, mixed) with an mTOR inhibitor (e.g., rapamycin or a variant thereof). In some embodiments, increasing the ratio of CD3+FOXP3+ cells to CD3+FOXP3- cells in a T cell population in a subject is specific to a specific tissue region (e.g., a specific tissue region associated with one or more autoimmune disorders).
[0146] In certain embodiments, the invention provides a method for increasing the ratio of CD3+FOXP3+ cells to CD3+FOXP3- cells in a T cell population in a subject (e.g., a human subject having an autoimmune disorder or at risk of having an autoimmune disorder), comprising administering to the subject a composition comprising one or more nanoparticles associated with one or more tolerogenic antigens, and subsequently (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.) administering to the subject a composition comprising a nanoparticle capable of expanding antigen-specific Tregs (e.g., CD4 + CD25 高 Foxp3 + ), wherein the "antigen specificity" is specific for one or more tolerogenic antigens associated with the nanoparticles comprising the one or more tolerogenic antigens. In some embodiments, increasing the ratio of CD3+FOXP3+ cells to CD3+FOXP3- cells in a T cell population in a subject is specific for a specific tissue region (e.g., a specific tissue region associated with one or more autoimmune disorders).
[0147] In certain embodiments, the present invention provides a method for treating, preventing and / or ameliorating a disorder, comprising administering to a subject (e.g., a human subject having an autoimmune disorder (e.g., celiac disease) or at risk of having an autoimmune disorder (e.g., celiac disease)), comprising administering to the subject a composition comprising one or more nanoparticles, and subsequently (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.) administering to the subject a composition comprising a Treg cell capable of expanding Tregs (e.g., CD4 + CD25 高 Foxp3 + ) is a composition comprising one or more immunomodulators (e.g., human cytokines (e.g., IL-2, IL-2 mutant proteins, IL-2 variants, or IL-2 / IC)) of a subject. In some embodiments, the composition comprising one or more nanoparticles is associated (e.g., compounded, conjugated, encapsulated, absorbed, adsorbed, mixed) with an mTOR inhibitor (e.g., rapamycin or a variant thereof). In some embodiments, the treatment, prevention, and / or alleviation of one or more autoimmune disorders in a subject is specific to a specific tissue region (e.g., a specific tissue region associated with an autoimmune disorder).
[0148] In certain embodiments, the invention provides a method for treating, preventing, and / or ameliorating a disorder, comprising administering to a subject (e.g., a human subject having an autoimmune disorder (e.g., celiac disease) or at risk of having an autoimmune disorder (e.g., celiac disease)) a composition comprising one or more nanoparticles associated with one or more tolerogenic antigens (e.g., one or more tolerogenic antigens associated with an autoimmune disorder), and subsequently (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.) administering to the subject a composition comprising a nanoparticle capable of expanding antigen-specific Tregs (e.g., CD4 + CD25 高 Foxp3 + ), wherein the "antigen specificity" is specific for one or more tolerogenic antigens associated with the nanoparticles comprising the one or more tolerogenic antigens associated with the nanoparticles. In some embodiments, the treatment, prevention and / or alleviation of one or more disorders in the subject is specific for a specific tissue region (e.g., a specific tissue region associated with the disorder).
[0149] This approach is not limited to treating a specific condition.
[0150] In some embodiments, the disorder is an autoimmune disorder. Examples of autoimmune disorders include, but are not limited to, multiple sclerosis (MS), celiac disease, rheumatoid arthritis, primary biliary cholangitis, primary sclerosing cholangitis, MOG antibody disease, diabetes (e.g., type 1 diabetes), thyroid autoimmune diseases (e.g., Hashimoto's thyroiditis, Graves' disease), thyroid-related eye and skin diseases, hypoparathyroidism, Addison's disease, premature ovarian failure, autoimmune hypophysitis, pituitary autoimmune diseases, immune gastritis, pernicious anemia, celiac disease, vitiligo, myasthenia gravis, pemphigus vulgaris, and the like. variants, bullous pemphigoid, dermatitis herpetiformis, Duling disease, epidermolysis bullosa acquisita, systemic sclerosis, mixed connective tissue disease, Sjögren's syndrome, systemic lupus erythematosus, Goodpasture's syndrome, rheumatic heart disease, autoimmune polyglandular syndrome type 1, Aicardi-Goutières syndrome, acute pancreatitis, age-dependent macular degeneration, alcoholic liver disease, liver fibrosis, metastasis, myocardial infarction, nonalcoholic steatohepatitis (NASH), Parkinson's disease, polyarthritis / fetal and neonatal anemia, sepsis, and inflammatory bowel disease.
[0151] In some embodiments, the disorder is a transplant-related disorder. In some embodiments, the disorder is one or more allergies. In some embodiments, the disorder is a respiratory disorder (e.g., asthma). In some embodiments, the disorder is graft-versus-host disease (GvHD).
[0152] In some embodiments, such a method (e.g., administering a composition comprising nanoparticles associated with one or more tolerogenic antigens, followed by administration of a composition comprising an immunomodulator capable of expanding Tregs) is further followed by administration of one or more tolerogenic antigens to a specific tissue region (e.g., a specific tissue region associated with one or more autoimmune diseases). In some embodiments, administration of one or more tolerogenic antigens to a specific tissue region is performed by injection and / or topical administration and / or subcutaneous administration. In some embodiments, administration of one or more tolerogenic antigens to a specific tissue region prevents immune tolerance in the specific tissue region.
[0153] In some embodiments, the nanoparticle is associated with an immunomodulator and is not associated with a tolerogenic antigen. In some embodiments, the nanoparticle is associated with a tolerogenic antigen and is further associated with an immunomodulator.
[0154] In some embodiments, a composition comprising an immunomodulator capable of expanding Tregs is included within a nanoparticle such that the nanoparticle is associated with the immunomodulator capable of expanding Tregs (e.g., thereby providing a composition comprising nanoparticles associated with an immunomodulator capable of expanding Tregs).
[0155] Immunomodulators
[0156] The present invention provides compositions comprising one or more immunomodulators.Such compositions are not limited to specific immunomodulators.
[0157] In some embodiments, the one or more immunomodulators are selected from: fingolimod; rapamycin; 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) or related ligands; trichostatin A; suberoylanilide hydroxamic acid (SAHA); statins; mTOR inhibitors; TGF-β signaling agents; TGF-β receptor agonists; histone deacetylase inhibitors; corticosteroids; mitochondrial function inhibitors; NF-κβ inhibitors; adenosine receptor agonists; prostaglandin E2 agonists (PGE2; phosphodiesterase inhibitors; proteasome inhibitors; kinase inhibitors; G protein-coupled receptor agonists; G protein-coupled receptor antagonists; glucocorticoids; retinoids; cytokine inhibitors; cytokine receptor inhibitors; cytokine receptor activators; peroxisome proliferator-activated receptor antagonists; peroxisome proliferator-activated receptor agonists; histone deacetylase inhibitors; calcineurin inhibitors; phosphatase inhibitors; PI3 KB inhibitors; autophagy inhibitors; aryl hydrocarbon receptor inhibitors; proteasome inhibitor I (PSI); oxidized ATP IDO; vitamin D3; cyclosporine; aryl hydrocarbon receptor inhibitors; resveratrol; azathioprine (Aza); 6-mercaptopurine (6-MP); 6-thioguanine (6-TG); FK506; sanglifehrin A; salmeterol; mycophenolate mofetil (MMF); aspirin and other COX inhibitors; niflumic acid; estriol; triptolide; OPN-305, OPN-401; eritoran (E5564); TAK-242; Cpn10; NI-0101; 1A6; AV411; IRS-954 (DV-1079); IMO-3100 ;CPG-52363;CPG-52364;OPN-305;ATNC05;NI-0101;IMO-8400;hydroxychloroquine;CU-CPT22;C29;ortho-vanillin;SSL3 protein;OPN-305;5SsnB;Vizantin;(+)-N-phenylethylnoroxymorphone;VB3323;monosaccharide 3;(+)-naltrexone and (+)-naloxone;HT52;HTB2;compound 4a;CNTO2424;TH1020;INH-ODN;E6446;AT791;CpG ODN 2088; ODN TTAGGG; COV08-0064; 2R9; GpG oligonucleotide; 2-aminopurine; Amiloxanol; Bay11-7082; BX795; CH-223191; Chloroquine; CLI-095; CU-CPT9a; Cyclosporine A; CTY387; Gefitinib; Glibenclamide; H-89; H-131; Isoliquiritigenin; MCC950; MRT67307; OxPAPC; Parthenolide; Pepinh-MYD; Pepinh-TRIF; Polymyxin B; R406; RU.521; VX-765; YM201636; Z-VAD-FMK; and AHR-specific ligands; including but not limited to 2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD); tryptamine (TA); and 6-formylindole[3,2b]carbazole (FICZ)).
[0158] In some embodiments, the immunomodulator is a cytokine. In some embodiments, the cytokine is a human cytokine. In some embodiments, the cytokine is selected from TGFβ, IL-1, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12A, IL12B, IL-15, IL-21 and IL-18.
[0159] In some embodiments, the immunomodulator is human IL-2. In some embodiments, the immunomodulator is low-dose IL-2. In some embodiments, the immunomodulator is PT101 or a variant thereof. In some embodiments, the immunomodulator is a mutant protein IL-2 and / or a variant thereof. In some embodiments, IL-2 is any of the IL-2 cytokines, IL-2 mutant proteins and / or IL-2 variants described below: U.S. Patent Nos. 11,091,527, 11,091,526, 11,077,195, 11,077,172, 10,960,079, 10,946,068, 10,766,938, 10,722,460, 10,174,092, 10,174,091; European Patent No. 3808764 and / or U.S. Patent Application Publication No. US20120315245.
[0160] In some embodiments, the immunomodulator is IL-2: anti-IL-2 antibody (clone: JES6-1) immune complex (IL-2 / IC).
[0161] In some embodiments, the IL-2 is Proleukin. In some embodiments, the IL-2 is administered at a dose of less than 14 MIU / m 2 Less than 12 MIU / m 2 Less than 10MIU / m 2 , less than 8MIU / m 2 Less than 6MIU / m 2 , less than 4MIU / m 2 Or less than 2MIU / m 2 IL-2 was administered at a dose of
[0162] In some embodiments, IL-2 is IL-2 with extended pharmacokinetic (PK). In some embodiments, the IL-2 with extended PK includes a fusion protein. In some embodiments, the fusion protein includes an IL-2 portion and a portion selected from the group consisting of an immunoglobulin fragment, human serum albumin, and Fn3. In some embodiments, the fusion protein includes an IL-2 portion operably connected to an immunoglobulin Fc domain. In some embodiments, the fusion protein includes an IL-2 portion operably connected to human serum albumin. In some embodiments, the IL-2 with extended PK includes an IL-2 portion conjugated to a non-protein polymer. In some embodiments, the non-protein polymer is polyethylene glycol.
[0163] In certain embodiments, the PK-extended IL-2 mutations result in altered affinity (e.g., higher affinity) for the IL-2Rα receptor compared to unmodified IL-2. Site-directed mutagenesis can be used to isolate IL-2 mutants that exhibit high affinity binding to CD25 (i.e., IL-2Rα) compared to wild-type IL-2. Increasing the affinity of IL-2 for IL-2Rα on the cell surface will increase the occupancy of the receptor within a limited IL-2 concentration range, as well as increase the local concentration of IL-2 on the cell surface.
[0164] In certain embodiments, IL-2 mutants are provided, which may be, but not necessarily, substantially purified and may be used as high affinity CD25 binders. IL-2 is a T cell growth factor that induces proliferation of antigen-activated T cells and stimulation of NK cells. Exemplary IL-2 mutants that are high affinity binders include those described in WO2013 / 177187A2. Other exemplary IL-2 mutants with increased affinity for CD25 are disclosed in U.S. Pat. No. 7,569,215, the contents of which are incorporated herein by reference.
[0165] IL-2 mutants may be at least or about 50%, at least or about 65%, at least or about 70%, at least or about 80%, at least or about 85%, at least or about 87%, at least or about 90%, at least or about 95%, at least or about 97%, at least or about 98%, or at least or about 99% identical in amino acid sequence to wild-type IL-2 (its precursor form or preferably mature form). Mutations may consist of changes in the number or composition of amino acid residues. For example, IL-2 mutants may have a greater or lesser number of amino acid residues than wild-type IL-2. Alternatively or in addition, IL-2 mutants may comprise substitutions of one or more amino acid residues present in wild-type IL-2.
[0166] The functions 42 required for making IL-2 mutants are routine in the art and can be performed by those of ordinary skill in the art without resorting to excessive experimentation. For example, mutations consisting of one or more substitutions of amino acid residues in IL-2 can be produced using PCR-assisted mutagenesis techniques (e.g., techniques known in the art and / or described herein for producing IL-2 mutants). Mutations consisting of deletions or additions of amino acid residues of the IL-2 polypeptide can also be produced using standard recombinant techniques. In the case of deletions or additions, the nucleic acid molecule encoding IL-2 is simply digested with a suitable restriction endonuclease. The resulting fragment can be expressed directly or further manipulated by, for example, connecting it to a second fragment. If the two ends of the nucleic acid molecule contain complementary nucleotides that overlap each other, the connection can be facilitated, but blunt-ended fragments can also be connected. PCR-generated nucleic acids can also be used to generate various mutant sequences.
[0167] In addition to generating IL-2 mutants by expression of nucleic acid molecules altered by recombinant molecular biology techniques, IL-2 mutants can also be chemically synthesized. Chemically synthesized polypeptides are usually generated by those skilled in the art.
[0168] As described above, IL-2 can also be prepared as a fusion or chimeric polypeptide, which includes IL-2 and a heterologous polypeptide (i.e., a polypeptide that is not IL-2). The heterologous polypeptide can increase the circulation half-life of the chimeric polypeptide in vivo, and thus can further enhance the properties of IL-2.
[0169] In certain embodiments, the chimeric polypeptide may include IL-2 and a polypeptide as an antigenic tag (such as a FLAG sequence). The FLAG sequence is recognized by a biotinylated, highly specific anti-FLAG antibody, as described herein (see also, Blanar et al., Science 256:1014, 1992; LeClair et al., Proc. Natl. Acad. Sci. USA 89:8145, 1992). In certain embodiments, the chimeric polypeptide further includes a C-terminal c-myc epitope tag.
[0170] It is well within the capabilities of one of ordinary skill in the art to construct chimeric polypeptides using only routine molecular biology techniques.
[0171] In certain embodiments, a composition comprising an immunomodulator (e.g., a human cytokine (e.g., IL-2, IL-2 mutein, IL-2 variant, or IL-2 / IC)) is capable of expanding Treg cells in a subject or sample. In fact, such a composition comprising an immunomodulator is capable of increasing the ratio of Treg to non-regulatory T cells. The ratio can be measured by determining the ratio of CD3+FOXP3+ cells to CD3+FOXP3- cells in a T cell population. The typical frequency of Tregs in human blood is 5-10% of total CD4+CD3+T cells, however, in autoimmune diseases, this percentage may be lower or higher. In a preferred embodiment, the percentage of Treg increases by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1000%. For a particular disease, the maximum multiple increase of Treg may be different; however, the maximum Treg frequency that can be obtained by IL-2 mutant protein treatment is 50% or 60% of total CD4+CD3+T cells. In certain embodiments, a composition comprising an immunomodulator (e.g., a human cytokine (e.g., IL-2, IL-2 mutant protein, IL-2 variant or IL-2 / IC)) is administered to a subject, and the ratio of regulatory T cells (Treg) to non-regulatory T cells in the subject's peripheral blood increases.
[0172] Because such compositions including immunomodulators (e.g., human cytokines (e.g., IL-2, IL-2 mutant proteins, IL-2 variants, or IL-2 / IC)) preferentially expand Tregs over other cell types, they are also useful for increasing the ratio of regulatory T cells (Tregs) to natural killer (NK) cells in the peripheral blood of a subject. The ratio can be measured by determining the ratio of CD3+FOXP3+ cells to CD16+ and / or CD56+ lymphocytes (which are CD19- and CD3-).
[0173] Nanoparticles
[0174] The present invention is not limited to a particular type or species of nanoparticles associated (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, mixed) with or without tolerogenic antigens for treating, preventing or ameliorating various types of autoimmune disorders (e.g., celiac disease).
[0175] Examples of nanoparticles include, but are not limited to, fullerenes (also known as C 60 , C 70 , C 76 , C 80 , C84 ), endohedral metallofullerenes (EMI's) buckyballs, which include additional atoms, ions or clusters within the fullerene cage), trimetallic nitride templated endohedral metallofullerenes (TNT EME, high symmetry tetraatomic molecular cluster intercalates, which are formed in trimetallic nitride templates within carbon cages), single-walled and multi-walled carbon nanotubes, branched and dendritic carbon nanotubes, gold nanorods, silver nanorods, single-walled and multi-walled boron / nitrate nanotubes, carbon nanotube peapods (nanotubes with internal metallofullerenes and / or other internal chemical structures), carbon nanohorns, carbon nanohorn peapods, liposomes, nanoshells, dendrimers, quantum dots, superparamagnetic nanoparticles, nanorods and cellulose nanoparticles. Particle embodiments may also include microparticles with the ability to increase effectiveness or selectivity. Other non-limiting exemplary nanoparticles include glass and polymer microspheres and nanospheres, biodegradable PLGA microspheres and nanospheres, gold, silver, carbon and iron nanoparticles.
[0176] In some embodiments, the nanoparticles are modified micelles. In these embodiments, the modified micelles include polyol polymers modified to include hydrophobic polymer blocks. The term "hydrophobic polymer block" as used in the present disclosure represents a polymer segment that is hydrophobic in itself. As used herein, the term "micelle" refers to an aggregate of molecules dispersed in a liquid. Typical micelles in aqueous solutions form aggregates, and their hydrophilic "head" regions are in contact with the surrounding solvent, isolating the hydrophobic single tail region in the center of the micelle. In some embodiments, the head region can be, for example, a surface region of a polyol polymer, and the tail region can be, for example, a hydrophobic polymer block region of a polyol polymer.
[0177] In addition to nanometer-scale, the present invention also includes the use of micron-scale particles. In the case of using microparticles, preferably they are relatively small, about 1-50 microns. For ease of discussion, the use of "nanoparticles" herein encompasses true nanoparticles (sizes of about 1 nm to about 1000 nm), microparticles (e.g., about 1 micron to about 50 microns), or both.
[0178] Examples of nanoparticles include, by way of example but not limitation, paramagnetic nanoparticles, superparamagnetic nanoparticles, metallic nanoparticles, fullerene-like materials, inorganic nanotubes, dendritic macromolecules, dendritic macromolecules with covalently attached metal chelates, nanofibers, nanohorns, nanoonions, nanorods, nanoropes, and quantum dots. In some embodiments, the nanoparticles are metallic nanoparticles (e.g., nanoparticles of gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or alloys of two or more thereof). The nanoparticles may include a core or a core and a shell, such as a core-shell nanoparticle.
[0179] In some embodiments, the nanoparticle is a sHDL nanoparticle. Generally, sHDL nanoparticles are composed of a mixture of HDL apolipoprotein and amphiphilic lipids.
[0180] The present invention is not limited to the use of a specific type or species of HDL apolipoproteins. HDL apolipoproteins include, for example, apolipoprotein AI (apo AI), apolipoprotein A-II (apo A-II), apolipoprotein A4 (apo A4), apolipoprotein Cs (apo Cs), apolipoprotein M (apo M) and apolipoprotein E (apo E). In some embodiments, the HDL apolipoprotein is selected from prepro apolipoprotein, prepro ApoA-I, pro ApoA-I, ApoA-I, prepro ApoA-II, pro ApoA-II, ApoA-II, apolipoprotein A-II xxx (apo A-II-xxx), prepro ApoA-IV, pro ApoA-IV, ApoA-V, prepro ApoE, pro ApoE, ApoE, prepro ApoA-lMilano, pro ApoA-Imilano, ApoA-lMilano, prepro ApoA-Iparis, pro ApoA-Iparis, ApoA-Iparis, and peptide mimetics of these proteins and mixtures thereof. Preferably, the carrier particles are composed of ApoA-I or ApoA-II, however, other lipoproteins including apolipoprotein A4, apolipoprotein Cs or apolipoprotein E can be used alone or in combination to formulate a carrier particle mixture for delivery of a therapeutic agent. In some embodiments, mimetics of such HDL apolipoprotein are used.
[0181] ApoA-I is synthesized by the liver and small intestine as a prepro-apolipoprotein, which is secreted as a preprotein that is rapidly cleaved to generate a mature polypeptide with 243 amino acid residues. ApoA-I is mainly composed of 6 to 8 different 22 amino acid repeats and 2 different 11 amino acid repeats, each of which has the spiral wheel characteristics of an amphipathic alpha helix separated by a linker portion, which is usually proline, and in some cases, a segment consisting of multiple residues. ApoA-I forms three types of stable complexes with lipids: small, lipid-poor complexes, called pre-β-1HDL; flat disc-shaped particles containing polar lipids (phospholipids and cholesterol), called pre-β-2HDL; and spherical particles containing both polar and non-polar lipids, called spherical or mature HDL (HDL3 and HDL2). Most HDL in the circulating population contains both ApoA-I and ApoA-II (the second major HDL protein).
[0182] In some embodiments, an ApoA-I agonist or mimetic is provided. In some embodiments, such an ApoA-I mimetic is capable of forming an amphipathic α-helix that simulates the activity of ApoA-I and has a specific activity close to or exceeding that of the natural molecule. In some cases, an ApoA-I mimetic is a peptide or peptide analog that: forms an amphipathic helix (in the presence of lipids), binds lipids, forms pre-β-like or HDL-like complexes, activates phosphatidylcholine: cholesterol acyltransferase (LCAT), increases the level of serum HDL fractions, and promotes cholesterol efflux.
[0183] The present invention is not limited to the use of a specific ApoA-I mimetic. In some embodiments, any ApoA-I mimetic described in Srinivasa, et al., 2014 Curr. Opinion Lipidology Vol. 25 (4): 304-308 is used. In some embodiments, any ApoA-I mimetic described in U.S. Patent Application Publication Nos. 20110046056 and 20130231459 is used.
[0184] In some embodiments, the "22A" ApoA-I mimetic (PVLDLFRELLNELLEALKQKLK) (SEQ ID NO: 4) is used (see, e.g., U.S. Pat. No. 7,566,695). In some embodiments, any of the following ApoA-I mimetics shown in Table 1 as described in U.S. Pat. No. 7,566,695 are used:
[0185] Table 1. ApoA-I mimetics
[0186]
[0187]
[0188]
[0189]
[0190]
[0191]
[0192]
[0193]
[0194]
[0195]
[0196]
[0197]
[0198] * indicates an N-terminally acetylated and C-terminally amidated peptide; indicates an N-terminally dansylated peptide; sp indicates a peptide that exhibited solubility issues under experimental conditions; X is Aib; Z is Nal; O is Orn; and ~ indicates a missing amino acid.
[0199] In some embodiments, an ApoA-I mimetic having the following sequence as described in U.S. Pat. No. 6,743,778 is used: Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu AlaPhe (SEQ ID NO: 255).
[0200] In some embodiments, any of the following ApoA-I mimetics as shown in Table 2 described in U.S. Patent Application Publication No. 2003 / 0171277 are used:
[0201] Table 2. ApoA-I mimetics
[0202]
[0203]
[0204]
[0205]
[0206]
[0207] In some embodiments, an Apo AI mimetic having the following sequence as described in US Patent Application Publication No. 2006 / 0069030 is used: FAEKFKEAVKDYFAKFWD (SEQ ID NO: 333).
[0208] In some embodiments, an Apo AI mimetic having the following sequence as described in U.S. Patent Application Publication No. 2009 / 0081293 is used: DWFKAFYDKVAEKFKEAF (SEQ ID NO: 334); DWLKAFYDKVAEKLKEAF (SEQ ID NO: 335); PALEDLRQGLLPVLESFKVFLSALEEYTKKLNTQ (SEQ ID NO: 336).
[0209] In some embodiments, an Apo A-I mimetic having one of the following sequences is used: WDRVKDLATVYVDVLKDSGRDYVSQF (SEQ ID NO:341), LKLLDNWDSVTSTFSKLREOL (SEQ ID NO:342), PVTOEFWDNLEKETEGLROEMS (SEQ ID NO:343), KDLEEVKAKVQ (SEQ ID NO:344), KDLEEVKAKVO (SEQ ID NO:345), PYLDDFQKKWQEEMELYRQKVE (SEQ ID NO:346), PLRAELQEGARQKLHELOEKLS (SEQ ID NO:347), PLGEEMRDRARAHVDALRTHLA (SEQ ID NO:348), PYSDELRQRLAARLEALKENGG (SEQ ID NO:349), ARLAEYHAKATEHLSTLSEKAK (SEQ ID NO:350), PALEDLROGLL (SEQ ID NO:351), PVLESFKVSFLSALEEYTKKLN (SEQ ID NO:352), PVLESFVSFLSALEEYTKKLN (SEQ ID NO:353), PVLESFKVSFLSALEEYTKKLN (SEQ ID NO:352), TVLLLTICSLEGALVRRQAKEPCV (SEQ ID NO:354), QTVTDYGKDLME (SEQ ID NO:355), KVKSPELOAEAKSYFEKSKE (SEQ ID NO:356), VLTLALVAVAGARAEVSADOVATV (SEQ ID NO:357), NNAKEAVEHLOKSELTOOLNAL (SEQ ID NO:358), LPVLVWLSIVLEGPAPAOGTPDVSS (SEQ ID NO:359), LPVLVVVLSIVLEGPAPAQGTPDVSS (SEQ ID NO:360), ALDKLKEFGNTLEDKARELIS (SEQ ID NO:361), VVALLALLASARASEAEDASLL (SEQ ID NO:362), HLRKLRKRLLRDADDLQKRLAVYOA (SEQ ID NO:363), AQAWGERLRARMEEMGSRTRDR (SEQ ID NO:364), LDEVKEQVAEVRAKLEEQAQ (SEQ ID NO:365), DWLKAFYDKVAEKLKEAF (SEQ ID NO:236), DWLKAFYDKVAEKLKEAFPDWAKAAYDKAAEKAKEAA (SEQ ID NO:366), PVLDLFRELLNELLEALKQKL (SEQ ID NO:367), PVLDLFRELLNELLEALKQKLA (SEQ ID NO:368), PVLDLFRELLNELLEALKQKLK (SEQ ID NO:4), PVLDLFRELLNELLEALKQKLA (SEQ ID NO:369), PVLDLFRELLNELLEALKKLLK (SEQ ID NO:370), PVLDLFRELLNELLEALKKLLA (SEQ ID NO:371), PLLDLFRELLNELLEALKKLLA (SEQ IDNO:372) and EVRSKLEEWFAAFREFAEEFLARLKS (SEQ ID NO:373).
[0210] Amphiphilic lipids include, for example, any lipid molecule having both a hydrophobic portion and a hydrophilic portion. Examples include phospholipids or glycolipids. Examples of phospholipids that can be used for sHDL-tolerogenic antigen nanoparticles include, but are not limited to: 1,2-dilauroyl-sn-glycero-3-phosphocholine; 1,2-dimyristoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1,2-distearoyl-sn-glycero-3-phosphocholine; 1,2-diacaproyl-sn-glycero-3-phosphocholine; 1,2-dibehenoyl-sn-glycero-3-phosphocholine; 1,2-dilignoceryl-sn-glycero-3-phosphocholine; 1,2-dimyristoleoyl-sn-glycero-3-phosphocholine; 1,2-dimyristoyl-sn-glycero-3-phosphocholine; Phosphocholine; 1,2-dipalmitoleoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1,2-dioleoyl-sn-glycero-3-phosphocholine; 1,2-dioleoyl-sn-glycero-3-phosphocholine; 1,2-diarachidonoyl-sn-glycero-3-phosphocholine; 1,2-dineuroyl-sn-glycero-3-phosphocholine; 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine; 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine; 1,2-dipentadecanoyl-sn-glycero-3-phosphoethanolamine Alcoholamine; 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine; 1,2-distearoyl-sn-glycero-3-phosphoethanolamine; 1,2-dipalmitoleoyl-sn-glycero-3-phosphoethanolamine; 1,2-ditransoleoyl-sn-glycero-3-phosphoethanolamine; 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; dioleoyl-sn-glycero-3-phosphoethanolamine-N-[3-(2-pyridyldithio)propionate]; 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine; 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidophenyl)butyramide]; 1, 2-Dixiezaoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidophenyl)butyramide]; 1,2-Dixiezaoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidomethyl)cyclohexane-carboxamide]; 1,2-Di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidomethyl)cyclohexane-carboxamide]; N-[(3-maleimido-1-oxyylidenepropyl)aminopropylpolyethylene glycol-carbamoyl]distearoylphosphatidyl-ethanolamine; N-[(3-maleimido-1-oxyylidenepropyl)aminopropylpolyethylene glycol-carbamoyl]distearoylphosphatidyl-ethanolamine;Distearoyl-N-(3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine; N-[(3-maleimido-1-oxyylidenepropyl)aminopropyl polyethylene glycol-carbamoyl] distearoylphosphatidyl-ethanolamine; Dimyristoyl-N-(3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine; Dioleoyl-N- (3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine; dipalmitoyl-N-(3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine; 1-palmitoyl-2-oleoyl-N-(3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine; phosphatidylcholine; phosphatidylinositol; phosphatidylserine; Phosphatidylethanolamine; distearoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine; dioleoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine; 1-palmitoyl-2-oleoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine; dipalmitoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine; dimyristoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine; 3-(N-succinimidyloxyglutaryl)aminopropyl and polyethylene glycol-carbamoyl distearoyl phosphatidyl-ethanolamine; N-(3-oxyylidenepropoxypolyethylene glycol)carbamoyl-distearoyl-ethanolamine. ;
[0211] In some embodiments, the sHDL nanoparticles have a molar ratio of phospholipids / HDL apolipoprotein of 2 to 250 (e.g., 10 to 200, 20 to 100, 20 to 50, 30 to 40).
[0212] In general, the sHDL nanoparticles so formed are spherical or disc-shaped and have a diameter of about 5 nm to about 20 nm (e.g., 4-75 nm, 4-60 nm, 4-50 nm, 4-22 nm, 6-18 nm, 8-15 nm, 8-10 nm, etc.) In some embodiments, the sHDL nanoparticles are subjected to size exclusion chromatography to produce a more uniform preparation.
[0213] Such compositions are not limited to specific tolerogenic antigens involved in autoimmune diseases (eg, MS or celiac disease).
[0214] Tolerogenic antigen
[0215] The present invention includes compositions and methods for treating autoimmune diseases (e.g., MS or celiac disease) comprising nanoparticles associated with a plurality of tolerogenic antigens (e.g., 1-30 tolerogenic antigens (e.g., 8-30 tolerogenic antigens per nanoparticle) involved in the autoimmune disease (e.g., MS or celiac disease), and methods of using such nanoparticles. In the present invention, a tolerogenic antigen is an antigen that has been identified as playing a role in the autoimmune disease (e.g., MS or celiac disease). In some embodiments, the tolerogenic antigen is about 3 amino acids in length. In some embodiments, the tolerogenic antigen is a single tolerogenic antigen of about 3 to about 50 amino acids in length (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids in length).
[0216] In celiac disease, the major antigens are tissue transglutaminase and gliadin (eg, α-, γ-, and ω-gliadins). Any antigen identified as a tissue transglutaminase or gliadin antigen may be used.
[0217] In some embodiments, the antigen associated with the nanoparticle comprises a gliadin polypeptide, such as a full-length gliadin polypeptide or any epitope of a gliadin polypeptide. In some embodiments, the antigen associated with the nanoparticle comprises a 33-mer polypeptide from α2-gliadin. In some embodiments, the 33-mer gliadin polypeptide has at least 90% (at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%) sequence identity to the polypeptide sequence of LQLQPFPQPELPYPQPELPYPQPELPYPQPQPF (SEQ ID NO: 374). In some embodiments, the antigen associated with the nanoparticle comprises an epitope of a 33-mer gliadin polypeptide. The epitope of the 33-mer gliadin polypeptide can be a polypeptide of any length shorter than the 33-mer polypeptide, for example, the length of the epitope can include between 25 and 3 (e.g., 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, or 3) amino acid residues, between 20 and 5 (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, or 5) amino acid residues, between 12 and 6 (e.g., 12, 11, 10, 9, 8, 7, or 6) amino acid residues, or 9 amino acids. Additional examples of epitopes of 33-gliadin that can be associated with nanoparticles include any of the epitopes described in Table 3, including SEQ ID Nos: 375-405. In some embodiments, the tolerogenic antigen associated with the nanoparticle may include any one of the antigens described in Table 4, including SEQ ID Nos: 406-580. In some embodiments, the antigen associated with the nanoparticle includes a polypeptide sequence having at least 85% (e.g., at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 95%, or 100%) sequence identity with any one of SEQ ID Nos: 375-580. In some embodiments, the tolerogenic antigen associated with the nanoparticle may include an antigen containing two or more (e.g., 2, 3, 4, 5, or 6) polypeptides having a polypeptide sequence of any two of SEQ ID Nos: 375-580. In some embodiments, a plurality of tolerogenic antigens associated with a nanoparticle (e.g., 1-30 (e.g., 6-30, or 8-30 (e.g., 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30)) tolerogenic antigens per nanoparticle) and every other tolerogenic antigen associated with the nanoparticle have the same identity.In some embodiments, the plurality of tolerogenic antigens associated with the nanoparticles include a population of 2-10 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10) different antigen sequences involved in the same disease; for example, the nanoparticles can be associated with 3-8 (e.g., 3, 4, 5, 6, 7, or 8), 4-6 (e.g., 4, 5, or 6), or 3-4 different polypeptide antigen sequences. In some embodiments, the nanoparticles can be associated with: (i) a first polypeptide population including an amino acid sequence of any one of SEQ ID Nos: 406-580, or a biologically active fragment or variant thereof, (ii) a second polypeptide population including an amino acid sequence of any one of SEQ ID Nos: 406-580, or a biologically active fragment or variant thereof, and (iii) a third polypeptide population including an amino acid sequence of any one of SEQ ID NOs: 406-580, or a biologically active fragment or variant thereof. In some cases, the first, second, and third polypeptide populations have different amino acid sequences. In some embodiments, the nanoparticles can be associated with: (i) a first polypeptide comprising the amino acid sequence LQPFPQPELPYPQPQ (SEQ ID NO: 474) or a biologically active fragment or variant thereof, (ii) a second polypeptide comprising the amino acid sequence QPFPQPEQPFPWQP (SEQ ID NO: 475) or a biologically active fragment or variant thereof, and (iii) a third polypeptide comprising the amino acid sequence PEQPIPEQPQPYPQQ (SEQ ID NO: 476) or a biologically active fragment or variant thereof. In some embodiments, the nanoparticles can be associated with: (i) a first polypeptide comprising the amino acid sequence LQPFPQPELPYPQPQ (SEQ ID NO: 474) or a biologically active fragment or variant thereof, (ii) a second polypeptide comprising the amino acid sequence PQQPFPQPEQPFPWQP (SEQ ID NO: 477) or a biologically active fragment or variant thereof, and (iii) a third polypeptide comprising the amino acid sequence FPEQPIPEQPQPYPQQ (SEQ ID NO: 478) or a biologically active fragment or variant thereof. In some embodiments, the nanoparticles can be associated with: (i) a first polypeptide comprising the amino acid sequence ELQPFPQPELPYPQPQ (SEQ ID NO: 506) or a biologically active fragment or variant thereof, (ii) a second polypeptide comprising the amino acid sequence EQPFPQPEQPFPWQP (SEQ ID NO: 507) or a biologically active fragment or variant thereof, and (iii) a third polypeptide comprising the amino acid sequence EPEQPIPEQPQPYPQQ (SEQ ID NO: 508) or a biologically active fragment or variant thereof.In some embodiments, the tolerogenic antigen having the polypeptide sequence of SEQ ID Nos: 506, 507 and 508 comprises an N-terminal pyroglutamic acid (pyroE). In some embodiments described herein, the tolerogenic antigen having the polypeptide sequence of SEQ ID Nos: 506, 507 and 508 comprises a C-terminal amide group. In some embodiments described herein, the tolerogenic antigen having the polypeptide sequence of SEQ ID Nos: 506, 507 and 508 comprises an N-terminal pyroE residue and a C-terminal amide group. In some embodiments, the nanoparticle can be associated with: (i) a first polypeptide comprising the amino acid sequence QLQPFPQPELPYPQPQ (SEQ ID NO: 509) or a biologically active fragment or variant thereof, (ii) a second polypeptide comprising the amino acid sequence QQPFPQPEQPFPWQP (SEQ ID NO: 510) or a biologically active fragment or variant thereof, and (iii) a third polypeptide comprising the amino acid sequence FPEQPIPEQPQPYPQQ (SEQ ID NO: 511) or a biologically active fragment or variant thereof. In some embodiments, the tolerogenic antigen having the polypeptide sequence of SEQ ID Nos: 509, 510, and 511 comprises an N-terminal acetyl group. In some embodiments described herein, the tolerogenic antigen having the polypeptide sequence of SEQ ID Nos: 509, 510, and 511 comprises a C-terminal amide group. In some embodiments described herein, the tolerogenic antigen having the polypeptide sequence of SEQ ID Nos: 509, 510, and 511 comprises an N-terminal acetyl group and a C-terminal amide group. In any of the embodiments described herein, the antigen population associated with the nanoparticle can be fully or partially deamidated. In some embodiments described herein, the tolerogenic antigen associated with the nanoparticle can include an N-terminal pyroglutamic acid (pyroE). In some embodiments described herein, the tolerogenic antigen associated with the nanoparticle can include an N-terminal acetyl group. In some embodiments described herein, the tolerogenic antigen associated with the nanoparticle can include an N-terminal amide group. In some embodiments described herein, the tolerogenic antigen associated with the nanoparticle can include a C-terminal amide group.
[0218] Table 3: CD4 + Celiac disease-associated T cell epitopes recognized by T cells
[0219]
[0220]
[0221] Table 4: Tolerogenic antigens
[0222]
[0223]
[0224]
[0225]
[0226]
[0227] In some embodiments, the tolerogenic antigen is a biologically active fragment of SEQ ID NO: 474. In some cases, the biologically active fragment of SEQ ID NO: 474 includes a polypeptide comprising the sequence of SEQ ID NO: 512. In some cases, the biologically active fragment of SEQ ID NO: 474 includes a polypeptide comprising the sequence of SEQ ID NO: 580.
[0228] In some cases, the tolerogenic antigen is a biologically active fragment of SEQ ID NO: 475. In some cases, the biologically active fragment of SEQ ID NO: 475 includes a polypeptide comprising the sequence of SEQ ID NO:542.
[0229] In some embodiments, the tolerogenic antigen is a biologically active fragment of SEQ ID NO: 476. In some cases, the biologically active fragment of SEQ ID NO: 476 includes a polypeptide comprising the sequence of SEQ ID NO:563.
[0230] In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPQPELPY (SEQ ID NO: 375). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PYPQPELPY (SEQ ID NO: 376). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQPELPYPQ (SEQ ID NO: 377). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence FRPEQPYPQ (SEQ ID NO: 378). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQQSFPEQQ (SEQ ID NO: 379). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence IQPEQPAQL (SEQ ID NO: 380). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QQPEQPYPQ (SEQ ID NO: 381). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence SQPEQEFPQ (SEQ ID NO: 382). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQPEQEFPQ (SEQ ID NO: 383). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QQPEQPFPQ (SEQ ID NO: 384). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQPEQPFCQ (SEQ ID NO: 385). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QQPFPEQPQ (SEQ ID NO: 386). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPQPEQPF (SEQ ID NO: 387). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQPEQPFPW (SEQ ID NO: 388). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFSEQEQPV (SEQ ID NO: 389). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence FSQQQESPF (SEQ ID NO: 390). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QQPIPEQPQ (SEQ ID NO: 391). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQPEQPFPQ (SEQ ID NO: 392). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PIPEQPQPY (SEQ ID NO: 393).In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence EQPIPEQPQ (SEQ ID NO: 394). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQPEQPFPQ (SEQ ID NO: 395). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PYPEQEEPF (SEQ ID NO: 396). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PYPEQEQPF (SEQ ID NO: 397). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFSEQEQPV (SEQ ID NO: 398). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence EGSFQPSQE (SEQ ID NO: 399). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence EQPQQPFPQ (SEQ ID NO: 400). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence EQPQQPYPE (SEQ ID NO: 401). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QGYYPTSPQ (SEQ ID NO: 402). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence EGSFQPSQE (SEQ ID NO: 403). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQQSFPEQE (SEQ ID NO: 404). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QGYYPTSPQ (SEQ ID NO: 405). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPQQPFPW (SEQ ID NO: 406). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPQQPIPV (SEQ ID NO: 407). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPEQPFPW (SEQ ID NO: 408). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPQPEQPIPV (SEQ ID NO: 409). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPELPFPQ (SEQ ID NO: 410). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence LPYPQPQLPYPQ (SEQ ID NO: 411). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence LPYPQPELPYPQ (SEQ ID NO: 412).In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPQLPYPQ (SEQ ID NO: 413). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPELPYPQ (SEQ ID NO: 414). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPQQPFSQ (SEQ ID NO: 415). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPEQPFSQ (SEQ ID NO: 416). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPQQPFCQ (SEQ ID NO: 417). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPEQPFCQ (SEQ ID NO: 418). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPQLPYSQ (SEQ ID NO: 419). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPELPYSQ (SEQ ID NO: 420). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence LQQQCSPVAMPQRLAR (SEQ ID NO: 421). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPQLPYLQ (SEQ ID NO: 422). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPELPYLQ (SEQ ID NO: 423). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QQFIQPQQPFPQ (SEQ ID NO: 424). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QQFIQPEQPFPQ (SEQ ID NO: 425). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence LERPWQQQPLPP (SEQ ID NO: 426). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence LERPWQEQPLPP (SEQ ID NO: 427). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PIPQQPEQPFPL (SEQ ID NO: 428). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QGQQGYYPISPQQSGQ (SEQ ID NO: 429). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QGQPGYYPTSPQQIGQ (SEQ ID NO: 430).In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PGQGQSGYYPTSPQQS (SEQ ID NO: 431). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQQTFPQQPQLP (SEQ ID NO: 432). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQQTFPEQPQLP (SEQ ID NO: 433). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence GQGQSGYYPTSPQQSG (SEQ ID NO: 434). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QYEVIRSLVLRTLPNM (SEQ ID NO: 435). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QVDPSGQVQWPQ (SEQ ID NO: 436). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QVDPSGEVQWPQ (SEQ ID NO: 437). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPQQPFPL (SEQ ID NO: 438). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPEQPFPL (SEQ ID NO: 439). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPQQPIPY (SEQ ID NO: 440). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPEQPIPY (SEQ ID NO: 441). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQQPVPQQPQPY (SEQ ID NO: 442). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQQPVPEQPQPY (SEQ ID NO: 443). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQPFPQQPIPQQPQPY (SEQ ID NO: 444). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QQPIPQQPQPY (SEQ ID NO: 445). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QQPIPEQPQPY (SEQ ID NO: 446). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QQFPQPQQPFPQ (SEQ ID NO: 447).In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QQFPQPEQPFPQ (SEQ ID NO: 448). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQQPIPQQPQPYPQQP (SEQ ID NO: 449). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QQPFPQQPFPQQPQPY (SEQ ID NO: 450). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPQQPFSW (SEQ ID NO: 451). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPEQPFSW (SEQ ID NO: 452). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQQPFPQQPQPYPQQP (SEQ ID NO: 453). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPQQPIPQ (SEQ ID NO: 454). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPEQPIPQ (SEQ ID NO: 455). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPQQPFPQ (SEQ ID NO: 456). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPEQPFPQ (SEQ ID NO: 457). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPQQPTPI (SEQ ID NO: 458). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPEQPTPI (SEQ ID NO: 459). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PAPIQPQQPFPQ (SEQ ID NO: 460). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PAPIQPEQPFPQ (SEQ ID NO: 461). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQQPFPQQPEQI (SEQ ID NO: 462). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQQPFPEQPEQI (SEQ ID NO: 463). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQQPFPQQPQQI (SEQ ID NO: 464). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQQPFPEQPQQI (SEQ ID NO: 465).In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPQQPEQIISQ (SEQ ID NO: 466). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPQQPEQIISQ (SEQ ID NO: 467). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPQQPEQIIPQ (SEQ ID NO: 468). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPQQPEQIIPQ (SEQ ID NO: 469). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPQQQLPL (SEQ ID NO: 470). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPEQQLPL (SEQ ID NO: 471). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence LFPLPQQPFPQ (SEQ ID NO: 472). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence LFPLPEQPFPQ (SEQ ID NO: 473). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence LQPFPQPELPYPQPQ (SEQ ID NO: 474). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPEQPFPWQP (SEQ ID NO: 475). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PEQPIPEQPQPYPQQ (SEQ ID NO: 476). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQQPFPQPEQPFPWQP (SEQ ID NO: 477). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence FPEQPIPEQPQPYPQQ (SEQ ID NO: 478). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PEQPIPEQPQPYPQQ (SEQ ID NO: 479). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQPFLPQLPYPQ (SEQ ID NO: 480). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QAFPQPQQTFPH (SEQ ID NO: 481). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence TPIQPQQPFPQ (SEQ ID NO: 482).In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPLQPQQPFPQ (SEQ ID NO: 483). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFTQPQQPTPI (SEQ ID NO: 484). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQLQQPQQP (SEQ ID NO: 485). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence VAHAIIMHQQQQQQQE (SEQ ID NO: 486). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence SYPVQPQQPFPQ (SEQ ID NO: 487). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQQPQPFPQQPVPQQP (SEQ ID NO: 488). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPWQPQQPFPQ (SEQ ID NO: 489). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPLQPQQPFPQ (SEQ ID NO: 490). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QQPFQPQQPFPQ (SEQ ID NO: 491). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence NPLQPQQPFPLQPQPP (SEQ ID NO: 492). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PLQPQQPFPLQPQPPQ (SEQ ID NO: 493). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PNPLQPQQPFPLQ (SEQ ID NO: 494). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence TIPQQPQQPFPL (SEQ ID NO: 495). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence SFSQQPQQPFPL (SEQ ID NO: 496). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence SFSEQPQQPFPL (SEQ ID NO: 497). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence YSPYQPQQPFPQ (SEQ ID NO: 498). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QLPLQPQQPFPQ (SEQ ID NO: 499).In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QQPQQPFPLQPQQPVP (SEQ ID NO: 500). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence IIPQQPQQPFPL (SEQ ID NO: 501). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PEQIIPQQPQQP (SEQ ID NO: 502). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence FLLQPQQPFSQ (SEQ ID NO: 503). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence IISQQPQQPFPL (SEQ ID NO: 504). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPQRPQQPFPQ (SEQ ID NO: 505). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence ELQPFPQPELPYPQPQ (SEQ ID NO: 506). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence EQPFPQPEQPFPWQP (SEQ ID NO: 507). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence EPEQPIPEQPQPYPQQ (SEQ ID NO: 508). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QLQPFPQPELPYPQPQ (SEQ ID NO: 509). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QQPFPQPEQPFPWQP (SEQ ID NO: 510). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence FPEQPIPEQPQPYPQQ (SEQ ID NO: 511). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PELP (SEQ ID NO: 512). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPELPYP (SEQ ID NO: 513). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQPELPY (SEQ ID NO: 514). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence FPQPELP (SEQ ID NO: 515). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PELPYPQP (SEQ ID NO: 516). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPELPYPQ (SEQ ID NO: 517).In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQPELPYP (SEQ ID NO: 518). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence FPQPELPY (SEQ ID NO: 519). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPQPELP (SEQ ID NO: 520). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PELPYPQPQ (SEQ ID NO: 521). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPELPYPQP (SEQ ID NO: 522). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence FPQPELPYP (SEQ ID NO: 523). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPQPELPY (SEQ ID NO: 524). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPELP (SEQ ID NO: 525). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPELPYPQPQ (SEQ ID NO: 526). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQPELPYPQP (SEQ ID NO: 527). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence FPQPELPYPQ (SEQ ID NO: 528). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPQPELPYP (SEQ ID NO: 529). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPELPY (SEQ ID NO: 530). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence LQPFPQPELP (SEQ ID NO: 531). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQPELPYPQPQ (SEQ ID NO: 532). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence FPQPELPYPQP (SEQ ID NO: 533). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPQPELPYPQ (SEQ ID NO: 534). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPELPYP (SEQ ID NO: 535). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence LQPFPQPELPY (SEQ ID NO: 536).In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence FPQPELPYPQPQ (SEQ ID NO: 537). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPQPELPYPQP (SEQ ID NO: 538). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence LQPFPQPELPYP (SEQ ID NO: 539). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPQPELPYPQPQ (SEQ ID NO: 540). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence LQPFPQPELPYPQ (SEQ ID NO: 541). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPEQPF (SEQ ID NO: 542). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPEQPFP (SEQ ID NO: 543). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQPEQPF (SEQ ID NO: 544). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPEQPFPW (SEQ ID NO: 545). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQPEQPFP (SEQ ID NO: 546). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence FPQPEQPF (SEQ ID NO: 547). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPEQPFPWQ (SEQ ID NO: 548). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence FPQPEQPFP (SEQ ID NO: 549). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPEQPFPWQP (SEQ ID NO: 550). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQPEQPFPWQ (SEQ ID NO: 551). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence FPQPEQPFPW (SEQ ID NO: 552). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPQPEQPFP (SEQ ID NO: 553). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPEQPF (SEQ ID NO: 554). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PQPEQPFPWQP (SEQ ID NO: 555).In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence FPQPEQPFPWQ (SEQ ID NO: 556). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPQPEQPFPW (SEQ ID NO: 557). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPEQPFP (SEQ ID NO: 558). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence FPQPEQPFPWQP (SEQ ID NO: 559). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPQPEQPFPWQ (SEQ ID NO: 560). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PFPQPEQPFPWQP (SEQ ID NO: 561). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPEQPFPWQ (SEQ ID NO: 562). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PIPEQPQ (SEQ ID NO: 563). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PIPEQPQP (SEQ ID NO: 564). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPIPEQPQ (SEQ ID NO: 565). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPIPEQPQP (SEQ ID NO: 566). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PIPEQPQPYP (SEQ ID NO: 567). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPIPEQPQPY (SEQ ID NO: 568). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence EQPIPEQPQP (SEQ ID NO: 569). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PEQPIPEQPQ (SEQ ID NO: 570). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PIPEQPQPYPQQ (SEQ ID NO: 571). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPIPEQPQPYPQ (SEQ ID NO: 572). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence EQPIPEQPQPYP (SEQ ID NO: 573).In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PEQPIPEQPQPY (SEQ ID NO: 574). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPIPEQPQPYPQQ (SEQ ID NO: 575). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence EQPIPEQPQPYPQ (SEQ ID NO: 576). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PEQPIPEQPQPYP (SEQ ID NO: 577). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence EQPIPEQPQPYPQQ (SEQ ID NO: 578). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PEQPIPEQPQPYPQ (SEQ ID NO: 579). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PDLP (SEQ ID NO: 580). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PELPYPQ (SEQ ID NO: 581). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPELPYPQP (SEQ ID NO: 582). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPFPQPELPYPQPQ (SEQ ID NO: 583). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence LQPFPQPELPYPQP (SEQ ID NO: 584). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PIPEQPQPYPQ (SEQ ID NO: 585). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence QPIPEQPQPYP (SEQ ID NO: 586). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence EQPIPEQPQPY (SEQ ID NO: 587). In some embodiments, the tolerogenic antigen comprises a polypeptide comprising the amino acid sequence PEQPIPEQPQP (SEQ ID NO: 588).
[0231] In some embodiments, such tolerogenic antigens include human allograft antigens. Examples of such human allograft antigens include, but are not limited to, subunits of various MHC class I and MHC class II haplotype proteins, and single amino acid polymorphisms on minor blood group antigens including RhCE, Kell, Kidd, Duffy, and Ss.
[0232] In some embodiments, a tolerogenic antigen is an autoantigen to which a subject (e.g., a human patient) has generated an autoimmune response or may generate an autoimmune response. Examples include proinsulin (e.g., for subjects with diabetes or at risk of diabetes), collagen (e.g., for subjects with rheumatoid arthritis or at risk of rheumatoid arthritis), and myelin basic protein (e.g., for subjects with multiple sclerosis or at risk of multiple sclerosis). There are many proteins that are human autoimmune proteins, a term that refers to various autoimmune diseases in which one or more proteins causing the disease are known or can be determined by conventional tests. Embodiments include testing patients to identify autoimmune proteins and generating antigens for molecular fusion and generating immune tolerance to the protein. Embodiments include antigens, or selecting antigens from one or more of the following proteins. In type 1 diabetes, several major antigens have been identified: insulin, proinsulin, preproinsulin, glutamic acid decarboxylase 65 (GAD-65), GAD-67, insulinoma-associated protein 2 (IA-2), and insulinoma-associated protein 2β (IA-2β); others include ICA69, ICA12 (SOX-13), carboxypeptidase H, Imogen 38, GLIMA38, chromogranin A, HSP-60, carboxypeptidase E, peripherin, glucose transporter 2, hepatocarcinoma-entero-pancreatic / pancreas-associated protein, S100β, glial fibrillary acidic protein, regeneration gene II, pancreatic duodenal homeobox 1, dystrophic myotonic kinase, islet-specific glucose-6-phosphatase catalytic subunit-associated protein, and SST G protein-coupled receptors 1-5. In thyroid autoimmune diseases, including Hashimoto's thyroiditis and Graves' disease, the major antigens include thyroglobulin (TG), thyroid peroxidase (TPO), and thyroid-stimulating hormone receptor (TSHR); other antigens include the sodium-iodide transporter (NIS) and megalin. In thyroid-related eye and skin diseases, in addition to thyroid autoantigens including TSHR, the antigen is the insulin-like growth factor 1 receptor. In hypoparathyroidism, the major antigen is the calcium-sensing receptor. In Addison's disease, the major antigens include 21-hydroxylase, 17α-hydroxylase, and P450 side-chain cleavage enzyme (P450scc); other antigens include ACTH receptor, P450c21, and P450c17. In premature ovarian failure, the major antigens include FSH receptor and α-enolase. In autoimmune hypophysitis or pituitary autoimmune diseases, the major antigens include pituitary-specific protein factor (PGSF) 1a and 2; another antigen is type 2 iodothyronine deiodinase. In multiple sclerosis, the major antigens include myelin basic protein, myelin oligodendrocyte glycoprotein, and proteolipid protein. In rheumatoid arthritis, the major antigen is collagen II. In immune gastritis, the major antigen is H + , K+ -ATPase. In pernicious anemia, the major antigen is intrinsic factor. In celiac disease, the major antigens are tissue transglutaminase and gliadin. In vitiligo, the major antigens are tyrosinase, and tyrosinase-related proteins 1 and 2. In myasthenia gravis, the major antigen is the acetylcholine receptor. In pemphigus vulgaris and variants, the major antigens are desmocollins 3, 1, and 4; other antigens include annexins (pemphaxin), desmocollins, plakoglobin, perifollicular proteins, desmoplakin, and acetylcholine receptors. In bullous pemphigoid, the major antigens include BP180 and BP230; other antigens include plectin and laminin 5. In dermatitis herpetiformis Duling disease, the major antigens include endomysial and tissue transglutaminase. In epidermolysis bullosa acquisita, the major antigen is collagen VII. In systemic sclerosis, the major antigens include matrix metalloproteinases 1 and 3, the collagen-specific chaperone heat-shock protein 47, fibrillin 1, and the PDGF receptor; other antigens include Scl-70, U1 RNP, Th / To, Ku, Jo1, NAG-2, centromere proteins, topoisomerase I, nucleolar proteins, RNA polymerases I, II, and III, PM-Slc, fibrillin, and B23. In mixed connective tissue disease, the major antigen is U1snRNP. In Sjögren's syndrome, the major antigens are the nuclear antigens SS-A and SS-B; other antigens include fodrin, poly(ADP-ribose) polymerase, and topoisomerase. In systemic lupus erythematosus, the major antigens include nuclear proteins containing the following: SS-A, high-mobility group protein B1 (HMGB1), nucleosomes, histones, and double-stranded DNA. In Goodpasture's syndrome, the major antigens include glomerular basement membrane proteins containing collagen IV. In rheumatic heart disease, the major antigen is cardiac myosin. Other autoantigens found in type 1 autoimmune polyglandular syndrome include aromatic L-amino acid decarboxylase, histidine decarboxylase, cysteine sulfenic acid decarboxylase, tryptophan hydroxylase, tyrosine hydroxylase, phenylalanine hydroxylase, hepatic P450 cytochromes P450 1A2 and 2A6, SOX-9, SOX-10, calcium-sensing receptor protein, and type 1 interferons interferon alpha, beta, and omega.
[0233] In some cases, the tolerogenic antigen is a foreign antigen against which the patient has developed an undesirable immune response. An example is a food antigen. Embodiments include testing the patient to identify the foreign antigen and generating a molecule fusion comprising the antigen and treating the patient to develop immune tolerance to the antigen or food. Examples of such foods and / or antigens are provided. Examples are from peanut: conarachin (Ara h 1), allergen II (Ara h 2), peanut agglutinin, conglutin (Ara h 6); from apple: 31 kDa major allergen / disease resistance protein homolog (Mal d 2), lipid transfer protein precursor (Mal d 3), major allergen Mal d 1.03D (Mal d 1); from milk: α-lactalbumin (ALA), lactotransferrin; from kiwifruit: actinidin (Act c 1, Act d 1), phytocystatin, thaumatin-like protein (Act d 2), kiwellin (Act d 5); from mustard: 2S albumin (Sin a 1), 11S globulin (Sin a 2), lipid transfer protein (Sin a 3), inhibitor protein (Sina 4); from celery: inhibitor protein (Api g 4), high molecular weight glycoprotein (Api g 5); from shrimp: Pen a 1 allergen (Pen a 1), allergen Pen m 2 (Pen m 2), tropomyosin fast isomer; from wheat and / or other cereals: high molecular weight glutenin, low molecular weight glutenin, α- and γ-gliadin, hordein, secalin, avena protein; from strawberry: major strawberry allergy Fra a 1-E (Fra a 1), from banana: inhibitor protein (Musxp 1). In some embodiments, the tolerogenic antigen is an antigenic peptide of any one of SEQ ID No: 589-742 (Table 5).
[0234] Table 5. Tolerogenic antigens (continued)
[0235]
[0236]
[0237]
[0238]
[0239]
[0240]
[0241]
[0242]
[0243]
[0244]
[0245]
[0246]
[0247]
[0248]
[0249] In some instances, the autoimmune disease is type 1 diabetes, and the tolerogenic antigen is derived from carboxypeptidase H, chromogranin A, glutamate decarboxylase, Imogen-38, insulin, insulinoma antigen-2 and 2β, islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), pancreatic β-cell antigen, or proinsulin.
[0250] In some instances, the autoimmune disease is MS and the tolerogenic antigen is derived from alpha-enolase, aquaporin-4, beta-arrestin, myelin basic protein, myelin oligodendrocyte glycoprotein, proteolipid protein, or S100-beta.
[0251] In some instances, the autoimmune disease is rheumatoid arthritis and the tolerogenic antigen is derived from citrullinated proteins, collagen II, heat shock proteins, gp130-RAPS, or human cartilage glycoprotein 39.
[0252] In some instances, the autoimmune disease is systemic lupus erythematosus and the tolerogenic antigen is derived from a La antigen, a nucleosomal histone and ribonucleoprotein (snRNP), a phospholipid-β-2 glycoprotein I complex, poly (ADP-ribose) polymerase, a glycoprotein gp70, or an Sm antigen of a U-1 small nuclear ribonucleoprotein complex.
[0253] In some cases, the autoimmune disease is scleroderma, and the tolerogenic antigen is derived from fibrillarin or small nucleolar proteins (snoRNPs).
[0254] In some embodiments, the autoimmune disease is Graves' disease and the tolerogenic antigen is derived from the thyroid stimulating factor receptor (TSH-R).
[0255] In some instances, the autoimmune disease is biliary cirrhosis and the tolerogenic antigen is derived from pyruvate dehydrogenase dihydrolipoamide acetyltransferase (PCD-E2).
[0256] In some embodiments, the autoimmune disease is alopecia areata and the tolerogenic antigen is derived from a hair follicle antigen.
[0257] In some instances, the autoimmune disease is ulcerative colitis, and the tolerogenic antigen is derived from human tropomyosin isoform 5 (hTM5).
[0258] In some cases, the tolerogenic antigen is derived from an antigen selected from the group consisting of: 17-hydroxylase, 21-hydroxylase, ADAMTS13, annexin A5, apoH, AQP4, aromatic acid carboxylase, basement membrane collagen type IV, BP-1, BP-2, carbonic anhydrase, carboxypeptidase H, cardiolipin, cardiolipin, chromogranin A, complement component 3, desmosome mucin 3, enolase, epidermal transglutaminase, GD1a, gliadin, glutamate receptor, glutamate Acid decarboxylase, glycoprotein IIb-IIIa or Ib-IX, GMCSF, gpIIb-IIIa or 1b-IX, GQ1b, GQ1b, histidine-tRNA, histone, HPA-1a, HPA-5b, HSP60, HSP70, HSP90, Hu, IA-2β, IAPP, ICA69, IFN-γ, IGRP, IL-1, insulin, insulinoma antigen-2, interferon omega, Jo1, keratin, Kir4.1 , LA, LKM-1, LKM-1, LKM-2, LKM-3, LP, major peripheral myelin protein P0, Mi-2, muscarinic acetylcholine receptor M1, MuSK protein; hypocretin, myelin-associated glycoprotein (MAG), myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), myelin-associated oligodendrocyte basic protein cardiac myosin, myeloperoxidase, neurofilaments, nicotinic acetylcholine receptor, orexin, outer surface protein (O SP), p62, phosphatidylserine, proteolipid protein (PLP), pyruvate dehydrogenase, Q-type calcium channel, Ro, sc170, signal recognition peptide, SMA, soluble liver antigen, sp100, synaptotagmin, thyroglobulin, thyroid peroxidase, tissue transglutaminase, TNF-α, topoisomerase, transglutaminase, type XVII collagen, U1-RNP, voltage-gated calcium channel, Yo, ZnT8, β2-glycoprotein I, or β2-glycoprotein I.
[0259] Tolerogenic antigens may also include, but are not limited to, hInsB 10-18 (HLVEALYLV(SEQ ID NO:743)), hIGRP 228-236(LNIDLLWSV(SEQ ID NO:744)), hIGRP 265-273 (VLFGLGFAI(SEQ ID NO:745)), IGRP 206-214 (VYLKTNVFL(SEQ ID NO:746)), NRP-A7(KYNKANAFL(SEQ ID NO:747)), NRP-I4(KYNIANVFL(SEQ ID NO:748)), NRP-V7(KYNKANVFL(SEQ ID NO:749)), YAI / Db(FQDENYLYL(SEQ ID NO:750)) and / or INS B 15-23 (LYLVCGERG (SEQ ID NO: 751)), and peptides and proteins disclosed in U.S. Publication No. 20050202032.
[0260] In certain aspects, the peptide antigen for treating type 1 diabetes is GAD65 114123 ,VMNILLQYVV(SEQ ID NO:752);GAD65 536-545 , RMMEYGTTMV (SEQ ID NO:753); GFAP 143-151 , NLAQTDLATV (SEQ ID NO:754); GFAP 214-222 , QLARQQVHV (SEQ ID NO:755); IA-2 172-180 , SLSPLQAEL (SEQ ID NO:756); IA-2 482-490 , SLAAGVKLL (SEQ ID NO:757); IA-2 805-813 , VIVMLTPLV (SEQ ID NO:758); ppIAPP 5-13 , KLQVFLIVL (SEQ ID NO:759); ppIAPP 9-17 , FLIVLSVAL (SEQ ID NO:760); IGRP 152-160 , FLWSVFMLI (SEQ ID NO:761); IGRP 211-219 , NLFLFLFAV (SEQ ID NO:762); IGRP 215-223 , FLFAVGFYL (SEQ ID NO:763); IGRP 222-230 , YLLLRVLNI (SEQ ID NO:764); IGRP 228-236 , LNIDLLWSV (SEQ ID NO:744); IGRP 265-273, VLFGLGFAI (SEQ ID NO:745); IGRP 293-301 , RLLCALTSL (SEQ ID NO: 765); Proinsulin L2-10 ,ALWMRLLPL (SEQ ID NO: 766); Proinsulin L3-11 ,LWMRLLPLL (SEQ ID NO: 767); Proinsulin L6-14 ,RLLPLLALL (SEQ ID NO: 768); Proinsulin B5-14 ,HLCGSHLVEA (SEQ ID NO: 769); Proinsulin B10-18 ,HLVEALYLV(SEQ ID NO:743); Proinsulin B14-22 ,ALYLVCGER (SEQ ID NO: 770); Proinsulin B15-24 ,LYLVCGERGF (SEQ ID NO: 771); Proinsulin B17-25 ,LVCGERGFF (SEQ ID NO: 772); Proinsulin B18-27 ,VCGERGFFYT (SEQ ID NO: 773); Proinsulin B20-27 ,GERGFFYT (SEQ ID NO: 774); Proinsulin B21-29 ,ERGFFYTPK (SEQ ID NO: 775); Proinsulin B25-C1 ,FYTPKTRRE(SEQ ID NO:776);Proinsulin B27-C5 ,TPKTRREAEDL (SEQ ID NO: 777); Proinsulin C20-28 ,SLQPLALEG (SEQ ID NO: 778); Proinsulin C25-33 ,ALEGSLQKR (SEQ ID NO: 779); Proinsulin C29-A5 ,SLQKRGIVEQ (SEQ ID NO: 780); Proinsulin A1-10 ,GIVEQCCTSI (SEQ ID NO: 781); Proinsulin A2-10 ,IVEQCCTSI (SEQ ID NO: 782); Proinsulin A12-20 , SLYQLENYC (SEQ ID NO: 783), or a combination thereof.
[0261] In a further aspect, tolerogenic antigens associated with multiple sclerosis (MS) may be used and include: MAG 287-295, SLLLELEEV (SEQ ID NO:784); MAG 509-517 , LMWAKIGPV (SEQ ID NO:785); MAG 556-564 , VLFSSDFRI (SEQ ID NO:786); MBP 110-118 , SLSRFSWGA (SEQ ID NO:787); MOG 114-122 , KVEDPFYWV (SEQ ID NO:788); MOG 166-175 , RTFDPHFLRV (SEQ ID NO:789); MOG 172-180 , FLRVPCWKI (SEQ IDNO:790); MOG 179-188 , KITLFVIVPV (SEQ ID NO:791); MOG 188-196 , VLGPLVALI (SEQ ID NO:792); MOG 181-189 , TLFVIVPVL (SEQ ID NO:793); MOG 205-214 , RLAGQFLEEL (SEQ ID NO:794); PLP 80-88 , FLYGALLLA (SEQ ID NO: 795), or a combination thereof.
[0262] In some cases, tolerogenic antigens associated with systemic lupus erythematosus can be used, including but not limited to FIEWNKLRFRQGLEW (SEQ ID NO: 796). In some cases, the tolerogenic antigen comprising a polypeptide having the sequence of SEQ ID NO: 796 comprises at least one amino acid portion that is a D-amino acid.
[0263] Multimeric tolerogenic antigen
[0264] In certain embodiments, the tolerogenic antigens provided herein are multimeric tolerogenic antigens. In one example, the multimeric tolerogenic antigen comprises two or more tolerogenic antigens (e.g., tolerogenic antigens described herein) connected by a linker (e.g., a peptide linker). In some cases, the tolerogenic antigen comprises the following N-terminal to C-terminal structure:
[0265] (P4-L4) n4 -(P3-L3) n3 -P2-(L1-P1) n1
[0266] wherein P1, P2, P3 and P4 are each independently selected from any tolerogenic antigen described herein (e.g., any tolerogenic antigen from Tables 3-5); L1, L3 and L4 are each independently a linker; and n1, n3 and n4 are each independently 0 or 1, wherein at least one of n1, n3 and n4 is 1.
[0267] In some cases, n1 is 1, n3 is 0, and n4 is 0, and the tolerogenic antigen comprises the following N-terminal to C-terminal structure:
[0268] P2-L1-P1.
[0269] In some cases, the peptide linker includes 2 to 200 amino acids (e.g., 5 to 50 (e.g., 5 to 20, 15 to 30, 25 to 40, or 35 to 50), 45 to 100 (e.g., 45 to 60, 55 to 70, 65 to 80, 75 to 90, or 85 to 100), 95 to 150 (e.g., 95 to 110, 105 to 120, 115 to 130, 125 to 140, or 135 to 150), or 145 to 200 amino acids (e.g., 145 to 160, 155 to 170, 165 to 180, 175 to 190, or 185 to 200)). In some cases, the peptide linker includes glycine (Gly) and serine (Ser) amino acids. In some cases, the peptide linker includes (GS) x 、(GGS) x , (GGGGS (SEQ ID NO: 797)) x 、(GGSG) x 、(SGGG) x The amino acid sequence of any one of , wherein x is an integer from 1 to 10. In certain embodiments, the linker comprises (GGGGS (SEQ ID NO: 797)) x wherein x is an integer from 2 to 5. In some cases, P2 and P1 are different tolerogenic antigens. In some cases, P2 and P1 are the same tolerogenic antigen.
[0270] In some cases, n1 is 1, n3 is 1, and n4 is 0, and the tolerogenic antigen includes the following N-terminal to C-terminal structure:
[0271] P3-L3-P2-L1-P1.
[0272] In some cases, each peptide linker independently includes 2 to 200 amino acids (e.g., 5 to 50 (e.g., 5 to 20, 15 to 30, 25 to 40, or 35 to 50), 45 to 100 (e.g., 45 to 60, 55 to 70, 65 to 80, 75 to 90, or 85 to 100), 95 to 150 (e.g., 95 to 110, 105 to 120, 115 to 130, 125 to 140, or 135 to 150), or 145 to 200 amino acids (e.g., 145 to 160, 155 to 170, 165 to 180, 175 to 190, or 185 to 200)). In some cases, the peptide linker includes glycine (Gly) and serine (Ser) amino acids. In some cases, the peptide linker includes (GS) x 、(GGS) x , (GGGGS (SEQ ID NO: 797)) x 、(GGSG) x 、(SGGG) x The amino acid sequence of any one of , wherein x is an integer from 1 to 10. In certain embodiments, the linker comprises (GGGGS (SEQ ID NO: 797)) x wherein x is an integer from 2 to 5. In some cases, P3, P2 and / or P1 are different tolerogenic antigens. In some cases, P3, P2 and / or P1 are the same tolerogenic antigen.
[0273] In some cases, n1 is 1, n3 is 1, and n4 is 1, and the tolerogenic antigen comprises the following N-terminal to C-terminal structure:
[0274] P4-L4-P3-L3-P2-L1-P1.
[0275] In some cases, each peptide linker independently includes 2 to 200 amino acids (e.g., 5 to 50 (e.g., 5 to 20, 15 to 30, 25 to 40, or 35 to 50), 45 to 100 (e.g., 45 to 60, 55 to 70, 65 to 80, 75 to 90, or 85 to 100), 95 to 150 (e.g., 95 to 110, 105 to 120, 115 to 130, 125 to 140, or 135 to 150), or 145 to 200 amino acids (e.g., 145 to 160, 155 to 170, 165 to 180, 175 to 190, or 185 to 200)). In some cases, the peptide linker includes glycine (Gly) and serine (Ser) amino acids. In some cases, the peptide linker includes (GS) x 、(GGS) x , (GGGGS (SEQ ID NO: 797)) x 、(GGSG)x 、(SGGG) x The amino acid sequence of any one of , wherein x is an integer from 1 to 10. In certain embodiments, the linker comprises (GGGGS (SEQ ID NO: 797)) x wherein x is an integer from 2 to 5. In some cases, P4, P3, P2 and / or P1 are different tolerogenic antigens. In some cases, P4, P3, P2 and / or P1 are the same tolerogenic antigen.
[0276] In some embodiments, the tolerogenic antigen is conjugated to the nanoparticle phospholipid in a manner that promotes strong immune tolerance upon administration to a subject (e.g., a human subject having or at risk for an autoimmune disorder (e.g., MS or celiac disease)).
[0277] In some embodiments, the tolerogenic antigen is conjugated to the nanoparticle phospholipid via a thiol-reactive and reduction-insensitive bond between the tolerogenic antigen and the nanoparticle phospholipid. In fact, the thiol-reactive and reduction-insensitive bond between the tolerogenic antigen and the nanoparticle phospholipid promotes strong immune tolerance. In some embodiments, the phospholipid is, for example, N-(3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine.
[0278] In some embodiments, the tolerogenic antigen is conjugated to the nanoparticle phospholipid via an amine-mediated interaction. For example, in some embodiments, the amine-mediated interaction is through an amine-reactive phospholipid (e.g., dioleoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine (DOPE-NHS)). In some embodiments, the amine-mediated interaction is through an amine-reactive phospholipid with a self-destructive bond (e.g., a linker comprising an o-dithiobenzyl, p-dithiobenzyl, β-dithiobenzylcarbamate moiety, 2,2-dimethyl-4-mercapto-butyric acid, or a disulfide-carbonate / salt-based traceless linker).
[0279] In some embodiments, the amount of tolerogenic antigen associated with a particular nanoparticle is any amount that promotes strong immune tolerance upon administration to a subject (e.g., a human subject having or at risk for an autoimmune disorder (e.g., MS or celiac disease). In some embodiments, the amount of tolerogenic antigen associated with a particular nanoparticle is 1 to 30 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30).
[0280] Tolerogenic antigens can be prepared by a variety of techniques known in the art, depending on the nature of the molecule. Polynucleotide, polypeptide and carbohydrate antigens can be isolated from cells of the species to be treated in which they are enriched. Short peptides are conveniently prepared by amino acid synthesis. Longer proteins of known sequence can be prepared by synthesizing the coding sequence from a natural source or vector or by PCR amplifying the coding sequence and then expressing the coding sequence in a suitable bacterial or eukaryotic host cell.
[0281] In some embodiments of the compositions described herein, the nanoparticles with multiple tolerogenic antigens include a linker between the tolerogenic antigen and the nanoparticle. In some embodiments, the linker refers to a covalent bond or connection between the tolerogenic antigen and the phospholipid group of the nanoparticle. In some embodiments, the N-terminus and / or C-terminus of the tolerogenic antigen is modified with a terminal cysteine residue that is attached to the linker. In some embodiments, the N-terminus and / or C-terminus of the tolerogenic antigen is modified with a terminal C(S) n Polypeptide modification, wherein n is 1-10 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10) serine residues, and wherein the terminal serine residue is linked to a linker. In some embodiments, the N-terminus and / or C-terminus of the tolerogenic antigen is modified with a terminal CSS polypeptide, which is linked to a linker. In some embodiments, the linker is a thiol-reactive cross-linker. In some embodiments, the linker is a maleimide linker. In some embodiments, the linker is a pyridyl linker. In some embodiments, the N-terminus and / or C-terminus of the tolerogenic antigen is modified with a terminal cysteine residue, which is linked to a maleimide linker. In some embodiments, the N-terminus and / or C-terminus of the tolerogenic antigen is modified with a terminal cysteine residue, which is linked to a pyridyl linker. In some embodiments, the N-terminus and / or C-terminus of the tolerogenic antigen is modified with a terminal CSS polypeptide, which is linked to a maleimide linker. In some embodiments, the N-terminus and / or C-terminus of the tolerogenic antigen is modified with a terminal CSS polypeptide, which is linked to a pyridyl linker. The linker can be linked to a nucleoside or nucleotide modified on a nucleobase (e.g., Cys and Ser) or a sugar moiety at a first terminus and to a payload (e.g., a lipid, such as a phospholipid) at a second terminus.
[0282] The joint can be a chemical joint known to those skilled in the art. The joint can alternatively be a peptide joint. The joint can have a sufficient length so as not to interfere with the polypeptide sequence or lipid portion. Examples of chemical groups that can be incorporated into the joint include, but are not limited to, alkyl, alkenyl, alkynyl, amide, amino, ether, thioether, ester, alkylene, heteroalkylene, aryl or heterocyclic groups, each of which can be optionally substituted. The joint can include a synthetic group derived from, for example, a synthetic polymer (e.g., polyethylene glycol (PEG) polymer). In some embodiments, the joint can include one or more amino acid residues, such as D-amino acids or L-amino acid residues. Other examples of useful joints include those containing electrophiles, such as Michael acceptors (e.g., maleimide), activated esters, electron-deficient carbonyl compounds and aldehydes, etc., which are suitable for reacting with nucleophilic substituents present in antibodies, antigen-binding fragments, proteins, peptides and small molecules (such as amines and thiol moieties).
[0283] In the present invention, the linker between the multimeric tolerogenic antigens (e.g., L1, L3 and / or L4) can be a polypeptide comprising 2 to 200 amino acids (e.g., 5 to 50 (e.g., 5 to 20, 15 to 30, 25 to 40, or 35 to 50), 45 to 100 (e.g., 45 to 60, 55 to 70, 65 to 80, 75 to 90, or 85 to 100), 95 to 150 (e.g., 95 to 110, 105 to 120, 115 to 130, 125 to 140, or 150 to 160). 135 to 150), or 145 to 200 amino acids (e.g., 145 to 160, 155 to 170, 165 to 180, 175 to 190, or 185 to 200). In some embodiments, the linker between the multimeric tolerogenic antigens (e.g., L1, L3, and / or L4) is a polypeptide comprising at least 12 amino acids, such as 12-200 amino acids (e.g., 12-200, 12-180, 12-160, 12-140, 12-120, 12 -100, 12-90, 12-80, 12-70, 12-60, 12-50, 12-40, 12-30, 12-20, 12-19, 12-18, 12-17, 12-16, 12-15, 12-14, or 12-13 amino acids) (e.g., 14-200, 16-200, 18-200, 20-200, 30-200, 40-200, 50-200, 60-200, 70-200, 80-200, 90 In some embodiments, the linker between the multimeric tolerogenic antigens (e.g., L1, L3 and / or L4) is a polypeptide comprising 12-30 amino acids (e.g., 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acids).
[0284] Suitable peptide linkers are known in the art, and include, for example, peptide linkers comprising flexible amino acid residues such as glycine and serine. In certain embodiments, the linker may include a motif of GS, GGS, GGGGS (SEQ ID NO: 797), GGSG (SEQ ID NO: 798) or SGGG (SEQ ID NO: 799), for example, multiple or repeated motifs. In certain embodiments, the linker may include 2 to 12 amino acids, including the following motif: GS, for example, GS, GSGS (SEQ ID NO: 800), GSGSGS (SEQ ID NO: 801), GSGSGSGS (SEQ ID NO: 802), GSGSGSGSGS (SEQ ID NO: 803) or GSGSGSGSGSGS (SEQ ID NO: 804). In certain other embodiments, the linker may comprise 3 to 12 amino acids including the following motif: GGS, such as GGS, GGSGGS (SEQ ID NO: 805), GGSGGSGGS (SEQ ID NO: 806) and GGSGGSGGSGGS (SEQ ID NO: 807). In other embodiments, the linker may comprise 4 to 12 amino acids including the following motif, GGSG (SEQ ID NO: 808), such as GGSGGGSG (SEQ ID NO: 809) or GGSGGGSGGGSG (SEQ ID NO: 810). In other embodiments, the linker may comprise a motif of GGGGS (SEQ ID NO: 797), such as GGGGSGGGGSGGGGS (SEQ ID NO: 811). In certain embodiments, the linker is SGGGSGGGSGGGSGGGSGGG (SEQ ID NO: 812).
[0285] In a preferred embodiment, the peptide linker (e.g., L1, L3 and / or L4) is a peptide linker comprising an amino acid sequence of any one of (GS)x, (GGS)x, (GGGGS)x, (GGSG)x, (SGGG)x, wherein x is an integer from 1 to 50 (e.g., 1-40, 1-30, 1-20, 1-10 or 1-5). In a preferred embodiment, the peptide linker has the amino acid sequence (GGGGS) x , wherein x is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0286] In some embodiments, the peptide linker comprises only glycine residues, for example, at least 4 glycine residues (e.g., 4-200, 4-180, 4-160, 4-140, 4-40, 4-100, 4-90, 4-80, 4-70, 4-60, 4-50, 4-40, 4-30, 4-20, 4-19, 4-18, 4-17, 4-16, 4-15, 4-14, 4-13, 4-12, 4-11, 4-10, 4-9, 4-8, 4-7, 4-6, or 200, 100-200, 120-200, 140-200, 160-200, 180-200, or 190-200 glycine residues). In certain embodiments, the linker has 4-30 glycine residues (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 glycine residues). In some embodiments, a linker containing only glycine residues may not be glycosylated (e.g., O-linked glycosylation, also referred to as O-glycosylation), or may have a reduced level of glycosylation (e.g., reduced level of O-glycosylation) compared to, for example, a linker containing one or more serine residues (e.g., reduced level of O-glycosylation with glycans such as xylose, mannose, sialic acid, fucose (Fuc) and / or galactose (Gal) (e.g., xylose).
[0287] In some embodiments, a linker containing only glycine residues may not be O-glycosylated (e.g., O-xylosylated), or may have a reduced level of O-glycosylation (e.g., reduced level of O-xylosylation) compared to, for example, a linker containing one or more serine residues.
[0288] In some embodiments, linkers containing only glycine residues may not undergo proteolysis, or may have a reduced rate of proteolysis compared to, for example, linkers containing one or more serine residues.
[0289] In certain embodiments, the linker can comprise the following motif: GGGG (SEQ ID NO:813), such as GGGGGGGGG (SEQ ID NO:814), GGGGGGGGGGGGG (SEQ ID NO:815), GGGGGGGGGGGGGGGG (SEQ ID NO:816), or GGGGGGGGGGGGGGGGGGGG (SEQ ID NO:817). In certain embodiments, the linker can comprise a motif of GGGGG (SEQ ID NO: 818), such as GGGGGGGGGGGG (SEQ ID NO: 819), GGGGGGGGGGGGGGGG (SEQ ID NO: 820, or GGGGGGGGGGGGGGGGGGGG (SEQ ID NO: 821). In some embodiments, the linker is GGGGGGGGGGGGGGGGGGGGG (SEQ ID NO: 822).
[0290] In other embodiments, the linker can also contain amino acids other than glycine and serine, for example, GENLYFQSGG (SEQ ID NO: 823), SACYCELS (SEQ ID NO: 824), RSIAT (SEQ ID NO: 825), RPACKIPNDLKQKVMNH (SEQ ID NO: 826), GGSAGGSGSSGGSSGASGTGTAGGTGSGSGTGSG (SEQ ID NO: 827), AAANSSIDLISVPVDSR (SEQ ID NO: 828) or GGSGGGSEGGGSEGGGSEGGGSEGGGSEGGGSGGGS (SEQ ID NO: 829).
[0291] Tolerogenic antigen variants
[0292] In certain embodiments, amino acid sequence variants of the tolerogenic antigens of the present invention are contemplated. For example, it may be desirable to improve the tolerogenic antigenicity and / or other biological properties of the tolerogenic antigen. Amino acid sequence variants of the tolerogenic antigen may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the tolerogenic antigen, or by peptide synthesis. Such modifications include, for example, deletions and / or insertions and / or substitutions of residues within the amino acid sequence of the tolerogenic antigen. Any combination of deletions, insertions and substitutions may be performed to obtain the final construct, provided that the final construct has the desired characteristics, such as inducing antigen tolerance.
[0293] In certain embodiments, tolerogenic antigen variants having one or more amino acid substitutions are provided. Conservative substitutions are shown in Table 6 under the heading "Preferred Substitutions". More substantial variations are provided in Table 6 under the heading "Exemplary Substitutions" and are further described below with reference to amino acid side chain classes. Amino acid substitutions can be introduced into the tolerogenic antigen of interest and the products screened for a desired activity, e.g., retained / improved tolerogenic antigenicity.
[0294] Table 6. Exemplary and preferred amino acid substitutions
[0295]
[0296]
[0297] Amino acids can be grouped based on common side chain properties:
[0298] (1) Hydrophobicity: norleucine, Met, Ala, Val, Leu, Ile;
[0299] (2) Neutral hydrophilicity: Cys, Ser, Thr, Asn, Gln;
[0300] (3) Acidic: Asp, Glu;
[0301] (4) Basic: His, Lys, Arg;
[0302] (5) Residues that affect chain orientation: Gly, Pro;
[0303] (6) Aromatic: Trp, Tyr, Phe.
[0304] Non-conservative substitutions will entail exchanging a member of one of these classes for another class.
[0305] As described by Cunningham and Wells (1989) Science, 244: 1081-1085, a useful method for identifying residues or regions of tolerogenic antigens that can be targeted for mutagenesis is called "alanine scanning mutagenesis". In this method, residues or groups of target residues (e.g., charged residues such as Arg, Asp, His, Lys and Glu) are identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with the antigen is affected. Additional substitutions can be introduced at amino acid positions that show functional sensitivity to the initial substitutions. Alternatively or additionally, the crystal structure of the antigen-antibody complex is used to identify contact points between the antibody and the antigen. Such contact residues and adjacent residues can be targeted or eliminated as substitution candidates. Tolerogenic antigen variants can be screened to determine whether they include the desired properties.
[0306] Amino acid sequence insertions include amino- and / or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues.
[0307] In some embodiments, the tolerogenic antigen comprises an amide group at the C-terminus. In some embodiments, the tolerogenic antigen comprises a pyroglutamic acid residue at the N-terminus. In another embodiment, the tolerogenic antigen comprises an acetyl group at the N-terminus. In some embodiments, the tolerogenic antigen comprises a pyroglutamic acid residue at the N-terminus and an amide group at the C-terminus. In some embodiments, the tolerogenic antigen comprises an acetyl group at the N-terminus and an amide group at the C-terminus. In some embodiments, the tolerogenic antigen comprises an N-terminus or a C-terminus modified with a cysteine residue bound to a linker. In some embodiments, the tolerogenic antigen comprises an N-terminus and a C-terminus modified with a cysteine residue bound to a linker.
[0308] In some embodiments of any of the compositions described herein, a population of tolerogenic antigens is conjugated to the nanoparticle phospholipids in a manner that promotes strong immune tolerance upon administration to a subject, e.g., a human subject having or at risk of having an autoimmune disorder, e.g., MS, celiac disease, rheumatoid arthritis, primary biliary cholangitis, primary sclerosing cholangitis, MOG antibody disease, diabetes (e.g., type 1 diabetes), thyroid autoimmune disease (e.g., Hashimoto's thyroiditis, Graves' disease), thyroid-related eye and skin diseases, hypoparathyroidism, Addison's disease, premature ovarian failure, autoimmune hypophysitis, pituitary autoimmunity, diseases, immune gastritis, pernicious anemia, celiac disease, vitiligo, myasthenia gravis, pemphigus vulgaris and its variants, bullous pemphigoid, dermatitis herpetiformis, Duling disease, epidermolysis bullosa acquisita, systemic sclerosis, mixed connective tissue disease, Sjögren's syndrome, systemic lupus erythematosus, Goodpasture's syndrome, rheumatic heart disease, autoimmune polyglandular syndrome type 1, Aicardi-Goutières syndrome, acute pancreatitis, age-dependent macular degeneration, alcoholic liver disease, liver fibrosis, metastasis, myocardial infarction, non-alcoholic steatohepatitis (NASH), Parkinson's disease, polyarthritis / fetal and neonatal anemia, sepsis and inflammatory bowel disease.
[0309] In some embodiments, multiple tolerogenic antigens are conjugated to the nanoparticle phospholipids via thiol-reactive and reduction-insensitive bonds between the tolerogenic antigens and the nanoparticle phospholipids. Indeed, the thiol-reactive and reduction-insensitive bonds between the tolerogenic antigens and the nanoparticle phospholipids promote strong immune tolerance. In some embodiments, the phospholipid is N-(3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine.
[0310] In some embodiments, the tolerogenic antigen is conjugated to the nanoparticle phospholipid via an amine-mediated interaction (e.g., dioleoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine (DOPE-NHS)). In some embodiments, the amine-mediated interaction is dioleoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine (DOPE-NHS). In some embodiments, the amine-mediated interaction is through an amine-reactive phospholipid with a self-destructive bond (e.g., a linker comprising an o-dithiobenzyl, p-dithiobenzyl, β-dithiobenzylcarbamate moiety, 2,2-dimethyl-4-mercapto-butyric acid, or a disulfide-carbonate / salt-based traceless linker).
[0311] Nanoparticle characterization
[0312] The nanoparticles of the present invention can be characterized for size and uniformity by any suitable analytical technique. These include, but are not limited to, atomic force microscopy (AFM), electrospray ionization mass spectrometry, MALDI-TOF mass spectrometry, LC-MS / MS, 13 C nuclear magnetic resonance spectroscopy, high performance liquid chromatography (HPLC), size exclusion chromatography (SEC) equipped with multi-angle laser light scattering, dual UV and refractive index detectors, capillary electrophoresis and gel electrophoresis. These analytical methods ensure the homogeneity of the sHDL nanoparticle population and are essential for the final quality control of production for in vivo applications.
[0313] In some embodiments, gel permeation chromatography (GPC) to separate sHDL nanoparticles from liposomes and free ApoA-I mimetic peptides can be used to analyze sHDL-tolerogenic antigen nanoparticles. In some embodiments, size distribution and zeta potential are determined by dynamic light scattering (DLS) using, for example, a Malven Nanosizer instrument.
[0314] How to use
[0315] In certain embodiments, the present invention provides for the regulation of regulatory Tregs (e.g., CD4 + CD25 高 Foxp3+ ), comprising administering to a subject a composition comprising one or more nanoparticles, followed by administering to the subject (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.) a composition comprising one or more immunomodulators (e.g., human cytokines (e.g., IL-2, IL-2 mutant proteins, IL-2 variants, or IL-2 / IC)) that can expand Tregs in the subject. In some embodiments, the composition comprising one or more nanoparticles is associated (e.g., compounded, conjugated, encapsulated, absorbed, adsorbed, mixed) with an mTOR inhibitor (e.g., rapamycin or a variant thereof).
[0316] In certain embodiments, the present invention provides regulatory Tregs (e.g., CD4 + CD25 高 Foxp3 + ), comprising administering to a subject a composition comprising one or more nanoparticles associated with one or more tolerogenic antigens, followed by administering to the subject (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.) a composition comprising one or more immunomodulators (e.g., human cytokines (e.g., IL-2, IL-2 muteins, IL-2 variants, or IL-2 / IC)) capable of expanding antigen-specific Tregs, wherein “antigen specificity” is specific for one or more tolerogenic antigens associated with the nanoparticles comprising the one or more tolerogenic antigens.
[0317] In certain embodiments, the present invention provides a method for promoting strong immune tolerance to an antigen associated with an autoimmune disease in a subject (e.g., a human subject having an autoimmune disease or at risk of having an autoimmune disease), comprising administering to the subject a composition comprising one or more nanoparticles, and subsequently (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.), administering to the subject a composition comprising a Treg cell (e.g., CD4 + CD25 高 Foxp3 + ) is a composition comprising one or more immunomodulators (e.g., human cytokines (e.g., IL-2, IL-2 mutant proteins, IL-2 variants, or IL-2 / IC)). In some embodiments, the composition comprising one or more nanoparticles is associated (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, mixed) with an mTOR inhibitor (e.g., rapamycin or a variant thereof).
[0318] In certain embodiments, the invention provides a method for promoting strong immune tolerance to an antigen associated with an autoimmune disorder in a subject (e.g., a human subject having an autoimmune disorder or at risk of having an autoimmune disorder), comprising administering to the subject a composition comprising one or more nanoparticles associated with one or more tolerogenic antigens, and subsequently (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.), administering to the subject a composition comprising a nanoparticle capable of expanding antigen-specific Tregs (e.g., CD4 + CD25 高 Foxp3 + ) containing one or more immunomodulatory agents (e.g., human cytokines (e.g., IL-2, IL-2 muteins, IL-2 variants, or IL-2 / IC)), wherein the "antigen specificity" is specific for one or more tolerogenic antigens (which are associated with the nanoparticles associated with the one or more tolerogenic antigens).
[0319] In certain embodiments, the invention provides a method for increasing the ratio of CD3+FOXP3+ cells to CD3+FOXP3- cells in a T cell population in a subject (e.g., a human subject having an autoimmune disorder or at risk of having an autoimmune disorder), comprising administering to the subject a composition comprising one or more nanoparticles, and subsequently (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.) administering to the subject a composition comprising a nanoparticle capable of expanding Tregs (e.g., CD4 + CD25 高 Foxp3 + ) is a composition comprising one or more immunomodulators (e.g., human cytokines (e.g., IL-2, IL-2 mutant proteins, IL-2 variants, or IL-2 / IC)). In some embodiments, the composition comprising one or more nanoparticles is associated (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, mixed) with an mTOR inhibitor (e.g., rapamycin or a variant thereof).
[0320] In certain embodiments, the invention provides a method for increasing the ratio of CD3+FOXP3+ cells to CD3+FOXP3- cells in a T cell population in a subject (e.g., a human subject having an autoimmune disorder or at risk of having an autoimmune disorder), comprising administering to the subject a composition comprising one or more nanoparticles associated with one or more tolerogenic antigens, and subsequently (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.) administering to the subject a composition comprising a nanoparticle capable of expanding antigen-specific Tregs (e.g., CD4 + CD25 高 Foxp3+ ) containing one or more immunomodulatory agents (e.g., human cytokines (e.g., IL-2, IL-2 muteins, IL-2 variants, or IL-2 / IC)), wherein the "antigen specificity" is specific for one or more tolerogenic antigens (which are associated with the nanoparticles associated with the one or more tolerogenic antigens).
[0321] In certain embodiments, the present invention provides a method for treating, preventing and / or ameliorating a disorder, comprising administering to a subject (e.g., a human subject having an autoimmune disorder (e.g., celiac disease) or at risk of having an autoimmune disorder (e.g., celiac disease)), comprising administering to the subject a composition comprising one or more nanoparticles, and subsequently (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.) administering to the subject a composition comprising a Treg cell capable of expanding Tregs (e.g., CD4 + CD25 高 Foxp3 + ) is a composition comprising one or more immunomodulators (e.g., human cytokines (e.g., IL-2, IL-2 mutant proteins, IL-2 variants, or IL-2 / IC)) of a subject. In some embodiments, the composition comprising one or more nanoparticles is associated (e.g., compounded, conjugated, encapsulated, absorbed, adsorbed, mixed) with an mTOR inhibitor (e.g., rapamycin or a variant thereof). In some embodiments, the treatment, prevention, and / or alleviation of one or more autoimmune disorders in a subject is specific to a specific tissue region (e.g., a specific tissue region associated with an autoimmune disorder).
[0322] In certain embodiments, the invention provides a method for treating, preventing, and / or ameliorating a disorder, comprising administering to a subject (e.g., a human subject having an autoimmune disorder (e.g., celiac disease) or at risk of having an autoimmune disorder (e.g., celiac disease)) a composition comprising one or more nanoparticles associated with one or more tolerogenic antigens (e.g., one or more tolerogenic antigens associated with an autoimmune disorder), and subsequently (e.g., after 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.) administering to the subject a composition comprising a nanoparticle capable of expanding antigen-specific Tregs (e.g., CD4 + CD25 高 Foxp3 +), wherein the "antigen specificity" is specific for one or more tolerogenic antigens associated with the nanoparticles comprising the one or more tolerogenic antigens associated with the nanoparticles. In some embodiments, the treatment, prevention and / or alleviation of one or more disorders in the subject is specific for a specific tissue region (e.g., a specific tissue region associated with the disorder).
[0323] The immune system can be divided into two functional subsystems: the innate immune system and the acquired immune system. The innate immune system is the first line of defense against infection, and most potential pathogens are quickly neutralized by this system before they can cause, for example, an overt infection. The acquired immune system responds to the molecular structures of invading organisms, known as antigens. There are two types of acquired immune responses, which include humoral immune responses and cell-mediated immune responses. In humoral immune responses, antibodies secreted into body fluids by B cells bind to antigens derived from pathogens, leading to the elimination of pathogens through a variety of mechanisms, such as complement-mediated lysis. In cell-mediated immune responses, T cells that are able to destroy other cells are activated. For example, if proteins associated with a disease, such as MS or celiac disease, are present in the cell, they are proteolytically fragmented into peptides within the cell. Specific cell proteins then attach themselves to the antigens or peptides formed in this way and transport them to the cell surface, where they are presented to the body's molecular defense mechanisms, especially T cells. Cytotoxic T cells recognize these antigens and kill cells containing them.
[0324] The molecules that transport and present peptides on the cell surface are proteins called major histocompatibility complexes (MHC), which are called human leukocyte antigen (HLA) complexes in humans. MHC proteins are divided into two classes, called MHC class I and MHC class II. The protein structures of the two MHC classes are very similar; however, they have very different functions. MHC class I proteins are present on the surface of almost all cells in the body, including most tumor cells. MHC class I protein loads are usually derived from endogenous proteins or antigens of pathogens present in the cell, and are then presented to I or cytotoxic T lymphocytes (CTL). MHC class II proteins are present on dendritic cells, B lymphocytes, macrophages and other antigen presenting cells. They mainly present peptides processed from external antigen sources (i.e., outside the cell) to T helper (Th) cells. Most peptides bound to MHC class I proteins are derived from cytoplasmic proteins produced in the organism's own healthy host cells and generally do not stimulate an immune response. Therefore, the cytotoxic T lymphocytes that recognize such class I self-peptide presenting MHC molecules are missing in the thymus (central tolerance), or are missing or inactivated after they are released from the thymus, i.e., tolerated (peripheral tolerance). When MHC molecules present peptides to non-tolerant T lymphocytes, they can stimulate an immune response. Cytotoxic T lymphocytes have both T cell receptors (TCR) and CD8 molecules on their surfaces. T cell receptors can recognize and bind to peptides compounded with MHC class I molecules. Each cytotoxic T lymphocyte expresses a unique T cell receptor that can bind to a specific MHC / peptide complex.
[0325] Experiments conducted during the development of embodiments of the present invention led to the development of new strategies for inducing high frequencies of antigen-specific Tregs in vivo without the need for ex vivo cell manipulation. Such experiments led to the development and optimization of new strategies for combining nanodiscs with modified IL-2 to elicit unprecedented levels of antigen-specific Tregs in vivo. Notably, IL-2: anti-IL-2 antibody (clone: JES6-1) immune complexes (IL-2 / IC) have been shown to selectively induce polyclonal Tregs
[14] . Administration of IL-2 / IC together with free peptide or peptide tetramers has been reported to induce antigen-specific Tregs [15, 16]. However, the results of these previous attempts were rather poor antigen-specific Treg responses, with antigen-specific Treg frequencies in the CD4+ T cell compartment being less than 0.25% [15, 16].
[0326] It is foreseeable that it will be critical to properly deliver peptide antigens to lymphoid tissues together with IL-2 / IC to maximize antigen-specific Treg induction. The experiments described herein report for the first time that lymphatic-targeted nanodisc-mediated peptide delivery combined with IL-2 / IC resulted in a significant expansion of antigen-specific Tregs compared to IL-2 / IC alone.
[0327] It is also foreseeable that the actual treatment method is crucial. Such experiments show that subcutaneous nanodiscs should ideally be administered first, followed by systemic administration of IL-2 and / or mutant protein / engineered IL-2. This ensures that antigen-specific Tregs are first prepared and generated, and that the subsequent administration of mutant protein / engineered IL-2 triggers a robust proliferation of antigen-specific Tregs. It is further envisioned that a maintenance dose of nanodiscs and / or mutant protein / engineered IL-2 is administered to maintain antigen-specific Tregs for a long time.
[0328] This approach is not limited to treating a specific condition.
[0329] In some embodiments, the disorder is an autoimmune disorder. Such methods are not limited to treating a specific autoimmune disorder. Examples of autoimmune disorders include, but are not limited to, multiple sclerosis (MS), celiac disease, rheumatoid arthritis, primary biliary cholangitis, primary sclerosing cholangitis, MOG antibody disease, diabetes (e.g., type 1 diabetes), thyroid autoimmune diseases (e.g., Hashimoto's thyroiditis, Graves' disease), thyroid-related eye and skin diseases, hypoparathyroidism, Addison's disease, premature ovarian failure, autoimmune hypophysitis, pituitary autoimmune diseases, immune gastritis, pernicious anemia, celiac disease, vitiligo, myasthenia gravis, pemphigus vulgaris, and the like. variants, bullous pemphigoid, dermatitis herpetiformis, Duling disease, epidermolysis bullosa acquisita, systemic sclerosis, mixed connective tissue disease, Sjögren's syndrome, systemic lupus erythematosus, Goodpasture's syndrome, rheumatic heart disease, autoimmune polyglandular syndrome type 1, Aicardi-Goutières syndrome, acute pancreatitis, age-dependent macular degeneration, alcoholic liver disease, liver fibrosis, metastasis, myocardial infarction, nonalcoholic steatohepatitis (NASH), Parkinson's disease, polyarthritis / fetal and neonatal anemia, sepsis, and inflammatory bowel disease.
[0330] In some embodiments, the disorder is a transplant-related disorder. In some embodiments, the disorder is one or more allergies. In some embodiments, the disorder is a respiratory disorder (e.g., asthma). In some embodiments, the disorder is graft-versus-host disease (GvHD).
[0331] In some embodiments, such a method for treating or preventing an autoimmune disease further comprises co-administering (e.g., simultaneously or at different times) an additional therapeutic agent. Examples of such therapeutic agents include, but are not limited to, disease-modifying antirheumatic drugs (e.g., leflunomide, methotrexate, sulfasalazine, hydroxychloroquine), biologics (e.g., rituximab, infliximab, etanercept, adalimumab, golimumab), nonsteroidal anti-inflammatory drugs (e.g., ibuprofen, celecoxib, ketoprofen, naproxen, piroxicam, diclofenac), analgesics (e.g., acetaminophen, tramadol), immunomodulators (e.g., anakinra, abatacept), glucocorticoids (e.g., prednisone, methylprednisone), TNF-α inhibitors (e.g., adalimumab, pegseromab, etanercept, golimumab, infliximab), IL-1 inhibitors, and metalloproteinase inhibitors. In some embodiments, the therapeutic agent includes but is not limited to infliximab, adalimumab, etanercept, or parenteral or oral gold. In some cases, the therapeutic agent is an immunomodulator or immunosuppressant (e.g., a statin; an mTOR inhibitor such as rapamycin or a rapamycin analog; a TGF-β signaling agent; a TGF-β receptor agonist; a histone deacetylase inhibitor such as trichostatin A; a corticosteroid; a mitochondrial function inhibitor such as rotenone; a P38 inhibitor; an NF-κβ inhibitor such as 6Bio, dexamethasone, TCPA-1, IKK VII; adenosine receptor agonists; prostaglandin E2 agonists (PGE2), such as misoprostol; phosphodiesterase inhibitors, such as phosphodiesterase 4 inhibitors (PDE4), such as rolipram; proteasome inhibitors; kinase inhibitors; G protein-coupled receptor agonists; G protein-coupled receptor antagonists; glucocorticoids; retinoids; cytokine inhibitors; cytokine receptor inhibitors; cytokine receptor activators; peroxisome proliferator-activated receptor antagonists; peroxisome proliferator-activated receptor agonists; histone deacetylase inhibitors; calcineurin inhibitors; phosphatase inhibitors; PI3 KB inhibitors, such as TGX-221; autophagy inhibitors, such as 3-methyladenine; aryl hydrocarbon receptor inhibitors; proteasome inhibitor I (PSI); and oxidized ATP, such as P2X receptor blockers.Immunosuppressants also include IDO, vitamin D3, cyclosporines such as cyclosporine A, aryl hydrocarbon receptor inhibitors, resveratrol, azathioprine (Aza), 6-mercaptopurine (6-MP), 6-thioguanine (6-TG), FK506, sangliferin A, salmeterol, mycophenolate mofetil (MMF), aspirin and other COX inhibitors, niflumic acid, estriol; triptolide; OPN-305, OPN-401; eritoran (E5564); TAK-242; Cpn10; NI-0101; 1A6; AV411; IRS-954 (DV-1079); IMO-3100; CPG-52363; CPG-52364; OPN-305; ATNC05; NI-0101; IMO-8400; hydroxychloroquine; CU-CPT22; C29; o-vanillin; SSL3 protein; OPN-305; 5SsnB; Vizantin; (+)-N-phenylethylnoroxymorphone; VB3323; monosaccharide 3; (+)-naltrexone and (+)-naloxone; HT52; HTB2; compound 4a; CNTO2424; TH1020; INH-ODN; E6446; AT791; CpG ODN 2088; ODN TTAGGG; COV08-0064; 2R9; GpG oligonucleotide; 2-aminopurine; Amlexanox; Bay11-7082; BX795; CH-223191; Chloroquine; CLI-095; CU-CPT9a; Cyclosporine A; CTY387; Gefitinib; Glibenclamide; H-89; H-131; Isoliquiritigenin; MCC950; MRT67307; OxPA PC; parthenolide; Pepinh-MYD; Pepinh-TRIF; polymyxin B; R406; RU.521; VX-765; YM201636; Z-VAD-FMK; and AHR-specific ligands; including but not limited to 2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD); tryptamine (TA); and 6-formyl indole [3,2b] carbazole (FICZ). In a specific embodiment, the immunosuppressant is fingolimod; rapamycin; 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) or a related ligand; trichostatin A; and / or suberoylanilide hydroxamic acid (SAHA).
[0332] These methods are not limited to a particular manner of administering a composition comprising nanoparticles with or without associated tolerogenic antigens and / or a composition comprising an immunomodulator (e.g., a human cytokine (e.g., IL-2, IL-2 muteins, IL-2 variants, or IL-2 / IC)). Indeed, any acceptable method known to one of ordinary skill in the art can be used to administer any composition to a subject. Administration can be local (i.e., to a specific area, physiological system, tissue, organ, or cell type) or systemic. Such compositions can be administered by a variety of routes including, but not limited to, oral, inhalation (nasal or pulmonary), intravenous, intraperitoneal, intramuscular, transdermal, subcutaneous, topical, subcutaneous, sublingual, or rectal. Injections can be, for example, intravenous, intradermal, subcutaneous, intramuscular, or intraperitoneal. In some embodiments, injections can be performed at multiple locations.
[0333] Administration of the formulation can be accomplished by any acceptable method that allows an effective amount of any composition to achieve its desired effect. The specific mode selected will depend on factors such as the specific formulation, the severity of the subject being treated, and the dose required to induce an effective immune response. As generally used herein, an "effective amount" is an amount that is capable of inducing antigen-specific regulatory Tregs (e.g., CD4 + CD25 高 Foxp3 + ), and / or promote strong immune tolerance to antigens associated with autoimmune diseases, and / or induce an immune response in the treated subject. The actual effective amount of any such composition can vary depending on the specific antigen or combination used, the specific composition formulated, the mode of administration, and the age, weight, condition, and route of administration and disease or illness of the vaccinated individual.
[0334] Pharmaceutical composition
[0335] With clinical applications in mind, in some embodiments of the invention, compositions comprising nanoparticles associated with or without tolerogenic antigens and / or compositions comprising one or more immunomodulators (e.g., human cytokines (e.g., IL-2, IL-2 muteins, IL-2 variants, or IL-2 / IC)) are prepared as part of a pharmaceutical composition in a form suitable for the intended application. Typically, this requires the preparation of a composition that is substantially free of pyrogens and other impurities that may be harmful to humans or animals. However, in some embodiments of the invention, pure compositions comprising nanoparticles associated with or without tolerogenic antigens and / or compositions comprising immunomodulators (e.g., human cytokines (e.g., IL-2, IL-2 muteins, IL-2 variants, or IL-2 / IC)) can be administered using one or more of the routes described herein.
[0336] In a preferred embodiment, the composition is used in conjunction with appropriate salts and buffers so that the composition is delivered in a stable manner to allow uptake by target cells. Buffers are also used when either composition is introduced into a patient.
[0337] The aqueous composition includes a cell-effective amount of sHDL nanoparticles dispersed in a pharmaceutically acceptable carrier or aqueous medium. Such a composition is also referred to as an inoculum.
[0338] The phrase "pharmaceutically or pharmacologically acceptable" refers to molecular entities and compositions that do not produce adverse, allergic or other untoward reactions when administered to animals or humans. As used herein, "pharmaceutically acceptable carriers" include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. Unless any conventional media or agents are incompatible with the vectors or cells of the present invention, their use in therapeutic compositions is contemplated. Supplementary active ingredients may also be incorporated into the compositions.
[0339] In some embodiments of the invention, active compositions include classical pharmaceutical preparations. Administration according to these compositions of the invention is via any common route, as long as the target tissue is available via the route. This includes oral, nasal, buccal, rectal, vaginal, subcutaneous or topical. Alternatively, administration can be carried out by in situ, intradermal, subcutaneous, intramuscular, intraperitoneal or intravenous injection.
[0340] The active composition can also be administered parenterally or intraperitoneally or intratumorally. Solutions of the active compound as a free base or a pharmaceutically acceptable salt are prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, mixtures thereof, and oils. Under normal storage and use conditions, these preparations contain preservatives to prevent microbial growth.
[0341] The pharmaceutical form suitable for injectable use includes sterile aqueous solutions or dispersions and sterile powders for the temporary preparation of sterile injectable solutions or dispersions. The support body can be a solvent or dispersion medium comprising the following: for example, water, ethanol, polyols (for example, glycerol, propylene glycol and liquid polyethylene glycol, etc.), suitable mixtures thereof and vegetable oils. Suitable fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining the required particle size in the case of a dispersion and by using a surfactant. The effects of microorganisms can be prevented by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc. In many cases, it may be preferred to include isotonic agents, such as sugar or sodium chloride. The absorption of the injectable composition can be extended by using an agent such as aluminum monostearate and gelatin that delays absorption in the composition.
[0342] Sterile injectable solutions are prepared by introducing any one of the desired amounts of the composition into an appropriate solvent with the various other ingredients listed above (as required), followed by filtration sterilization. Typically, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile carrier containing a basic dispersion medium and the desired other ingredients from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, preferred preparation methods are vacuum drying and freeze drying techniques, which produce a powder of the active ingredient plus any additional desired ingredients from its previously sterile filtered solution.
[0343] When formulated, any one of the compositions is administered in a manner compatible with the dosage formulation and in a therapeutically effective amount. The preparation is easy to be administered in a variety of dosage forms, such as injectable solutions, drug release capsules, etc. For parenteral administration in aqueous solutions, for example, the solution is appropriately buffered if necessary and the liquid diluent is first made isotonic with enough saline or glucose. These specific aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. For example, a dose can be dissolved in 1 ml of isotonic NaCl solution and added to 1000 ml of subcutaneous infusion or injected at the infusion site of suggestion (see, for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). In some embodiments of the invention, active particles or activating agents are formulated in the treatment mixture to include about 0.0001 to 1.0 milligrams, or about 0.001 to 0.1 milligrams, or about 0.1 to 1.0 or even about 10 milligrams / dose. Multiple doses can be administered.
[0344] Additional formulations suitable for other modes of administration include vaginal suppositories and suppositories. Rectal suppositories or suppositories may also be used. Suppositories are solid dosage forms of various weights and shapes for insertion into the rectum, vagina or urethra, usually containing medication. After insertion, the suppository softens, melts or dissolves in the intracavitary fluid. Typically, for suppositories, traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from a mixture containing an active ingredient in the range of 0.5% to 10%, preferably 1%-2%. Vaginal suppositories or vaginal suppositories are usually spherical or ovoid and weigh about 5 g each. Vaginal medications are available in a variety of physical forms, such as creams, gels or liquids, which are different from the classic concept of suppositories. The composition may also be formulated as an inhaler.
[0345] Reagent test kit
[0346] In some embodiments, the invention also provides kits comprising a composition comprising one or more nanoparticles associated with or without one or more tolerogenic antigens as described herein and / or a composition comprising one or more immunomodulators (e.g., human cytokines (e.g., IL-2, IL-2 muteins, IL-2 variants, or IL-2 / IC)). In some embodiments, the kits include one or more of the reagents and tools necessary to produce any of the compositions and methods of using any of such compositions.
[0347] Example
[0348] The following examples are provided to illustrate and further illustrate certain preferred embodiments and aspects of the present invention and should not be construed as limiting the scope thereof.The use of pronouns such as "we," "our," and "I" refers to the inventive entity.
[0349] Example I.
[0350] Preparation of antigen-loaded nanodiscs:
[0351] DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine) and DOPE-MAL (N-(3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine) were purchased from NOF AMERICA CORPORATION. DMPC and ApoA1 mimetic peptide 22A (PVLDLFRELLBELLEALKQKLK) powders were mixed and hydrated in 10 mM sodium phosphate buffer (DMPC:22A=2:1, mass ratio), and then subjected to heating and cooling cycles to obtain blank synthetic HDL nanodiscs, followed by sonication at room temperature for 5 min. In order to load the antigen peptide into the blank nanodisc, the cysteine-terminated antigen peptide was first conjugated with DOPE-MAL (antigenic peptide:DOPE-MAL=2:1, molar ratio). The DOPE-peptide was then added to a blank nanodisc (22A: antigen peptide = 5: 1, mass ratio) and incubated for 1 h at room temperature on an orbital oscillator with gentle shaking. Unreacted antigen peptides were removed by using a Zeba spin desalting column (Pierce). The antigen peptide used in this study was OVA-II (OVA323-339) peptide, CSS-ISQAVHAAHAEINEAGR. Peptide loading efficiency was measured by LC-MS. Nanodisc-OVA-II was analyzed by gel permeation chromatography (GPC) equipped with a TSKgel G3000SWxl column (7.8mm ID×30cm, Tosoh Bioscience LLC). The hydrodynamic size and zeta potential of the nanodisc samples were measured by dynamic light scattering (DLS, Zetasizer Nano ZSP).
[0352] Preparation of mouse IL-2: anti-IL-2 immune complex (IL-2 / IC):
[0353] IL-2 / anti-IL-2 mAb immune complex (IL-2 / IC) was prepared as previously reported
[15] . 0.1 mg of anti-IL-2 mAb (JES6-1A12, InVivoMAb, BioX-Cell, Lebanon, NH) was mixed with recombinant murine IL-2 (20 μg, PeproTech, Rocky Hill, NJ) in 2 mL of HBSS (Mediatech, Herndon, VA) in vitro and incubated for 10 min at room temperature. The resulting IL-2 / IC was then administered as a single 0.1 mL injection containing 1 μg of murine IL-2 and 5 μg of IL-2 mAb.
[0354] Animal studies
[0355] Animals were cared for in accordance with federal, state and local guidelines. All work performed on animals was in accordance with and approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Michigan, Ann Arbor. Seven-week-old female C57BL / 6 mice were randomly divided into 5 groups of 5 mice each. Next, on days 0, 7 and 14, 0.1 mL of nanodisc-OVA-II (containing 0.1 mg of OVA-II peptide) was subcutaneously injected at the tail base of mice in groups 1, 2 and 3. In addition, group 1 received intraperitoneal (ip) administration of 0.1 mL of prepared IL-2 / IC solution (as described above) on days 1, 2 and 3 after each injection of nanodisc-OVA-II. Group 2 received intraperitoneal (ip) administration of 0.1 mL of prepared IL-2 / IC solution (as described above) on days 3, 4 and 5 after each injection of nanodisc-OVA-II. Group 3 mice did not receive IL-2 / IC. Group 4 mice received IL-2 / IC alone on days 1, 2, and 3 for weeks 0, 1, and 2 (similar to Group 1 without injection of Nanodisc-OVA-II). Group 5 received PBS. Peripheral blood was collected on days 7, 14, 21, and 28 for flow cytometry analysis.
[0356] Flow cytometric analysis
[0357] At the specified time point, 150-200uL of blood was collected from a single mouse into an EDTA-coated test tube. The blood volume was transferred to a 1.5mL Eppendorf test tube for red blood cell lysis. Red blood cells were lysed by adding 1mL ACK lysis buffer to each blood volume, and the test tube was shaken at room temperature for five minutes. Five minutes later, the test tube was centrifuged at 600g for 5 minutes and the supernatant was discarded. The pellet was resuspended in 1mL ACK lysis buffer and immediately centrifuged at 600g for 5 minutes. The supernatant was discarded, and the PBMC was resuspended in PBS and transferred to a 96-well plate and washed once with PBS before FACS staining. For surface staining, the cells were first incubated with eBioscience Fixable Viability Dye eFluor450 in PBS at room temperature in the dark for 10 minutes. The PBMC was washed with 200uL PBS and centrifuged at 600g for five minutes. The supernatant was discarded and the samples were suspended in Fc blocker (anti-CD16 / 32) in FACS buffer (PBS + 1% BSA). Blocking was allowed to proceed for 10 minutes at room temperature in the dark, after which OT-II tetramers were added to the wells at a final dilution of 1:40 in FACS buffer. OT-II tetramers (NIH Tetramer Core Facility, Atlanta, GA) were incubated with PBMCs at room temperature in the dark for 1 hour. Surface antibodies were added to the samples at a final dilution of 1:100 20 minutes before the end of the OT-II tetramer incubation. After incubation of the tetramers and surface, the PBMCs were washed with 200uL FACs buffer and centrifuged at 600g for 5 minutes. For Foxp3 intracellular staining, eBioscience was used according to the kit instructions. TM Foxp3 / Transcription Factor Staining Buffer Set. To measure total cell counts, add 50uL of Life Technologies Absolute Counting Beads to fully stained PBMC samples prior to collection on the BioRad ZE5 Analyzer. Analyze FSC files using FlowJo.
[0358] Characterization of Antigen-Loaded Nanodiscs:
[0359] Synthesis and Characterization of HDL Nanodisc OVA-II
[0360] Blank HDL nanodiscs presented an average diameter of 8.9±2.1 nm, (PDI=0.137), while OVA-II-loaded HDL nanodiscs presented an average diameter of 10.4±2.6 nm, (PDI=0.095, Figure 1The loading efficiency of OVA-II in sHDL was ∼99%, as quantified by LC-MS ( Figure 2 ). And the synthesized blank nanodiscs and nanodisc-OVA-II were further characterized by gel permeation chromatography (GPC) analysis, and nanodisc-OVA-II showed a single uniform peak with a short retention time in GPC analysis (0.8 mL / min, PBS as mobile phase, column: TSKgel G3000SWxl, TOSOH Bioscience).
[0361] Analysis of Antigen-Specific T Cells in Mice:
[0362] use Figure 4 The indicated protocol was sc administered to C57BL / 6 mice with Nanodisc-OVA-II (ND-OVA-II) and treated with IL-2 / IC via the ip route. Control groups included either ND-OVA-II, IL-2 / IC or PBS treatment alone. Systemic immune responses were measured by flow cytometry on days 7 and 14 after the initial ND-OVA-II administration.
[0363] By day 7, animals in groups 2 and 4 that received either ND-OVA-II in combination with IL-2 / IC or IL-2 / IC on days 3, 4, and 5 (D3, 4, 5) showed an increase in CD4 + The frequency of T cells increased ( Figure 5 , Figure 6a). Animals in Group 1 that received a combination of ND-OVA-II and IL-2 / IC on days 1, 2, and 3 (D1, 2, 3) induced significantly higher frequencies of OT-II tetramers + Antigen-specific CD4 + T cells ( Figure 5 6b). Compared with mice in groups 3 and 5 treated with ND-OVA-II or PBS, mice in groups 1, 2, and 4 that received the combination of ND-OVA-II and IL-2 / IC or IL-2 / IC alone showed a decrease in total CD4 + CD25 + Foxp3 + T regulatory cells (T reg ) (Figure 6c). Importantly, ND-OVA-II+IL-2 / IC (D1, 2, 3) induced OT-II tetramers. + CD25 + Foxp3 + T reg These OVA-specific T reg Total T regAlthough mice in group 2 that received ND-OVA-II+IL-2 / IC (D3, 4, 5) expanded fewer antigen-specific Tregs (Fig. 6d), these cells showed a significant increase in total CD25 Tregs compared with Tregs induced by ND-OVA-II+IL-2 / IC (D1, 2, 3) or IL-2 / IC alone. + Foxp3 + T reg and OT-II tetramer + CD25 + Foxp3 + T reg Significantly higher CD25 expression in WT mice (Fig. 6e, f).
[0364] By day 14, mice receiving IL-2 / IC (D1, 2, 3) had significantly higher CD4 + T cells increased ( Figure 7 , Figure 8a). On days 3, 4, and 5 (D3, 4, 5), the combination of ND-OVA-II and IL-2 / IC or IL-2 / IC showed a decrease in CD4 + The frequency of T cells increased ( Figure 7 , Figure 8a). Like day 7, animals treated with ND-OVA-II+IL-2 / IC (D1, 2, 3) showed antigen-specific OT-II tetramers+CD4 + Further expansion of T cells to CD4 + ~20% of T cells ( Figure 7 8b). Compared with ND-OVA-II and PBS control, the total T reg increased by 5 and 10 times respectively ( Figure 7 , 8c). Like day 7, animals treated with ND-OVA-II+IL-2 / IC (D1, 2, 3) showed antigen-specific T reg Further expansion of the total T reg 8d ), which stained positive for OT-II tetramers.
[0365] For day 14 samples, in addition to assessing cell population frequency, Life Technologies Absolute Counting Beads were added to the flow samples to measure cell counts. ND-OVA-II+IL-2 / IC (D3, 4, 5) animals showed the highest T regTotal number, an average of about 99,000 CD4 cells per 2 mL of blood + CD25 + Foxp3 + ND-OVA-II+IL-2 / IC (D1, 2, 3) mice had the highest number of antigen-specific T cells (Figure 8c). reg , about 16,400 CD4 cells are counted per 2 mL of blood + CD25 + Foxp3 + OT-II tetramer + In addition, total Treg and OT-II tetramers were measured + T reg Similar to the data on day 7, ND-OVA-II+IL-2 / IC (D3, 4, 5) treatment increased the expression of total and OT-II tetramers compared with all other groups. + T reg The expression of both CD25 and GITR was the highest in the middle stratum (Fig. 8e, f).
[0366] These findings are summarized in Figure 9. ND-OVA-II+IL-2 / IC (D1, 2, 3) treatment increased the total T cells in PBMCs on both days 7 and 14. reg ND-OVA-II+IL-2 / IC (D1, 2, 3) treatment increased the antigen-specific OT-II tetramer in CD4+ T cells in PBMCs. + Foxp3 + CD25 + T reg ND-OVA-II+IL-2 / IC (D1, 2, 3) treatment increased the antigen-specific OT-II tetramers in total CD4+ T cells from ∼3% on day 7 to ∼6.5% on day 14, respectively (Fig. 9b), which represents a 6-fold and 20-fold improvement over IL-2 / IC treatment alone. Notably, ND-OVA-II+IL-2 / IC (D1, 2, 3) treatment increased the antigen-specific OT-II tetramers in total CD4+ T cells from ∼3% on day 7 to ∼6.5% on day 14, respectively (Fig. + Foxp3 - CD25 + T conv The expression of β-actin in the mitochondria was 0.1% and 0.1% at day 7 and 14, respectively (Fig. 9c).
[0367] On the other hand, ND-OVA-II+IL-2 / IC (D3, 4, 5) treatment reduced the total T cells in CD4+ T cells in PBMCs. regThe expansion was from ∼35% on day 7 to ∼50% on day 14 ( FIG. 9 a ). ND-OVA-II+IL-2 / IC (D3, 4, 5) treatment increased antigen-specific OT-II tetramers in CD4+ T cells in PBMCs. + Foxp3 + CD25 + T reg ND-OVA-II+IL-2 / IC (D3, 4, 5) treatment also increased antigen-specific OT-II tetramers in total CD4+ T cells from ∼0.2% on day 7 to ∼2% on day 14 (Fig. 9b), representing a 6-fold improvement over IL-2 / IC treatment alone by day 14. + Foxp3 - CD25 + T conv The expression of β-actin in the mitochondria was 0.1% on day 7 and 0.6% on day 14, respectively (Fig. 9c).
[0368] Although ND-OVA-II+IL-2 / IC (D3, 4, 5) animals obtained a lower number and percentage of antigen-specific T reg (Fig. 9b), but compared with the ND-OVA-II+IL-2 / IC (D1, 2, 3) and IL-2 / IC only (D3, 4, 5) groups, they showed a decrease in total T cells in CD4+ cells. reg The significant expansion of T cells stimulated by ND-OVA-II+IL-2 / IC (D3, 4, 5) and the higher expression of CD25 and GITR (Fig. 6e, f, Fig. 8e, f). The increase in CD25 and GITR expression indicates that T cells stimulated by ND-OVA-II+IL-2 / IC (D3, 4, 5) reg Can be more effective.
[0369] Example II.
[0370] Tregs are potent mediators of immune tolerance in inflamed tissues. However, how to promote and control the migration of Tregs into certain tissues remains poorly understood. It is envisioned that circulating Tregs can be recruited to certain tissues by applying their cognate antigens to local tissues. We anticipate that peptide-MHC-II complexes displayed on antigen-presenting cells in local tissues will elicit T cell responses, leading to the secretion of chemokines and the recruitment of Tregs to tissues. Therefore, this approach may be beneficial for recruiting Tregs to local tissues and mediating local immune tolerance.
[0371] Furthermore, this approach may be broadly applicable even to autoimmune diseases where the autoantigens have not yet been identified. Although autoantigens are well defined in subclasses of autoimmune diseases, many autoimmune diseases have undefined autoantigens. Therefore, it would be beneficial to develop an antigen-nonspecific approach to induce Tregs in systemic circulation and promote their tissue infiltration into certain tissues or organs.
[0372] In Example I, we have reported that combining antigen-loaded nanodiscs with IL-2 / IC treatment resulted in a robust induction of antigen-specific Tregs in the blood circulation. In this example (Example II), it was shown that antigen-specific Tregs in the blood circulation can be recruited to the ear dermis to which the antigen was applied. Therefore, it is envisioned that combined treatment of antigen nanodiscs with IL-2 / IC or mutant IL-2, followed by application of autoantigens (either by injection or topical application) can drive Tregs to infiltrate certain tissues and organs.
[0373] Preparation of antigen-loaded nanodiscs:
[0374] DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine) and DOPE-MAL (N-(3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine) were purchased from NOF AMERICA CORPORATION. DMPC and ApoA1 mimetic peptide 22A (PVLDLFRELLBELLEALKQKLK) powders were mixed and hydrated in 10 mM sodium phosphate buffer (DMPC:22A=2:1, mass ratio), and then subjected to heating and cooling cycles to obtain blank synthetic HDL nanodiscs, followed by sonication at room temperature for 5 min. In order to load the antigen peptide into the blank nanodisc, the cysteine-terminated antigen peptide was first conjugated with DOPE-MAL (antigenic peptide:DOPE-MAL=2:1, molar ratio). The DOPE-peptide was then added to a blank nanodisc (22A: antigen peptide = 5: 1, mass ratio) and incubated for 1 h at room temperature on an orbital oscillator with gentle shaking. Unreacted antigen peptides were removed by using a Zeba spin desalting column (Pierce). The antigen peptide used in this study was OVA-II (OVA323-339) peptide, CSS-ISQAVHAAHAEINEAGR. Peptide loading efficiency was measured by LC-MS. Nanodisc-OVA-II was analyzed by gel permeation chromatography (GPC) equipped with a TSKgel G3000SWxl column (7.8mm ID×30cm, Tosoh Bioscience LLC). The hydrodynamic size and zeta potential of the nanodisc samples were measured by dynamic light scattering (DLS, Zetasizer Nano ZSP).
[0375] Preparation of mouse IL-2: anti-IL-2 immune complex (IL-2 / IC):
[0376] IL-2 / anti-IL-2 mAb immune complex (IL-2 / IC) was prepared as previously reported [1]. 0.1 mg of anti-IL-2 mAb (JES6-1A12, InVivoMAb, BioX-Cell, Lebanon, NH) was mixed with recombinant murine IL-2 (20 μg, PeproTech, Rocky Hill, NJ) in 2 mL of HBSS (Mediatech, Herndon, VA) in vitro and incubated for 10 min at room temperature. The resulting IL-2 / IC was then administered as a single 0.1 mL injection containing 1 μg of murine IL-2 and 5 μg of IL-2 mAb.
[0377] Animal studies
[0378] Animals were cared for in compliance with federal, state, and local guidelines. All work performed on animals was in accordance with and approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Michigan, Ann Arbor. Seven-week-old female C57BL / 6 mice were randomly divided into three groups of five mice each. On day 0, mice received 2.8×10 OT-II transgenic mice from 9-12 weeks old via retro-orbital injection. 6 CD4 +Adoptive cell transfer (ACT) of T cells. Next, mice in groups 1 and 2 were injected subcutaneously at the base of the tail with 0.1 mL of nanodisc-OVA-II (containing 0.1 mg of OVA-II peptide) on days 0, 7, and 14. In addition, group 1 received intraperitoneal (ip) administration of 0.1 mL of the prepared IL-2 / IC solution (described above) on days 3, 4, and 5 after each injection of nanodisc-OVA-II. Mice in group 2 received ACT+nanodisc-OVA-II treatment alone, and mice in group 3 received ACT+PBS as a control group. On day 25, mice were anesthetized by inhalation of isoflurane and 10 mg of either OVA-II peptide or an irrelevant MOG35-55 peptide in PBS was intradermally administered to the left and right ears, respectively, using a 29G needle syringe (BD SAFETYGLIDE 0.5ML insulin syringe 29G×0.5”). 24 hours later, mice were euthanized and cell suspensions from the ears were prepared. Briefly, the ears were removed and divided into dorsal and ventral halves, and the cartilage was removed. The skin was cut into small pieces and digested in a solution of 5 mg / ml DNase I (Sigma-Aldrich) and 3 mg / ml collagenase III (Sigma-Aldrich) in RPMI 1640 containing 2% FBS at 37°C for 90 min. The cell suspension was passed through a 70 μm filter and washed before flow cytometric analysis.
[0379] Flow cytometric analysis
[0380] For surface staining, total cells from each ear digest were transferred to a 96-well plate and incubated with eBioscience Fixable Viability Dye eFluor450 in PBS for 10 minutes at room temperature in the dark. The samples were washed with 200uL PBS and centrifuged at 600g for five minutes. The supernatant was discarded and the cells were suspended in Fc blockers (anti-CD16 / 32) in FACS buffer (PBS+1% BSA). Blocking was allowed to proceed for 10 minutes in the dark at room temperature, after which OT-II tetramers were added to the wells at a final dilution of 1:40 in FACS buffer. OT-II tetramers (NIH Tetramer CoreFacility, Atlanta, GA) were incubated with FACs samples at room temperature in the dark for 1 hour. Surface antibodies were added to the samples at a final dilution of 1:100 20 minutes before the end of the OT-II tetramer incubation. After incubation of tetramers and surfaces, cells were washed with 200uF ACs buffer and centrifuged at 600g for 5 minutes. For Foxp3 intracellular staining, eBioscience TMFoxp3 / Transcription Factor Staining Buffer Set. To measure total cell counts, add 25uL of Life Technologies Absolute Counting Beads to fully stained samples prior to collection on the BioRad ZE5 Analyzer. Analyze FSC files using FlowJo.
[0381] Analysis of antigen-specific T cells following antigen challenge in the ear.
[0382] 2.8 x 10 6 CD4 + OVA-II T cells (ACT). One day later, nanodisc-OVA-II (ND-OVA-II) was administrated sc and used Fig.10 The protocol shown treated mice with IL-2 / IC via the ip route. Control groups included ACT+ND-OVA-II or ACT+PBS treatment. On day 25 after the initial ND vaccination, mice were challenged via intradermal injection of 10ug of OVA-II peptide in the right ear or injection of an irrelevant MOG peptide in the left ear. 24 hours later, left and right ears were excised, processed into single cell suspensions, and stained for flow cytometric analysis. In mice treated with ACT+ND-OVA-II+IL-2 / IC (D3, 4, 5), ears challenged with the OVA-II specific peptide contained an average of 13,000 total CD4 + In addition, in mice treated with ACT+ND-OVA-II+IL-2 / IC (D3, 4, 5) or ACT+ND-OVA-II, ears challenged with OVA-II peptide showed total CD4 + CD25 + Foxp3 + T reg and antigen-specific OT-II-tetramer + CD4 + CD25 + Foxp3 + T reg In mice treated with ACT+ND-OVA-II+IL-2 / IC (D3, 4, 5), CD4 + CD25 + Foxp3 + T reg and OT-II tetramer + T regThe number of T cells in the ACT+ND-OVA-II+IL-2 / IC (D3, 4, 5) mice increased by 3.2 and 3.8 times, respectively (Fig. 11B, C). When compared with ACT+ND-OVA-II or ACT+PBS controls challenged with OVA-II peptide, ACT+ND-OVA-II+IL-2 / IC (D3, 4, 5) mice showed an average of antigen-specific T cells migrating to the ear tissue. reg The total number of cells increased by 5 or 1000-fold (Fig. 11C).
[0383] Example III.
[0384] Materials and Methods
[0385] Preparation of antigen-loaded nanodiscs
[0386] DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine) and DOPE-MAL (N-(3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine) were purchased from NOF AMERICA CORPORATION and Avanti PolarLipids, respectively. DMPC and ApoA1 mimetic peptide 22A (PVLDLFRELLBELLEALKQKLK) powders were mixed and hydrated in 10 mM sodium phosphate buffer (DMPC:22A=2:1, mass ratio), and then subjected to heating and cooling cycles to obtain blank synthetic HDL nanodiscs (NDs), followed by ultrasonic treatment at room temperature for 2 min. In order to load the antigen peptide into the blank nanodisc, the cysteine-terminated antigen peptide was first conjugated with DOPE-MAL (antigenic peptide:DOPE-MAL=1.5:1, molar ratio). The DOPE-peptide was then added to a blank nanodisc (22A: antigen peptide = 5: 1, mass ratio) and incubated for 1 h at room temperature on an orbital oscillator with gentle shaking. Unreacted antigen peptides were removed by using a Zeba spin desalting column (Pierce). The antigen peptide used in this study was the OVA-II (OVA323-339) peptide, ISQAVHAAHAEINEAGR. Peptide loading efficiency was measured by LC-MS.
[0387] Preparation of mouse IL-2:anti-IL-2 immune complex (IL-2 / IC)
[0388] IL-2 / anti-IL-2 mAb immune complex (IL-2 / IC) was prepared as previously reported
[15] . 1 mg of anti-IL-2 mAb (JES6-1A12, InVivoMAb, BioX-Cell, Lebanon, NH) was mixed with 0.2 mg of recombinant murine IL-2 (PeproTech, Rocky Hill, NJ) in 20 mL of HBSS (Mediatech, Herndon, VA) in vitro and incubated at room temperature for 10 min. The resulting IL-2 / IC was then administered to experimental animals as a single 0.1 mL injection containing 1 μg of murine IL-2 and 5 μg of IL-2 mAb.
[0389] Animal studies
[0390] Animals were cared for in accordance with federal, state and local guidelines. All work performed on animals was approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Michigan, Ann Arbor. Seven-week-old female C57BL / 6 mice were randomly divided into 6 groups of 5 mice each. For Group 1 (ND-OVA_D-3, +7+IL2 / IC_D3, 4, 5): On days -3 and 7, 0.1 mL of ND-OVA (containing 0.1 mg OVA-II peptide) was subcutaneously injected into the tail base of each mouse; On days 0, 1, 2 and 10, 11, 12, 0.1 mL of IL2 / IC (containing 1 μg mouse IL-2 and 5 μg IL-2 mAb) was injected intraperitoneally (ip) into each mouse. For Group 2 (ND-OVA_D-4, +6+IL2 / IC_D4, 5, 6): On days -4 and 6, 0.1 mL of ND-OVA (containing 0.1 mg OVA-II peptide) was injected subcutaneously at the base of the tail of each mouse; on days 0, 1, 2 and 10, 11, 12, 0.1 mL of IL2 / IC (containing 1 μg mouse IL-2 and 5 μg IL-2 mAb) was injected intraperitoneally (ip) into each mouse. For Group 3 (ND-OVA_D-3, +7+IL2 / IC_D3, 4, 5, 6, 7): On days -3 and 7, 0.1 mL of ND-OVA (containing 0.1 mg OVA-II peptide) was injected subcutaneously at the base of the tail of each mouse; on days 0, 1, 2, 3, 4 and 10, 11, 12, 13, 14, 0.1 mL of IL2 (containing 1 μg mouse IL-2) was injected intraperitoneally (ip) into each mouse. For Group 4 (ND-OVA_D-1, +9+IL2 / IC_D1, 2, 3, 4, 5): On days -1 and 9, 0.1 mL of ND-OVA (containing 0.1 mg OVA-II peptide) was injected subcutaneously at the base of the tail of each mouse; On days 0, 1, 2, 3, 4 and 10, 11, 12, 13, 14, 0.1 mL of IL2 (containing 1 μg mouse IL-2) was injected intraperitoneally (ip) into each mouse. For Group 5 (IL2 / IC_D3, 4, 5): On days 0, 1, 2 and 10, 11, 12, 0.1 mL of IL2 / IC (containing 1 μg mouse IL-2 and 5 μg IL-2 mAb) was injected intraperitoneally (ip) into each mouse. For group 6 (IL2 / IC_D1, 2, 3, 4, 5): On days 0, 1, 2, 3, 4 and 10, 11, 12, 13, 14, 0.1 mL IL2 (containing 1 μg murine IL-2) was injected intraperitoneally (ip) into each mouse as Fig.12The injections were performed using a 29G needle syringe (BD SAFETYGLIDE 0.5ML insulin syringe 29G X 0.5"). On days 5, 15, and 25, peripheral blood was collected from mice for flow cytometry analysis.
[0391] Flow cytometric analysis
[0392] At the specified time point, 150-200uL of blood was collected from a single mouse into an EDTA-coated test tube. The blood volume was transferred to a 1.5mL Eppendorf test tube for red blood cell lysis. Red blood cells were lysed by adding 1mL ACK lysis buffer to each blood volume, and the test tube was shaken at room temperature for five minutes. Five minutes later, the test tube was centrifuged at 600g for 5 minutes and the supernatant was discarded. The pellet was resuspended in 1mL ACK lysis buffer and immediately centrifuged at 600g for 5 minutes. The supernatant was discarded, and the PBMC was resuspended in PBS and transferred to a 96-well plate and washed once with PBS before FACS staining. For surface staining, the cells were first incubated with eBioscience Fixable Viability Dye eFluor450 in PBS at room temperature in the dark for 10 minutes. The PBMC was washed with 200uL PBS and centrifuged at 600g for five minutes. The supernatant was discarded and the samples were suspended in Fc blocker (anti-CD16 / 32) in FACS buffer (PBS + 1% BSA). Blocking was allowed to proceed for 10 minutes at room temperature in the dark, after which OT-II tetramers were added to the wells at a final dilution of 1:40 in FACS buffer. OT-II tetramers (NIH Tetramer Core Facility, Atlanta, GA) were incubated with PBMCs at room temperature in the dark for 1 hour. Surface antibodies were added to the samples at a final dilution of 1:100 20 minutes before the end of the OT-II tetramer incubation. After incubation of the tetramers and surface, the PBMCs were washed with 200uL FACs buffer and centrifuged at 600g for 5 minutes. For Foxp3 intracellular staining, eBioscience was used according to the kit instructions. TM Foxp3 / Transcription Factor Staining Buffer Set. To measure total cell counts, add 50uL of Life Technologies Absolute Counting Beads to fully stained PBMC samples prior to collection on the BioRad ZE5 Analyzer. Analyze FSC files using FlowJo.
[0393] result
[0394] Optimization of dosing regimen and comparison of ND+wtIL2 and ND+IL2 / IC
[0395] use Fig.12 The scheme shown, nanodisc-OVA-II (ND-OVA) was administered sc to C57BL / 6 mice and treated with IL-2 immune complex (IL-2 / IC) or wild-type IL-2 protein (IL-2) via the ip route. We found in Example I that IL-2 / IC injections given closer to the initial ND-OVA vaccination can expand OT-II tetramers + Foxp3-CD25 + Tconv cells (Example I, Figure 9c). To optimize the ND vaccination and IL-2 / IC combination therapy, we tested two schemes: IL-2 / IC was delivered for three consecutive days starting three days (Group 1) or four days (Group 2) after vaccination. We compared these two schemes with ND vaccination plus wtIL-2 protein therapy. The half-life of IL-2 protein in vivo is significantly shorter than that of IL-2 / IC. Therefore, we included five doses of IL-2 starting three days (Group 3) or one day (Group 4) after ND-OVA vaccination. The control groups included IL-2 / IC alone (Group 5) and IL-2 (Group 6) treatment ( Fig.12 ). Systemic immune responses were measured by flow cytometry on days 5, 15, and 25 after the first injection of IL-2 / IC or IL-2.
[0396] The frequency of CD4+ T cells in lymphocytes was similar in the vaccine groups over the course of the vaccine regimen, with only the IL-2 / IC alone control showing a decrease in CD4 T cells on day 15 (Figure 13a). Group 1 and Group 2 mice that received ND-OVA+IL-2 / IC on D3, 4, 5 or D4, 5, 6 showed almost identical CD4+ T cell responses in PBMCs.
[0397] On days 5 and 15, animals that received ND-OVA+IL-2 / IC on D3, 4, 5 or D4, 5, 6 exhibited CD4+CD25+Foxp3+T regulatory cells (Tregs) compared to animals in groups 3 and 4 that received ND-OVA+IL-2. reg Importantly, the combination of ND-OVA + IL-2 / IC expanded total T cells by more than ∼1.6-fold compared to IL-2 / IC alone. reg However, ND-OVA+IL-2 and IL-2 alone failed to reg Ten days after the last vaccine cycle, T cells in animals treated with IL-2 / IC increased by more than 10% (Figure 13b). reg has returned to the baseline (Figure 13b).
[0398] In addition to the total T regsAnimals in groups 1 and 2 elicited robust antigen-specific OT-II responses compared to all other groups. After one vaccine cycle, total OT-II tetramer+ and OT-II tetramer+Foxp3+CD25+T reg The second round of vaccination further increased the total CD4+ cells and T cells in the total CD4+ cells to 0.76% and 0.44% of the total CD4+ cells, respectively (Fig. 13c, d). reg Antigen-specific cells increased to ∼2.5% and ∼1.5%, respectively, representing a 3.3-fold increase from day 5 (Fig. 13c, d). Notably, by day 15, antigen-specific OT-II T cells were significantly increased in ND-OVA+IL-2 / IC mice compared with mice treated with ND-OVA+IL-2 or IL-2 alone. reg The increase was ~55-fold (Fig. 13d).
[0399] In order to check the effect of the vaccine regimen on other immune cell subsets, we measured the frequency and absolute number of CD8+T cells, activated CD8+CD44hi T cells and NK cells in PBMC (Figure 14). The frequency of CD8+ cells was similar between the groups, with an average range of 40-50% from the 5th day to the 25th day (Figure 14a). On the 15th day, two of the four mice from the separate IL-2 / IC group showed significantly elevated CD8+T cells greater than 64%, while the frequency of CD8+T cells in the other two mice was within the average range. From the 5th day to the 25th day, the absolute number of CD8+T cells in every 2mL blood was between 0.38-1.0x106 (Figure 14b). From the 5th day to the 25th day, it was found that the frequency of activated CD8+CD44hi was between 24-60% of total CD8+T cells, and the absolute number was between 0.10-0.33x106 per 2mL blood (Figure 14c, d). Finally, the frequency and absolute number of NK cells were 16-42% of CD3-CD45+ cells and 1.6-2.8×106 per 2 mL of blood, respectively (Fig. 14e, f).
[0400] These results highlight three important findings: (1) Adding ND to IL-2 / IC therapy increased total T reg The frequency of IL-2 protein was not able to amplify the total T reg and antigen-specific T reg (Fig. 13b, d), and (3) delaying IL-2 / IC injection from D3, 4, 5 to D4, 5, 6 after ND-OVA vaccination did not significantly affect total T reg or antigen-specific T reg amplification.
[0401] Example IV
[0402] Materials and Methods
[0403] Preparation of antigen-loaded nanodiscs
[0404] DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine) and DOPE-MAL (N-(3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine) were purchased from NOF AMERICA CORPORATION. DMPC and ApoA1 mimetic peptide 22A (PVLDLFRELLBELLEALKQKLK) powders were mixed and hydrated in 10 mM sodium phosphate buffer (DMPC:22A=2:1, mass ratio), and then subjected to heating and cooling cycles to obtain blank synthetic HDL nanodiscs, followed by sonication at room temperature for 5 min. In order to load the antigen peptide into the blank nanodisc, the cysteine-terminated antigen peptide was first conjugated with DOPE-MAL (antigenic peptide:DOPE-MAL=2:1, molar ratio). The DOPE-peptide was then added to a blank nanodisc (22A: antigen peptide = 5: 1, mass ratio) and incubated for 1 h at room temperature on an orbital oscillator with gentle shaking. Unreacted antigen peptides were removed by using a Zeba spin desalting column (Pierce). The antigen peptides used in this study were p31 peptide (YVRPLWVRME), InsB9-23 peptide, and full-length C peptide. Peptide loading efficiency was measured by LC-MS. Nanodiscs were analyzed by gel permeation chromatography (GPC) equipped with a TSKgel G3000SWxl column (7.8mm ID×30cm, Tosoh Bioscience LLC). The hydrodynamic size and zeta potential of the nanodisc samples were measured by dynamic light scattering (DLS, Zetasizer Nano ZSP).
[0405] Preparation of mouse IL-2:anti-IL-2 immune complex (IL-2 / IC)
[0406] IL-2 / anti-IL-2 mAb immune complex (IL-2 / IC) was prepared as previously reported
[15] . 0.1 mg of anti-IL-2 mAb (JES6-1A12, InVivoMAb, BioX-Cell, Lebanon, NH) was mixed with recombinant murine IL-2 (20 μg, PeproTech, Rocky Hill, NJ) in 2 mL of HBSS (Mediatech, Herndon, VA) in vitro and incubated for 10 min at room temperature. The resulting IL-2 / IC was then administered as a single 0.1 mL injection containing 1 μg of murine IL-2 and 5 μg of IL-2 mAb.
[0407] Animal studies
[0408] Animals were cared for in accordance with federal, state and local guidelines. All work performed on animals was approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Michigan, Ann Arbor. Seven to nine-week-old male NOD mice were randomly divided into 4 groups of 5-10 mice per group. On the 0th day, 0.1 mL of nanodisc-p31 (containing 0.1 mg p31 peptide) was subcutaneously injected at the tail base of mice in groups 1 and 2. In addition, the first group received intraperitoneal (ip) administration of 0.1 mL of prepared IL-2 / IC solution (as described above) on the 3rd, 4th and 5th days after each injection of nanodisc-p31. The mice in group 2 received separate nanodisc-p31 treatment, and the mice in groups 3 and 4 received IL-2 / IC and PBS as control groups, respectively. On the 11th day, 2 million pre-activated BDC2.5 splenocytes and 2 million pre-activated NY8.3 splenocytes were injected intravenously into mice, respectively. The mice were thereafter monitored for the onset of diabetes using a OneTouch Ultra2 blood glucose meter via the tail vein, and animals with two consecutive blood glucose levels above 250 mg / dl were considered diabetic.
[0409] result
[0410] Therapeutic efficacy of ND and IL-2 / IC combination in transplantation T1D model.
[0411] Using the protocol shown in FIG. 15A , NOD mice were treated subcutaneously with nanodisc-p31 (ND-p31) and subsequently treated with IL-2 / IC via the ip route. Control groups included either PBS or IL-2 / IC or ND alone. On day 6 after the last IL-2 / IC treatment, mice were transplanted with 3 million pre-activated BDC2.5 splenocytes and 3 million pre-activated NY8.3 splenocytes via retro-orbital injection ( FIG. 15A ). In mice treated with IL-2 / IC, the transfer of diabetogenic T cells resulted in the onset of diabetes as fast as mice in the PBS group ( FIG. 15B ). In addition, one mouse treated with p31-ND alone was protected from diabetes. In sharp contrast, more than 70% of mice treated with p31-ND+IL-2 / IC combined were protected from the disease.
[0412] We also evaluated the therapeutic efficacy of the ND+IL-2 / IC combination using the same experimental setup, using InsB9-23 and Ins-C peptides ( FIG. 15A ). In mice treated with IL-2 / IC or PBS, the transfer of diabetogenic BDC2.5 and NY8.3 T cells resulted in hyperglycemia within a week ( FIG. 15C ). One mouse in the InsB-ND+InsC-ND treatment was protected from diabetes. In sharp contrast, more than 70% of mice receiving the InsB-ND+InsC-ND+IL-2 / IC combination did not develop diabetes.
[0413] Taken together, these results demonstrate that a single round of ND combined with IL-2 / IC therapy produces potent bystander suppression and robust disease efficacy in an adoptive transfer model of T1D.
[0414] Equivalent form
[0415] Without departing from the spirit or essential features of the present invention, the present invention may be implemented in other specific forms. Therefore, it is considered that the aforementioned embodiments are illustrative in all aspects and do not limit the present invention described herein. Therefore, the scope of the present invention is indicated by the appended claims rather than the above description, and all changes within the equivalent meaning and scope of the claims should be included therein.
[0416] Join by reference
[0417] The entire disclosure of each patent document and scientific literature mentioned herein is incorporated herein by reference for all purposes. The following references are incorporated herein by reference in their entirety:
[0418] 1. Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and immune tolerance. cell 133, 775-787, 2008.
[0419] 2.Shevach, EMApplication of IL-2therapy to target T regulatory cell function. Trends in immunology 33, 626-632, 2012.
[0420] 3.Hirakawa,M.,Matos,T.,Liu,H.,Koreth,J.,Kim,H.T.,Paul,N.E.,Murase,K.,Whangbo,J.,Alho,A.C.&Nikiforow,S.Low-dose IL-2selectively activates subsetsof CD4+Tregs and NK cells.JCI insight 12016.
[0421] 4.Rosenzwajg,M.,Lorenzon,R.,Cacoub,P.,Pham,H.P.,Pitoiset,F.,El Soufi,K.,RIbet,C.,Bernard,C.,Aractingi,S.&Banneville,B.Immunological and clinicaleffects of low-dose interleukin-2across 11autoimmune diseases in a single,open clinical trial.Annals of the rheumatic diseases 78,209-217,2019.
[0422] 5.Higginson-Scott,N.,Otipoby,K.L.&Viney,J.PT101:A Treg selectiveagonist IL-2mutein therapy for autoimmunity.(Am Assoc Immnol,2020).
[0423] 6.Ghelani,A.,Bates,D.,Conner,K.,Wu,M.-Z.,Lu,J.,Hu,Y.-L.,Li,C.-M.,Chaudhry,A.&Sohn,S.J.Defining the Threshold IL-2Signal Required for Inductionof Selective Treg Cell Responses Using Engineered IL-2Muteins.Frontiers inImmunology 11,1106,2020.
[0424] 7.Peterson,L.B.,Bell,C.J.,Howlett,S.K.,Pekalski,M.L.,Brady,K.,Hinton,H.,Sauter,D.,Todd,J.A.,Umana,P.&Ast,O.A long-lived IL-2mutein thatselectively activates and expands regulatory T cells as a therapy forautoimmune disease.Journal of autoimmunity 95,1-14,2018.
[0425] 8.Khoryati,L.,Pham,M.N.,Sherve,M.,Kumari,S.,Cook,K.,Pearson,J.,Bogdani,M.,Campbell,D.J.&Gavin,M.A.An IL-2mutein engineered to promoteexpansion of regulatory T cells arrests ongoing autoimmunity in mice.Scienceimmunology 52020.
[0426] 9.globenewswire.com / en / news-release / 2021 / 01 / 04 / 2152594 / 0 / en / Pandion-Therapeutics-Announces-Positive-Top-Line-Phase-1a-Clinical-Data-Showing-PT101-was-Well-Tolerated-and-Selectively-Expanded-Regulatory-T-cells.html.
[0427] 1 / 20 / 2022,2022.
[0428] 10.Mills,K.H.&McGuirk,P.Antigen-specific regulatory T cells—theirinduction and role in infection.Seminars in immunology.
[0429] 11.Legoux,F.P.,Lim,J.-B.,Cauley,A.W.,Dikiy,S.,Ertelt,J.,Mariani,T.J.,Sparwasser,T.,Way,S.S.&Moon,J.J.CD4+T cell tolerance to tissue-restrictedself antigens is mediated by antigen-specific regulatory T cells rather thandeletion.Immunity 43,896-908,2015.
[0430] 12.Tang,Q.,Henriksen,K.J.,Bi,M.,Finger,E.B.,Szot,G.,Ye,J.,Masteller,E.L.,McDevitt,H.,Bonyhadi,M.&Bluestone,J.A.In vitro-expanded antigen-specificregulatory T cells suppress autoimmune diabetes.The Journal of experimentalmedicine 199,1455-1465,2004.
[0431] 13.Spence,A.,Purtha,W.,Tam,J.,Dong,S.,Kim,Y.,Ju,C.-H.,Sterling,T.,Nakayama,M.,Robinson,W.H.&Bluestone,J.A.Revealing the specificity ofregulatory T cells in murine autoimmune diabetes.Proceedings of the NationalAcademy of Sciences 115,5265-5270,2018.
[0432] 14.Webster,K.E.,Walters,S.,Kohler,R.E.,Mrkvan,T.,Boyman,O.,Surh,C.D.,Grey,S.T.&Sprent,J.In vivo expansion of T reg cells with IL-2-mAb complexes:induction of resistance to EAE and long-term acceptance of islet allograftswithout immunosuppression.Journal of Experimental Medicine 206,751-760,2009.
[0433] 15.Manirarora,J.N.&Wei,C.-H.Combination therapy using IL-2 / IL-2monoclonal antibody complexes,rapamycin,and islet autoantigen peptidesincreases regulatory T cell frequency and protects against spontaneous andinduced type 1 diabetes in nonobese diabetic mice.The Journal ofImmunology195,5203-5214,2015.
[0434] 16.Izquierdo,C.,Ortiz,A.Z.,Presa,M.,Malo,S.,Montoya,A.,Garabatos,N.,Mora,C.,Verdaguer,J.&Stratmann,T.Treatment of T1D via optimized expansion ofantigen-specific Tregs induced by IL-2 / anti-IL-2 monoclonal antibodycomplexes and peptide / MHC tetramers.Scientific reports 8,1-14,2018.
[0435] 17.Kuai,R.,Li,D.,Chen,Y.E.,Moon,J.J.&Schwendeman,A.High-densitylipoproteins:nature's multifunctional nanoparticles.ACS Nano 10,3015-3041,2016.
[0436] 18.Kuai,R.,Ochyl,L.J.,Bahjat,K.S.,Schwendeman,A.&Moon,J.J.Designervaccine nanodiscs for personalized cancer immunotherapy.Nat Mater16,489-496,2017。
Claims
1. A method comprising administering to a subject: A composition comprising nanoparticles; and A composition comprising an immunomodulatory agent capable of expanding regulatory T cells (Tregs) in the subject.
2. The method according to claim 1, in, The nanoparticles are associated with one or more tolerogenic antigens, wherein administration of a composition comprising nanoparticles associated with one or more tolerogenic antigens, followed by administration of a composition comprising an immunomodulator capable of expanding Tregs, results in one or more of the following: Treating, preventing and / or alleviating one or more disorders of the subject; Promoting strong immune tolerance of the subject to autoimmune disease-related antigens; In vivo expansion of Tregs (e.g., CD3+FOXP3+ cells) in a subject; and increasing the ratio of CD3+FOXP3+ cells to CD3+FOXP3- cells in the T cell population in the subject; and, wherein the antigen is specific for one or more tolerogenic antigens associated with the nanoparticles associated with the one or more tolerogenic antigens.
3. The method according to claim 2, wherein: The composition including the immunomodulator capable of expanding Tregs is included in the nanoparticle, such that the nanoparticle is associated with the immunomodulator capable of expanding Tregs.
4. The method according to claim 2-3, wherein: The composition comprising nanoparticles associated with one or more tolerogenic antigens is administered before and not simultaneously with the composition comprising an immunomodulator capable of expanding Tregs (e.g., 1 second before, 2 seconds before, 1 minute before, 1 hour before, 1 day before, 1 week before, 1 month before, 1 year before, etc.).
5. The method according to claim 4, wherein: The composition comprising an immunomodulator capable of expanding Tregs is administered within thirty days of administering the composition comprising nanoparticles associated with one or more tolerogenic antigens.
6. The method according to claim 1, 2 or 3, wherein: The nanoparticles are sHDL nanoparticles.
7. The method according to claim 6, wherein: The sHDL nanoparticles include a mixture of at least one phospholipid and at least one HDL apolipoprotein or apolipoprotein mimetic.
8. The method according to claim 7, wherein: The phospholipids are selected from the group consisting of: 1,2-dilauroyl-sn-glycero-3-phosphocholine; 1,2-dimyristoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1,2-distearoyl-sn-glycero-3-phosphocholine; 1,2-diazanoyl-sn-glycero-3-phosphocholine; 1,2-dibehenoyl-sn-glycero-3-phosphocholine; 1,2-dilignoceryl-sn-glycero-3-phosphocholine; 1,2-dimyristoleoyl-sn-glycero-3-phosphocholine; 1,2-dimyristoyl-sn-glycero-3-phosphocholine; 1,2-Dipalmitoleoyl-sn-glycero-3-phosphocholine; 1,2-Dipalmitoleoyl-sn-glycero-3-phosphocholine; 1,2-Dioleoyl-sn-glycero-3-phosphocholine; 1,2-Dioleoyl-sn-glycero-3-phosphocholine; 1,2-Dioleoyl-sn-glycero-3-phosphocholine; 1,2-Diarachidonoyl-sn-glycero-3-phosphocholine; 1,2-Dicerol-sn-glycero-3-phosphocholine; 1,2-Dilauroyl-sn-glycero-3-phosphoethanolamine; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine; 1,2-dipentadecanoyl-sn-glycero-3-phosphoethanolamine; 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine; 1,2-distearoyl-sn-glycero-3-phosphoethanolamine; 1,2-dipalmitoleoyl-sn-glycero-3-phosphoethanolamine; 1,2-ditransoleoyl-sn-glycero-3-phosphoethanolamine; 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; dioleoyl-sn-glycero-3-phosphoethanolamine-N-[3-(2-pyridyldithio)propionate]; 1,2-dipalmitoyl-sn-glycero-3-phosphothioethanolamine; 1,2-Di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidophenyl)butyramide]; 1,2-Dixiezaoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidophenyl)butyramide]; 1,2-Dixiezaoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidophenyl)butyramide]; 1,2-Dixiezaoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidomethyl)cyclohexane-carboxamide]; 1,2-Di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidomethyl)cyclohexane-carboxamide]; N-[(3-maleimidophenyl) Distearylphosphatidylethanolamine; N-[(3-maleimide-1-oxyylidenepropyl)aminopropylpolyethylene glycol-carbamoyl] distearylphosphatidylethanolamine; Distearyl-N-(3-maleimide-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine; N-[(3-maleimide-1-oxyylidenepropyl)aminopropylpolyethylene glycol-carbamoyl] distearylphosphatidylethanolamine; Dimyristoyl-N-(3-maleimide-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine; Dioleoyl Acyl-N-(3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine; dipalmitoyl-N-(3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine; 1-palmitoyl-2-oleoyl-N-(3-maleimido-1-oxyylidenepropyl)-L-α-phosphatidylethanolamine; phosphatidylcholine; phosphatidylinositol; phosphatidylserine; phosphatidylethanolamine; distearoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine; dioleoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine; 1-palmitoyl-2-oleoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine; dipalmitoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine; dimyristoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine; 3-(N-succinimidyloxyglutaryl)aminopropyl and polyethylene glycol-carbamoyl distearoyl phosphatidyl-ethanolamine; N-(3-oxyylidenepropoxypolyethylene glycol)carbamoyl-distearoyl-ethanolamine.
9. The method according to claim 7, wherein: The HDL apolipoprotein component is selected from the group consisting of: apolipoprotein AI (apoA-I), apolipoprotein A-II (apoA-II), apolipoprotein A-II xxx (apoA-II-xxx), apolipoprotein A4 (apoA4), apolipoprotein Cs (apoCs), apolipoprotein E (apoE), apolipoprotein AI milano (apoA-I-milano), apolipoprotein A-I paris (apoA-I-paris), apolipoprotein M (apoM), HDL apolipoprotein mimics, prepro apolipoproteins, prepro ApoA-I, pro ApoAI, prepro ApoA-II, pro ApoAII, prepro ApoA-IV, pro ApoA-IV, ApoA-V, prepro ApoE, pro ApoE, prepro ApoAI Milano , pro-ApoA-I Milano , Maehara ApoA-I Paris , pro-ApoA-I Paris and mixtures thereof.
10. The method according to claim 7, wherein: The apolipoprotein mimetic is described by any one of the following: SEQ ID NO: 1-336 and WDRVKDLATVYVDVLKDSGRDYVSQF (SEQ ID NO: 341), LKLLDNWDSVTSTFSKLREOL (SEQ ID NO: 342), PVTOEFWDNLEKETEGLROEMS (SEQ ID NO: 343), KDLEEVKAKVQ (SEQ ID NO: 344), KDLEEVKAKVO (SEQ ID NO: 345), PYLDDFQKKWQEEMELYRQKVE (SEQ ID NO: 346), PLRAELQEGARQKLHELOEKLS (SEQ ID NO: 347), PLGEEMRDRARAHVDALRTHLA (SEQ ID NO: 348), PYSDELRQRLAARLEALKENGG (SEQ ID NO: 349), ARLAEYHAKATEHLSTLSEKAK (SEQ ID NO: 350), PALEDLROGLL (SEQ ID NO: 351), PVLESFKVSFLSALEEYTKKLN (SEQ ID NO: 352), PVLESFVSFLSALEEYTKKLN (SEQ ID NO: 353), PVLESFKVSFLSALEEYTKKLN (SEQ ID NO: 352), TVLLLTICSLEGALVRRQAKEPCV (SEQ ID NO: 354), QTVTDYGKDLME (SEQ ID NO: 355), KVKSPELOAEAKSYFEKSKE (SEQ ID NO: 356), VLTLALVAVAGARAEVSADOVATV (SEQ ID NO: 357), NNAKEAVEHLOKSELTOOLNAL (SEQ ID NO: 358), LPVLVWLSIVLEGPAPAOGTPDVSS (SEQ ID NO: 359), LPVLVVVLSIVLEGPAPAQGTPDVSS (SEQ ID NO: 360), ALDKLKEFGNTLEDKARELIS (SEQ ID NO: 361), VVALLALLASARASEAEDASLL (SEQ ID NO: 362), HLRKLRKRLLRDADDLQKRLAVYOA (SEQ ID NO: 363), AQAWGERLRARMEEMGSRTRDR (SEQ ID NO: 364), LDEVKEQVAEVRAKLEEQAQ (SEQIDNO: 365), DWLKAFYDKVAEKLKEAF (SEQ ID NO: 236), DWLKAFYDKVAEKLKEAFPDWAKAAYDKAAEKAKEAA (SEQ ID NO: 366), PVLDLFRELLNELLEALKQKL (SEQ ID NO: 367), PVLDLFRELLNELLEALKQKLA (SEQ ID NO: 368), PVLDLFRELLNELLEALKQKLK (SEQ ID NO: 4), PVLDLFRELLNELLEALKQKLA (SEQ ID NO: 369), PVLDLFRELLNELLEALKKLLK (SEQ ID NO: 370), PVLDLFRELLNELLEALKKLLA (SEQ ID NO: 371), PLLDLFRELLNELLEALKKLLA (SEQ ID NO: 372) and EVRSKLEEWFAAFREFAEEFLARLKS (SEQ ID NO: 373).
11. The method according to claims 2-10, wherein: The one or more tolerogenic antigens are tolerogenic antigens comprising a length of 3 amino acids to 50 amino acids.
12. The method according to claims 2-10, wherein: The one or more tolerogenic antigens are tolerogenic antigens comprising a polypeptide comprising the amino acid sequence of any one of SEQ ID Nos: 375-796.
13. The method according to claims 2-10, wherein: The one or more tolerogenic antigens are human allograft antigens.
14. The method according to claim 13, wherein: The human allograft antigens are selected from subunits of various MHC class I and MHC class II haplotype proteins, and single amino acid polymorphisms on minor blood group antigens including RhCE, Kell, Kidd, Duffy and Ss.
15. The method according to claims 2-10, wherein: The one or more tolerogenic antigens are specific for type 1 diabetes.
16. The method according to claim 15, wherein: The tolerogenic antigen is selected from Insulin, proinsulin, preproinsulin, glutamate decarboxylase 65 (GAD-65), GAD-67, insulinoma-associated protein 2 (IA-2), insulinoma-associated protein 2β (IA-2β), ICA69, ICA12 (SOX-13), carboxypeptidase H, Imogen 38, GLIMA38, chromogranin A, HSP-60, carboxypeptidase E, peripherin, glucose transporter 2, hepatocarcinoma-entero-pancreatic / pancreas-associated protein, S100β, glial fibrillary acidic protein, regeneration gene II, pancreatic duodenal homeobox 1, dystrophic myotonic kinase, islet-specific glucose-6-phosphatase catalytic subunit-associated protein, and SST G protein-coupled receptors 1-5.
17. The method according to claims 2-10, wherein: The tolerogenic antigens are specific for one or more of the following conditions: rheumatoid arthritis, multiple sclerosis, primary biliary cholangitis, primary sclerosing cholangitis, MOG antibody disease, diabetes, thyroid autoimmune disease, thyroid-related eye and skin disease, hypoparathyroidism, Addison's disease, premature ovarian failure, autoimmune hypophysitis, pituitary autoimmune disease, immune gastritis, pernicious anemia, celiac disease, vitiligo, myasthenia gravis, pemphigus vulgaris and its variants, bullous pemphigoid, dermatitis herpetiformis, Duling's disease, epidermolysis bullosa acquired , systemic sclerosis, mixed connective tissue disease, Sjögren's syndrome, systemic lupus erythematosus, Goodpasture's syndrome, rheumatic heart disease, autoimmune polyglandular syndrome type 1, Aicardi-Goutières syndrome, acute pancreatitis, age-dependent macular degeneration, alcoholic liver disease, liver fibrosis, metastasis, myocardial infarction, non-alcoholic steatohepatitis (NASH), Parkinson's disease, polyarthritis / fetal and neonatal anemia, sepsis and inflammatory bowel disease, inflammatory bowel disease, transplant-related disorders, one or more allergies, respiratory disorders (e.g., asthma), and GVHD.
18. The method according to claims 2-10, wherein: The one or more tolerogenic antigens include one or more tolerogenic antigens selected from the group consisting of thyroglobulin (TG), thyroid peroxidase (TPO), thyroid stimulating hormone receptor (TSHR), sodium iodide transporter (NIS), megalin, thyroid autoantigens including TSHR, insulin-like growth factor 1 receptor, calcium sensing receptor, 21-hydroxylase, 17α-hydroxylase and P450 side chain cleavage enzyme (P450scc), ACTH receptor, P450c21, P450c17, FSH receptor, α-enolase, pituitary-specific protein factor (PGSF) 1a and 2, and type 2 iodothyronine deiodinase, myelin basic protein, myelin oligodendrocyte glycoprotein, proteolipid protein, collagen II, H + , K + -ATPase, tissue transglutaminase and gliadin, tyrosinase, tyrosinase-related proteins 1 and 2, acetylcholine receptor, desmocollins 3, 1 and 4, pemphaxin, desmocollins, plakoglobin, perifocal proteins, desmoplakin, acetylcholine receptor, BP180, BP230, plectin, laminin 5, endomysium, tissue transglutaminase, collagen VII, matrix metalloproteinases 1 and 3, collagen-specific chaperone heat-shock protein 47, fibrillin 1, PDGF receptor, Scl-70, U1 RNP, Th / To, Ku, Jo1, NAG-2, centromere proteins, topoisomerase I, nucleolar proteins, RNA polymerases I, II and III, PM-Slc, fibrillarin, B23, U1snRNP, nuclear antigens SS-A and SS-B, cytosolic proteins, poly (ADP-ribose) polymerase, topoisomerase, nuclear proteins including SS-A, high mobility group protein B1 (HMGB1), nucleosomes, histones, double-stranded DNA, glomerular basement membrane proteins including collagen IV, cardiac myosin, aromatic L-amino acid decarboxylase, histidine decarboxylase, cysteine sulfenic acid decarboxylase, tryptophan hydroxylase, tyrosine hydroxylase, phenylalanine hydroxylase, hepatic P450 cytochromes P450 1A2 and 2A6, SOX-9, SOX-10, calcium-sensing receptor protein, and type 1 interferons interferon alpha, beta, and omega.
19. The method according to claims 2-10, wherein: The one or more tolerogenic antigens are specific for celiac disease.
20. The method according to claim 19, wherein: The tolerogenic antigen is selected from the group consisting of gliadin, glutenin and fragments thereof capable of inducing immune response.
21. The method according to claim 20, wherein: The tolerogenic antigen is selected from gliadin or a fragment thereof.
22. The method according to claim 21, wherein: The tolerogenic antigen is selected from the group consisting of alpha, gamma and omega gliadins or fragments thereof.
23. The method according to claim 21 or 22, wherein: The tolerogenic antigen comprises a polypeptide having at least 90% sequence identity to the polypeptide sequence of any one of SEQ ID NOs: 375-580.
24. The method according to claim 23, wherein: The tolerogenic antigen includes a polypeptide having at least 90% sequence identity to any one of the polypeptide sequences of SEQ ID NOs: 375-580.
25. The method according to claim 24, wherein: The tolerogenic antigen includes a polypeptide having a polypeptide sequence of any one of SEQ ID NOs: 375-580.
26. The method according to claim 25, wherein: The tolerogenic antigens include two or more polypeptide sequences having the sequence of any one of SEQ ID NOs: 375-580.
27. The method according to claims 2-10, wherein: The tolerogenic antigen is a multimeric tolerogenic antigen comprising the following N-terminal to C-terminal structure: (P4-L4) n4 -(P3-L3) n3 -P2-(L1-P1) n1 Among them, P1, P2, P3 and P4 are each independently a tolerogenic antigen; L1, L3 and L4 are each independently a linker; and n1, n3 and n4 are each independently 0 or 1, wherein at least one of n1, n3 and n4 is 1.
28. The composition according to claim 27, wherein n1 is 1, n3 is 0, and n4 is 0, and the tolerogenic antigen comprises the following N-terminal to C-terminal structure: P2-L1-P1.
29. The method according to claims 27-28, wherein: L1 is a peptide linker comprising 2 to 200 amino acids.
30. The method according to claims 27-29, wherein: L1 is a peptide linker comprising 5 to 50 amino acids.
31. The method according to claims 27-30, wherein: L1 is a peptide linker comprising glycine (G) and serine (S) residues.
32. The method according to claims 27-31, wherein: L1 is included (GS) x 、(GGS) x or (GGGGS) x A peptide linker having an amino acid sequence of , wherein x is an integer from 1 to 10.
33. The method according to claims 27-32, wherein: P1 and P2 each include different tolerogenic antigens.
34. The method according to claims 27-32, wherein: P1 and P2 each include the same tolerogenic antigens.
35. The composition according to claim 27, wherein n1 is 1, n3 is 1, and n4 is 0, and the tolerogenic antigen includes the following N-terminal to C-terminal structure: P3-L3-P2-L1-P1.
36. The composition according to claims 27-32, wherein L1 and L3 are each independently selected peptide linkers comprising 2 to 200 amino acids.
37. The method of claim 27, wherein: L1 and L3 are each independently selected peptide linkers comprising 5 to 50 amino acids.
38. The method of claim 27, wherein: L1 and L3 are each independently selected peptide linkers comprising glycine (G) and serine (S) residues.
39. The method of claim 35, wherein: L1 and L3 are each independently selected including (GS) x 、(GGS) x or (GGGGS) x A peptide linker having an amino acid sequence of , wherein x is an integer from 1 to 10.
40. The method of claim 35, wherein: P1, P2 and / or P3 each include a different tolerogenic antigen.
41. The method of claim 34, wherein: P1, P2 and P3 each include the same tolerogenic antigens.
42. The method of claim 27, wherein: n1 is 1, n3 is 1, and n4 is 1, and the tolerogenic antigen includes the following N-terminal to C-terminal structure: P4-L4-P3-L3-P2-L1-P1.
43. The method of claim 42, wherein: L1 and L2 are each independently selected peptide linkers comprising 2 to 200 amino acids.
44. The method of claim 43, wherein: L1, L2 and L3 are each independently selected peptide linkers comprising 5 to 50 amino acids.
45. The method of claim 43, wherein: L1, L2 and L3 are each independently selected peptide linkers comprising glycine (G) and serine (S) residues.
46. The method of claim 42, wherein: L1, L2 and L3 are each independently selected including (GS) x 、(GGS) x or (GGGGS (SEQ ID NO: 219)) x A peptide linker having an amino acid sequence of , wherein x is an integer from 1 to 10.
47. The method according to any one of claims 42, wherein: P1, P2, P3 and / or P4 each include a different tolerogenic antigen.
48. The method of claim 42, wherein: P1, P2, P3 and P4 each include the same tolerogenic antigens.
49. The method according to claims 2-10, wherein: The number of tolerogenic antigens associated with a particular nanoparticle includes a population of 1 to 30 tolerogenic antigens per nanoparticle.
50. The method of claim 49, wherein: The number of tolerogenic antigens associated with a particular nanoparticle includes a population of 1 to 10 tolerogenic antigens per particle.
51. The method of claim 49, wherein: The number of tolerogenic antigens associated with a particular nanoparticle included a population of 6 tolerogenic antigens per particle.
52. The method of claim 49, wherein: The number of tolerogenic antigens associated with a particular nanoparticle included a population of 8 tolerogenic antigens per particle.
53. The method of claim 50, wherein: The population of tolerogenic antigens associated with a particular nanoparticle is the same tolerogenic antigen.
54. The method of claim 49, wherein: The population of tolerogenic antigens associated with a particular nanoparticle includes from 1 to 5 different tolerogenic antigens.
55. The method of claim 48, wherein: The population of tolerogenic antigens associated with a particular nanoparticle includes 3 to 4 different tolerogenic antigens.
56. The method of claim 54, wherein: The population of tolerogenic antigens is specific for 1 to 3 different diseases.
57. The method of claim 54, wherein: The population of tolerogenic antigens are specific for the same disease.
58. The method of claim 2, wherein: The population of tolerogenic antigens associated with specific nanoparticles includes: (i) a first polypeptide population including an amino acid sequence of any one of SEQ ID NOs: 406-588, or a biologically active fragment or variant thereof, (ii) a second polypeptide population including an amino acid sequence of any one of SEQ ID NOs: 406-588, or a biologically active fragment or variant thereof, and (iii) a third polypeptide population including an amino acid sequence of any one of SEQ ID NOs: 406-588, or a biologically active fragment or variant thereof.
59. The method of claim 58, wherein: The first polypeptide population includes the amino acid sequence of SEQ ID NO: 474, or a biologically active fragment or variant thereof, (ii) the second polypeptide population includes the amino acid sequence of any one of SEQ ID NO: 406-588, or a biologically active fragment or variant thereof, and (iii) the third polypeptide population includes the amino acid sequence of any one of SEQ ID NO: 406-588, or a biologically active fragment or variant thereof.
60. The method of claim 58, wherein: The population of tolerogenic antigens associated with specific nanoparticles includes: (i) a first polypeptide population including an amino acid sequence of SEQ ID NO: 474, or a biologically active fragment or variant thereof, (ii) a second polypeptide population including an amino acid sequence of SEQ ID NO: 475, or a biologically active fragment or variant thereof, and (iii) a third polypeptide population including an amino acid sequence of any one of SEQ ID NOs: 406-588, or a biologically active fragment or variant thereof.
61. The method of claim 60, wherein: The third polypeptide population includes the amino acid sequence of SEQ ID NO: 476, or a biologically active fragment or variant thereof.
62. The method of claim 59, wherein: The second polypeptide population comprises the amino acid sequence of SEQ ID NO: 477 or a biologically active fragment or variant thereof, and / or the third polypeptide population comprises the amino acid sequence of SEQ ID NO: 478 or a biologically active fragment or variant thereof.
63. The method of claim 58, wherein: The first polypeptide population includes the amino acid sequence of SEQ ID NO:506, or a biologically active fragment or variant thereof, (ii) the second polypeptide population includes the amino acid sequence of any one of SEQ ID NO:406-588, or a biologically active fragment or variant thereof, and (iii) the third polypeptide population includes the amino acid sequence of any one of SEQ ID NO:406-588, or a biologically active fragment or variant thereof.
64. The method of claim 63, wherein: The population of tolerogenic antigens associated with specific nanoparticles includes: (i) a first polypeptide population including an amino acid sequence of SEQ ID NO: 506, or a biologically active fragment or variant thereof, (ii) a second polypeptide population including an amino acid sequence of SEQ ID NO: 507, or a biologically active fragment or variant thereof, and (iii) a third polypeptide population including an amino acid sequence of any one of SEQ ID NOs: 406-588, or a biologically active fragment or variant thereof.
65. The method of claim 64, wherein: The third polypeptide population includes the amino acid sequence of SEQ ID NO: 508, or a biologically active fragment or variant thereof.
66. The method of claim 23, wherein: The tolerogenic antigen comprises a polypeptide having at least 90% sequence identity with the polypeptide sequence of SEQ ID NO:
374.
67. The method of claim 66, wherein: The tolerogenic antigen comprises a polypeptide having at least 95% sequence identity to the polypeptide of SEQ ID NO:
374.
68. The method of claim 67, wherein: The tolerogenic antigen comprises a polypeptide having at least 97% sequence identity to the polypeptide of SEQ ID NO:
374.
69. The method of claim 68, wherein: The tolerogenic antigen comprises the polypeptide sequence of SEQ ID NO:
374.
70. The method of claim 69, wherein: The tolerogenic antigen comprises a fragment of SEQ ID NO: 374, comprising a length of 6-12 amino acid residues.
71. The method of claim 2, wherein: The tolerogenic antigen includes an amide group at the C-terminus.
72. The method of claim 2, wherein: The tolerogenic antigen includes a pyroglutamic acid residue at the N-terminus.
73. The method of claim 2, wherein: The tolerogenic antigen includes an acetyl group at the N-terminus.
74. The method of claim 2, wherein: The tolerogenic antigen includes a pyroglutamic acid residue at the N-terminus and an amide group at the C-terminus.
75. The method of claim 2, wherein: The tolerogenic antigen includes an acetyl group at the N-terminus and an amide group at the C-terminus.
76. The method of claim 2, wherein: The tolerogenic antigen includes an N-terminus or a C-terminus modified with a cysteine residue that binds to a linker.
77. The method of claim 2, wherein: The tolerogenic antigen includes an N-terminus and a C-terminus modified with a cysteine residue bound to a linker.
78. The method of claim 7, wherein: The one or more tolerogenic antigens are conjugated to the nanoparticle phospholipids.
79. The method of claim 7, wherein: The one or more tolerogenic antigens are conjugated to the nanoparticle phospholipids between each tolerogenic antigen and the nanoparticle phospholipids.
80. The method of claim 79, wherein: The nanoparticle phospholipids are selected from Dioleoyl-N-(3-maleimido-1-oxylidenepropyl)-L-α-phosphatidylethanolamine; Distearoyl-N-(3-maleimido-1-oxylidenepropyl)-L-α-phosphatidylethanolamine; 1-palmitoyl-2-oleoyl-N-(3-maleimido-1-oxylidenepropyl)-L-α-phosphatidylethanolamine; Dipalmitoyl-N-(3-maleimido-1-oxylidenepropyl)-L-α-phosphatidylethanolamine; and Dimyristoyl-N-(3-maleimido-1-oxylidenepropyl)-L-α-phosphatidylethanolamine.
81. The method of claim 7, wherein: The one or more tolerogenic antigens are conjugated to the nanoparticle phospholipids via amine-mediated interactions.
82. The method of claim 81, wherein: The nanoparticle phospholipid is dioleoyl-N-(succinimidyloxy-glutaryl)-L-α-phosphatidylethanolamine (DOPE-NHS).
83. The method of claim 81, wherein: The amine-mediated interaction is through an amine-reactive phospholipid having a self-destructive bond.
84. The method according to claim 1 or 2, in, The nanoparticle is associated with an immunomodulatory agent and is not associated with a tolerogenic antigen; or Therein, the nanoparticles are associated with tolerogenic antigens and are also associated with immunomodulators.
85. The method of claim 84, wherein: The immunomodulator is one or more of the following: fingolimod; rapamycin; 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) or related ligands; trichostatin A; suberoylanilide hydroxamic acid (SAHA); statins; mTOR inhibitors; TGF-β signaling agents; TGF-β receptor agonists; histone deacetylase inhibitors; corticosteroids; mitochondrial function inhibitors; NF-κβ inhibitors; adenosine receptor agonists; prostaglandin E2 agonists (PGE2; phosphodiesterase inhibitors; proteasome inhibitors; kinase inhibitors; G protein-coupled receptor agonists; G protein-coupled receptor antagonists; glucocorticoids; retinoids; cytokine inhibitors; cytokine receptor inhibitors; cytokine receptor activators; peroxisome proliferator-activated receptor antagonists; peroxisome proliferator-activated receptor agonists; histone deacetylase inhibitors; calcineurin inhibitors; phosphatase inhibitors; PI3 KB inhibitor; autophagy inhibitor; aryl hydrocarbon receptor inhibitor; proteasome inhibitor I (PSI); oxidized ATP IDO; vitamin D3; cyclosporine; aryl hydrocarbon receptor inhibitor; resveratrol; azathioprine (Aza); 6-mercaptopurine (6-MP); 6-thioguanine (6-TG); FK506; sanglifehrin A; salmeterol; mycophenolate mofetil (MMF); aspirin and other COX inhibitors; niflumic acid; estriol; triptolide; OPN-305, OPN-401; eritoran (E5564); TAK-242; Cpn10; NI-0101; 1A6; AV411; IRS-954 (DV-1079); IMO-3100; CPG-52363; CPG-52364; OPN-3 05;ATNC05;NI-0101;IMO-8400;hydroxychloroquine;CU-CPT22;C29;ortho-vanillin;SSL3 protein;OPN-305;5SsnB;Vizantin;(+)-N-phenylethylnoroxymorphone;VB3323;monosaccharide 3;(+)-naltrexone and (+)-naloxone;HT52;HTB2;compound 4a;CNTO2424;TH1020;INH-ODN;E6446;AT791;CpG ODN 2088;ODNTTAGGG;COV08-0064;2R9;GpG oligonucleotide;2-aminopurine;Amlexanox;Bay11-7082;BX795;CH-223191;chloroquine;CLI-095; CU-CPT9a; cyclosporine A; CTY387; gefitinib; glibenclamide; H-89; H-131; Isoliquiritigenin; MCC950; MRT67307; OxPAPC; Parthenolide; Pepinh-MYD; Pepinh-TRIF; Polymyxin B; R406; RU.521; VX-765; YM201636; Z-VAD-FMK; and AHR specific ligands; including but not limited to 2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD); tryptamine (TA); and 6-formylindole[3,2b]carbazole (FICZ).
86. The method of claim 84, wherein: The immunomodulator is a cytokine.
87. The method of claim 86, wherein: The cytokine is a human cytokine.
88. The method of claim 86, wherein: The cytokine is selected from TGFβ, IL-1, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12A, IL12B, IL-15, IL-21 and IL-18 and any variants / mutants thereof.
89. The method of claim 84, wherein: The immunomodulator is selected from human IL-2 or a variant thereof, low-dose IL-2 or a variant thereof, PT101 or a variant thereof, an IL-2 mutant protein and an IL-2: anti-IL-2 antibody immune complex (IL-2 / IC).
90. The method of claim 84, wherein: The immunomodulator is selected from the group consisting of: extended pharmacokinetic (PK) IL-2, extended PK IL-2 including fusion proteins (e.g., immunoglobulin fragments, human serum albumin, Fn3), IL-2 portions operably linked to immunoglobulin Fc domains, IL-2 portions conjugated to non-protein polymers (e.g., polyethylene glycol), and IL-2 mutant proteins that are high affinity CD25 binders.
91. The method of claim 2, wherein: The one or more disorders are selected from transplant-related disorders, One or more allergies, Respiratory disorders (eg, asthma), GVHD, and An autoimmune disease selected from the group consisting of rheumatoid arthritis, multiple sclerosis, primary biliary cholangitis, primary sclerosing cholangitis, MOG antibody disease, diabetes, thyroid autoimmune disease, thyroid-related eye disease, thyroid-related skin disease, hypoparathyroidism, Addison's disease, premature ovarian failure, autoimmune hypophysitis, pituitary autoimmune disease, immune gastritis, pernicious anemia, celiac disease, vitiligo, myasthenia gravis, pemphigus vulgaris and its variants, bullous pemphigoid, dermatitis herpetiformis Lin's disease, epidermolysis bullosa acquisita, systemic sclerosis, mixed connective tissue disease, Sjögren's syndrome, systemic lupus erythematosus, Goodpasture's syndrome, rheumatic heart disease, autoimmune polyglandular syndrome type 1, Aicardi-Goutières syndrome, acute pancreatitis, age-dependent macular degeneration, alcoholic liver disease, liver fibrosis, metastasis, myocardial infarction, nonalcoholic steatohepatitis (NASH), Parkinson's disease, polyarthritis / fetal and neonatal anemia, sepsis, and inflammatory bowel disease.
92. The method of claim 91, wherein: The one or more autoimmune disorders is a single autoimmune disorder.
93. The method of claim 1, wherein: The one or more immunomodulators are selected from the group consisting of: fingolimod; rapamycin; 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) or related ligands; trichostatin A; suberoylanilide hydroxamic acid (SAHA); Statins; mTOR inhibitors; TGF-β signaling agents; TGF-β receptor agonists; histone deacetylase inhibitors; corticosteroids; inhibitors of mitochondrial function; NF-κβ inhibitors; adenosine receptor agonists; prostaglandin E2 agonists (PGE2; phosphodiesterase inhibitors; proteasome inhibitors; kinase inhibitors; G protein-coupled receptor agonists; G protein-coupled receptor antagonists; glucocorticoids; retinoids; cytokine inhibitors; cytokine receptor inhibitors; cytokine receptor activators; peroxisome proliferator-activated receptor antagonists; peroxisome proliferator-activated receptor agonists; histone deacetylase inhibitors; calcineurin inhibitors; phosphatase inhibitors; PI3 KB inhibitors; autophagy inhibitors; aryl hydrocarbon receptor inhibitors; proteasome inhibitor I (PSI); oxidized ATP IDO; vitamin D3; cyclosporine; aryl hydrocarbon receptor inhibitors; resveratrol; azathioprine (Aza); 6-mercaptopurine (6-MP); 6-thioguanine (6-TG); FK506; sanglifehrin A; salmeterol; mycophenolate mofetil (MMF); aspirin and other COX inhibitors; niflumic acid; estriol; triptolide; OPN-305, OPN-401; eritoran (E5564); TAK-242; Cpn10; NI-0101; 1A6;AV411;IRS-954(DV-1079);IMO-3100;CPG-52363;CPG-52364;OPN-305;ATNC05;NI-0101;IMO-8400;hydroxychloroquine;CU-CPT22;C29;ortho-vanillin;SSL3 protein;OPN-305;5SsnB;Vizantin;(+)-N-phenylethylnoroxymorphone;VB3323;monosaccharide 3;(+)-naltrexone and (+)-naloxone;HT52;HTB2;compound 4a;CNTO2424;TH1020;INH-ODN;E6446;AT791;CpG ODN 2088;ODN TTAGGG;COV08-0064;2R9;GpG oligonucleotide; 2-aminopurine; Amlexanox; Bay11-7082; BX795; CH-223191; Chloroquine; CLI-095; CU-CPT9a; Cyclosporine A; CTY387; Gefitinib; Glibenclamide; H-89; H-131; Isoliquiritigenin; MCC950; MRT67307; OxPAPC; Parthenolide; Pepinh-MYD; Pepinh-TRIF; Polymyxin B; R406; RU.521; VX-765; YM201636; Z-VAD-FMK; and AHR specific ligands; including but not limited to 2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD); tryptamine (TA); and 6-formylindole[3,2b]carbazole (FICZ).
94. The method of claim 1, wherein: The immunomodulator is a cytokine.
95. The method of claim 94, wherein: The cytokine is a human cytokine.
96. The method of claim 94, wherein: The cytokine is selected from TGFβ, IL-1, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12A, IL12B, IL-15, IL-21 and IL-18 and any variants and / or mutant proteins thereof.
97. The method of claim 1, wherein: The immunomodulator is selected from human IL-2 or a variant thereof, low-dose IL-2 or a variant thereof, PT101 or a variant thereof, or a mutant protein IL-2 or a variant thereof.
98. The method of claim 1, wherein: The immunomodulator is IL-2: anti-IL-2 antibody immune complex (IL-2 / IC).
99. The method of claim 1, wherein: The composition comprising one or more immunomodulators capable of expanding Tregs is administered after (e.g., 1 second, 2 seconds, 1 minute, 1 hour, 1 day, 1 week, 1 month, 1 year, etc.) administration of the composition comprising nanoparticles.
100. The method of claim 1, wherein: The subject is a human subject.
101. The method of claim 1, wherein: The subject is a human subject having or at risk of having an autoimmune disorder.
102. The method of claim 1, wherein: The amount of CD3+FOXP3+ cells in the T cell population in the subject is lower than the amount of CD3+FOXP3- cells.
103. The method according to claim 2 or 3, in, The treating, preventing and / or ameliorating one or more autoimmune disorders in the subject is specific to a particular tissue region; wherein promoting strong immune tolerance of the subject to autoimmune disease-associated antigens is specific to a particular tissue region; wherein the in vivo expansion of Tregs (e.g., CD3+FOXP3+ cells) in the subject is specific to a particular tissue region; and Wherein, increasing the ratio of CD3+FOXP3+ cells to CD3+FOXP3- cells in the T cell population in the subject is specific to a specific tissue region.
104. The method of claim 103, wherein: The specific tissue region is associated with one or more autoimmune disorders.
105. The method according to claim 103 or 104, in, The administration of the composition comprising nanoparticles associated with the one or more tolerogenic antigens followed by the administration of the composition comprising an immunomodulator capable of expanding Tregs is further subsequent to the administration of the one or more tolerogenic antigens and / or nanoparticles associated with the tolerogenic antigens to the specific tissue region.
106. The method of claim 105, wherein: The one or more tolerogenic antigens are administered to the specific tissue area by one or more administration techniques selected from the group consisting of injection, topical administration, subcutaneous, oral, intranasal, inhalation, rectal and transdermal.
107. The method of claim 105 or 106, wherein: The administration of one or more tolerogenic antigens to the specific tissue region prevents immune tolerance within the specific tissue region.
108. The method of claim 1, wherein: Compositions including an immunomodulator capable of expanding Tregs are capable of expanding antigen-specific Tregs.
109. A kit comprising: The composition comprising nanoparticles as claimed in claim 1; as well as The composition of claim 1 comprising an immunomodulator capable of expanding Treg.
110. A kit comprising: The composition comprising nanoparticles as claimed in claim 1; The composition of claim 1 comprising an immunomodulator capable of expanding Treg; and One or more tolerogenic antigens formulated for topical administration and / or administration by injection.
